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ABSTRACT 
Pre-eclampsia is a disorder of unknown aetiology that affects about 5% of Sri 
Lankan women during their pregnancy. It is most likely a multifactorial 
disorder that is caused by the interaction of genetic and environmental factors. 
Recent advances in genetics have resulted in a surge of investigations into 
genetic factors underlying pre-eclampsia. These studies have been conducted 
mainly in the white Caucasians in the West and the Japanese in the East.  
 
The investigations described in this thesis therefore were undertaken in a 
genetically distinct South Asian Sinhalese population in Sri Lanka and 
replicated in a white Caucasian population in Nottingham, UK. Four candidate 
genes; Epidermal Growth Factor (EGF) and Transforming Growth Factor 
Alpha (TGFA), which may play a role in placentation; Angiotensinogen 
(ANG), which is involved in blood pressure regulation; and 5,10-
Methylenetetrahydrofolate reductase (MTHFR), which is an enzyme involved 
in folate metabolism, were examined. 
 
These investigations consisted of the following: Recruitment of 80 population 
volunteers each from the Sinhala, Sri Lankan Tamil and Moor racial groups in 
Sri Lanka, establishing the allele/haplotype frequency for the candidate genes 
in those volunteers and in 80 white Caucasian population volunteers, and 
comparing their allele/haplotype frequencies; recruitment of 180 Sinhalese 
women with pre-eclampsia and 180 normotensive pregnant Sinhalese women, 
 xi 
establishing the allele/haplotype frequencies of the candidate genes in these 
women and in 74 white Caucasian women with pre-eclampsia and 81 
normotensive pregnant white Caucasian women, comparing the pre-eclampsia 
phenotype of the Sinhalese with that of the white Caucasians, examining the 
association of the candidate genes with pre-eclampsia, and examining the 
association of the candidate genes with quantitative traits such as birth weight 
and blood pressure in normotensive pregnant women; and examining the 
functional effects of polymorphisms in the angiotensinogen gene on gene 
expression. 
 
The phenotyping results of the Sinhalese women reflect the severe morbidity 
associated with pre-eclampsia elsewhere, and highlight the severe perinatal 
mortality associated with pre-eclampsia in the Sinhalese. The population 
genetic results show considerable similarity between allele/haplotype 
frequencies of the Sri Lankan racial groups and considerable variation 
between them and the white Caucasians. The EGF gene was associated with 
pre-eclampsia in the Sinhalese and with the weight of babies at birth in both 
the Sinhalese and the white Caucasians. The TGFA, ANG and MTHFR genes 
were not associated with either pre-eclampsia or any quantitative trait. The 
angiotensinogen reporter gene expression studies revealed the possible 
existence of a repressor element in the 3 untranslated region of the 
angiotensinogen gene, but this finding needs confirmation by further 
investigations.  
 xii 
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1. INTRODUCTION 
The development, in the later half of pregnancy, of new-onset hypertension 
and proteinuria that resolves postpartum  pre-eclampsia  is a potentially life 
threatening condition. It appears to be a disease unique to human pregnancies. 
It is an enigmatic condition because in spite of rigorous investigation, the 
underlying aetiology remains obscure. This thesis describes new investigations 
into the aetiology of pre-eclampsia using molecular genetic and 
epidemiological methods in the Sinhalese in the Sri Lankan population and 
attempts at replicating the results in the white Caucasians in Nottingham, UK. 
 
This introductory chapter is intended to serve several purposes. It begins by 
highlighting the significant health related implications of pre-eclampsia and 
the challenges faced by clinicians in diagnosing the condition. In doing so 
reference will be made to relevant Sri Lankan scientific literature that may not 
be widely available. Copies of these are provided in a separate folder bound to 
the back cover of this thesis. The second section of this introduction is on the 
investigation of genetic factors involved in pre-eclampsia. It examines the 
evidence for a genetic basis for pre-eclampsia, the evidence for the possible 
location of pre-eclampsia susceptibility gene(s), and the approaches and the 
future directions such investigations may take. The third section is on the 
pathophysiology of the disease. It briefly surveys the evidence for the widely 
accepted two-stage hypothesis on the pathogenesis of pre-eclampsia and 
concludes by identifying two novel candidate genes (EGF and TGFA) that 
 2 
have not been examined before in any population and two more candidate 
genes from among those that have already been studied that require further 
evaluation in the light of this hypothesis. The next four sections are devoted to 
each candidate gene. In each section a survey will be made of the available 
data on the genomic structure, the regulation of the gene as far as it is relevant 
to these investigations, and the functional effects of the protein encoded by the 
gene. Each section concludes by identifying genetic markers within or near the 
candidate gene that have been selected for the investigations described in this 
thesis. This chapter concludes with a statement of the hypothesis and the 
objectives of this thesis.  
 
The second chapter is on methods. It describes the validation of the urine 
protein heat coagulation test (HCT) that was central to the establishment of the 
diagnosis of pre-eclampsia in Sri Lanka; recruitment of subjects and 
phenotyping; generic molecular biology methods; specific genotyping and 
functional assays used for these investigations and statistical methods. Results 
are reported in the third chapter. The fourth chapter is a discussion of the 
results. The final chapter summarises the conclusions of this thesis. 
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1.1. The burden of hypertensive disorders of pregnancy 
Pre-eclampsia is a major medical problem in pregnancy throughout the world. 
To appreciate the burden of this problem, however, it has to be considered in 
the wider context of the spectrum of hypertensive disorders of pregnancy: 
Gestational Hypertension (GH), Pre-Eclampsia (PE), a majority of cases of 
Eclampsia (E) and HELLP Syndrome (Haemolysis, Elevated Liver enzymes, 
Low Platelet count in association with hypertension). Gestational hypertension 
is the occurrence of de novo hypertension in pregnancy. Pre-eclampsia is the 
occurrence of significant proteinuria in addition to de novo hypertension (see 
section 1.2.1). Eclampsia is the occurrence of generalised convulsions during 
pregnancy, labour, or within seven days of delivery which is not caused by 
epilepsy or other convulsive disorders. The HELLP syndrome, the definition 
of which may vary slightly from country to country, is usually indicated by the 
presence of an abnormal peripheral blood smear, with schistocytes and/or burr 
cells; serum lactate dehydrogenase, bilirubin, and transaminase more than 
twice the upper limit of normal, and platelet count less than 100x109/L. 
 
1.1.1. Incidence of hypertensive disorders of pregnancy 
There are many reports on the occurrence of hypertensive disorders of 
pregnancy in different parts of the world. Very few of these, however, could 
be used to estimate their incidence with any degree of reliability and an even 
smaller number could be used for comparison. The reported incidence shows 
great variation. This may be attributable to differences in definition, 
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population composition, demographic and obstetric characteristics, actual 
disease incidence, or access to and availability of antenatal care services 
(World Health Organisation, 1987). A population based international 
collaborative study designed to control for these factors found that clinically 
recognised hypertension during pregnancy varied by a factor of 25 (Incidence 
range 1.2% to 31.0%) between countries. Even using a strict definition of 
proteinuric hypertension, the incidence varied by a factor of five (Incidence 
range 1.5% to 8.3%) (World Health Organisation, 1988).  
 
In the only Sri Lankan study of its kind hypertensive disorders of pregnancy 
have been reported to occur in 4.9% of pregnancies delivering in a tertiary 
care hospital (Jayawardana and Fernando, 1995). This study and another from 
the same hospital (Jayawardana, 1994), report the proportion of hypertensive 
women having pre-eclampsia (43.4% and 46.5% respectively) as being not 
much less than that of gestational hypertension (51.1% and 53.4% 
respectively). In another Sri Lankan study proteinuria defined as >2 g/L was 
present in 37.2% of patients with hypertension in pregnancy (Jegasothy, 
Thayalasekaran and Sivasuriya, 1983). This definition of proteinuria is much 
more rigorous than the currently accepted definition for significant proteinuria 
in pregnancy of ≥0.5g/L. Even so, in the West, proteinuria is usually reported 
to occur in only one-fifth or less of women with de novo hypertension in 
pregnancy (Zhang, Meikle and Trumble, 2003). It is possible therefore, that 
Sri Lankan women who develop de novo hypertension in pregnancy may go 
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on to develop the more severe form of the disease spectrum  pre-eclampsia  
than do women in the West. This may perhaps be explained if Sri Lankan 
women were to have lower blood pressure levels prior to pregnancy than do 
women in the West, because then they may be expected to have developed 
severe disease by the time their blood pressure reached the diagnostic 
threshold, which is of course a Western definition. This possibility is 
examined in the analysis of the pre-eclampsia phenotype in section 3.1.3. 
 
Similar observations can be made with respect to eclampsia. Eclampsia has 
been reported to occur in 0.28% of pregnancies in Peradeniya in Central Sri 
Lanka (Jayawardana
 et al., 1995), 0.38% of pregnancies in Galle in Southern 
Sri Lanka (Goonewardene and Sirisena, 1984-85), and 0.66% of pregnancies 
in Jaffna in Northern Sri Lanka (Jegasothy
 et al., 1983). This is many times 
more than that in the United Kingdom (0.049%: Douglas and Redman, 1994), 
United States of America (0.056%: Saftlas, Olson, Franks, Atrash and Pokras, 
1990, 0.1%: Zhang
 et al., 2003), and Finland (0.024%: Ekholm, Salmi and 
Erkkola, 1999).  
 
1.1.2. Morbidity and mortality associated with hypertensive disorders of 
pregnancy 
In the developed world, the syndrome of pre-eclampsia and eclampsia is one 
of the two most common causes of maternal mortality (The National Institute 
for Clinical Excellence, The Scottish Executive Health Department and The 
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Department of Health Social Services and Public Safety Northern Ireland, 
2001). However, it is the developing world, where pre-eclampsia is the third 
commonest cause of maternal death behind haemorrhage and infection (World 
Health Organisation, 1999), that accounts for the overwhelming majority of 
the estimated 50 000 annual maternal deaths from hypertensive disorders of 
pregnancy. In Africa, Latin America, and the Caribbean, pre-eclampsia and 
eclampsia is estimated to account for 20-25% of maternal deaths (Duley, 
1992).  
 
Sri Lanka stands out in the developing world as a country that has made vast 
strides in improving maternal health. The overall maternal mortality rate in Sri 
Lanka in 1995 was 2.4 per 10 000 deliveries compared with 15 per 10 000 
deliveries in 1970 (Seneviratne and Rajapaksa, 2000). Hypertensive disorders 
of pregnancy accounted for 10.3% of maternal deaths in 1997 (Family Health 
Bureau, 1998). This, however, does not mean that severe maternal morbidity 
associated with hypertensive disorders of pregnancy is any less than has been 
reported in other parts of the world (Zhang
 et al., 2003) as evidenced by the 
analysis of the pre-eclampsia phenotype in Sri Lankan women recruited for 
the investigations described in this thesis (see section 3.1). 
 
Since the cure for pre-eclampsia is delivery there is also a considerably 
increased morbidity and mortality from iatrogenic prematurity. In one Sri 
Lankan study as many as 34% of infants born of pregnancies complicated by 
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pre-eclampsia required special care (Jayawardana, 1994). Perinatal mortality 
rates (PNMR) in pregnancies complicated by pre-eclampsia are low in the 
West where it is reported to be less than 5% (Baldwin, Leighton, Kilby, 
Wyldes, Churchill
 et al., 2001, Zhang et al., 2003). In comparison, perinatal 
mortality rates of 17% (Jegasothy
 et al., 1983), 14.8% (Goonewardene and 
Kularatna, 1992),  23.2% (Jayawardana, 1994), and 24.1% (Jayawardana
 et 
al., 1995) have been reported in Sri Lankan studies. 
 
1.1.3. Recurrence of pre-eclampsia in subsequent pregnancies 
The repeated occurrence of pre-eclampsia or gestational hypertension in 
several pregnancies of the same woman is not a rare event. The recurrence of 
pre-eclampsia or gestational hypertension in subsequent pregnancies in some 
studies has been as high as 50% (Chesley, 1980, Campbell, MacGillivray and 
Carr-Hill, 1985, Sibai, el-Nazer and Gonzalez-Ruiz, 1986, Sibai, Mercer and 
Sarinoglu, 1991, Makkonen, Heinonen and Kirkinen, 2000, Zhang, Troendle 
and Levine, 2001). Some retrospective studies estimating the recurrence risks 
of pre-eclampsia, however, may not give the true picture, as they have not 
been able to verify the diagnosis by examining case notes since strict criteria 
may not have been applied to diagnose the condition in the past. Indeed in 
some studies, including that of long term studies by Chesley and colleagues 
(Chesley, Annitto and Cosgrove, 1976, Chesley, 1980), eclampsia has been 
used as a surrogate for the diagnosis of pre-eclampsia as the former was likely 
to be more accurate. 
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A previous normal pregnancy, and to some extent even a previous abortion, is 
associated with a markedly lowered incidence of pre-eclampsia (Dekker, 
Robillard and Hulsey, 1998). The protective effect of multiparity is lost, 
however, with a change of partner (Robillard, Hulsey, Alexander, Keenan, de 
Caunes
 et al., 1993, Trupin, Simon and Eskenazi, 1996, Dekker, Tubbergen, 
Valk, Althuisius and Lachmeijer, 1998). Robillard and colleagues coined the 
word primipaternity to describe this phenomenon, suggesting that pre-
eclampsia might be a problem of primipaternity rather than primigravidity 
because the patterns of changing paternity were significantly correlated with 
pre-eclampsia in multiparae (Robillard, Dekker and Hulsey, 1999). 
 
In contrast to these findings, two groups who analysed the data from the 
Medical Birth Registry of Norway covering all births in that country from 
1967 to 1998 independent of each other concluded that a change of partner 
may in fact decrease the risk of pre-eclampsia in a subsequent pregnancy 
(Trogstad, Eskild, Magnus, Samuelsen and Nesheim, 2001, Skjaerven, Wilcox 
and Lie, 2002). This casts a strong element of doubt on the entire concept of 
primipaternity.  In both these studies the risk of pre-eclampsia was shown to 
increase as the interval between pregnancies became longer. Skjaerven et al. 
(2002) report that this increased risk applies to all women, but Trogstad et al. 
(2001) report that it applies only to women who were normotensive in their 
first pregnancy and observed that the risk of pre-eclampsia for women who 
have had pre-eclampsia in their first pregnancies reduced with longer inter 
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pregnancy intervals. However, these registry based epidemiological studies are 
prone to error. Firstly the paternity recorded in such registers may not be 
accurate since it is well known that there is a significant rate (5-20%) of false 
claimed paternities in stable couples in developed countries (Macintyre and 
Sooman, 1991, Lucassen and Parker, 2001). Secondly early terminations of 
pregnancies may not be recorded in Medical Birth Registers and as such 
pregnancies taken as first and second may not actually be the first and second 
pregnancies of a woman. Finally there may not be adequate data to confirm 
that the diagnosis of pre-eclampsia was based on uniform criteria in all cases 
over the years. 
 
1.1.4. Long term sequelae of pre-eclampsia 
Chesley, Annitto and Cosgrove (1976) who followed up a group of women 
with eclampsia delivering in the period 1931 through 1951, upto1973-74 were 
the first to provide definitive data on the possible long term sequelae of 
eclampsia. They did not find an excess rate of hypertension or an increase in 
cardiovascular morbidity or mortality in general in women who had eclampsia 
only in their first pregnancy. Women who had eclampsia as multiparae, 
however, had a greater incidence of hypertension as well as higher death rates 
from all causes, specifically cardiovascular disease later in life. Fisher and 
colleagues (1981) reported similar results in a group of women with pre-
eclampsia. They also showed that an age and race matched group of women 
who were normotensive during pregnancy were at a significantly lower risk of 
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developing hypertension later in life than the population at large. These 
findings suggested that pre-eclampsia/eclampsia in second or subsequent 
pregnancy may unmask hypertension in women who are destined to have 
chronic hypertension later in life and that they are at greater risk of these 
complications than women in the population at large.  
 
Some of these early findings, however, are in conflict with more recent data 
(Sibai
 et al., 1986, Marin, Gorostidi, Portal, Sanchez, Sanchez et al., 2000). 
There seems to be agreement on the finding that women who have 
normotensive pregnancies are at a lower risk of long-term hypertension than 
the general female population of a similar age. Women who develop pre-
eclampsia in their first pregnancy, however, seem to be at a higher risk of 
hypertension later in life and women who have pre-eclampsia/eclampsia in 
more than one pregnancy are at still greater risk (Sibai
 et al., 1986, Marin et 
al., 2000). Although Marin et al. (2000) reported, in agreement with Chesley 
et al. (1976), that eclampsia is not associated with a greater risk of long-term 
hypertension, they had studied only 14 women with eclampsia. The long-term 
neurological effects of women with eclampsia have also been subjected to 
investigation. It appears that acute manifestations are transient and that long 
term effects are rare (Sibai, Spinnato, Watson, Lewis and Anderson, 1985). 
There are no studies on the long-term sequelae of Sri Lankan women who 
develop pre-eclampsia. 
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In contrast to the controversy surrounding long-term risk of hypertension, data 
on the long-term risk of ischaemic heart disease (IHD) are more consistent. It 
has been found that women who have eclampsia or pre-eclampsia are at a 
greater risk of death from IHD than are women with normal pregnancies or 
women in the reference population (Jonsdottir, Arngrimsson, Geirsson, 
Sigvaldason and Sigfusson, 1995, Hannaford, Ferry and Hirsch, 1997). In a 
Norwegian cohort study women with pre-eclampsia who delivered pre-term 
were eight times more likely to die from IHD than women who had gestational 
hypertension and whose pregnancy went to term (Irgens, Reisaeter, Irgens and 
Lie, 2001). In another study done in Scotland, women with pre-eclampsia who 
delivered a small for gestational age infant were seven times more likely to 
have a hospital admission for IHD or die of IHD (Smith, Pell and Walsh, 
2001). Finally in a study done in the USA, severe pre-eclampsia was 
associated with a three fold increase in risk of cardiovascular disease 
(Kestenbaum, Seliger, Easterling, Gillen, Critchlow
 et al., 2003). This 
tendency for IHD later in life may antedate the pre-eclamptic pregnancy rather 
than be exacerbated by it as evidenced, for example, by the sharing of 
common risk factors such as increased body mass index in both conditions.  
  
The emerging picture of pre-eclampsia therefore, is of a life long illness 
(Brown, 2003) that carries a high degree of immediate as well as long term 
sequelae not only from hypertension and IHD, but also from stroke (Wilson, 
Watson, Prescott, Sunderland, Campbell
 et al., 2003) and venous thrombo-
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embolism (van Walraven, Mamdani, Cohn, Katib, Walker
 et al., 2003). As 
such, greater understanding of the aetiology of pre-eclampsia is vital to 
develop meaningful interventions to care for women who develop the 
condition. It can only be achieved by conducting research on volunteers 
affected with pre-eclampsia selected after carefully phenotyping the condition 
on the basis of strict research diagnostic criteria. 
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1.2. The diagnosis of pre-eclampsia  
Pre-eclampsia/eclampsia has its share of history and antiquity. The following 
short account of which is based on reviews by Thiagarajha (1943) and Chesley 
(1984).  
 
The pre-Hippocratic Kahun Papyrus from Egypt dating back almost 3000 
years alluded to eclampsia. Ancient Greeks also recognized pre-eclampsia: In 
pregnancy, the onset of drowsy headaches with heaviness is bad; such cases 
are perhaps liable to some sort of fits at the same time. There seems to be no 
mention of the condition, however, in any of the authenticated writings of 
Hippocrates, but Galens commentaries on Hippocrates aphorisms suggest 
that he knew of the violent manifestations in pregnancy. Similarly there is no 
mention of it in the writings of Susrutha the great Indian physician in the sixth 
century BC. In the tenth century AD, a famous monastic physician St. Gall 
had a trick played on him. It seems that he was about to examine the Duke of 
Bavaria and, as a trick the worthy nobleman substituted for his urine that of a 
woman who was pregnant. The priest after making his examination made the 
solemn announcement that the Duke would give birth to a child. This incident 
is perhaps the earliest record of recognition of proteinuria in pregnancy, albeit 
somewhat indirect.  
 
Scientific writing on pre-eclampsia/eclampsia really begins in the seventeenth 
century. Mauriceau, Barton, and Blundell all recognized the symptoms of pre-
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eclampsia. In 1840, Rayer observed proteinuria in three oedematous pregnant 
women. It was Lever and Simpson, however, who discovered proteinuria in 
eclampsia independently of each other in 1843. The hard bounding pulse of 
women with eclampsia had suggested arterial hypertension to the old time 
clinicians. Vinay, in 1884, used a primitive sphygmomanometer and found 
blood pressures ranging from 160 to 200 mmHg in pregnant proteinuric 
women; pressures up to 160 mmHg were said to be normal as estimated by his 
instrument. The discovery of eclamptic hypertension is generally credited to 
Vaquez and Nobecourt in 1897, but they remarked that they had confirmed 
Vinays observation. 
 
1.2.1. The definition 
The definition of pre-eclampsia has been the subject of much debate. Greater 
appreciation of the underlying pathophysiological changes of the disease, 
however, has enabled different expert groups working independently of each 
other to arrive at almost uniform criteria for its definition reflecting the known 
pathophysiology of the disorder (Brown, Hague, Higgins, Lowe, McCowan
 et 
al., 2000, National High Blood Pressure Education Program Working Group, 
2000). 
 
The International Society for the Study of Hypertension in Pregnancy (ISSHP) 
defines pre-eclampsia for research purposes as de novo hypertension (systolic 
blood pressure (SBP) ≥140 mmHg and diastolic blood pressure (DBP) ≥90 
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mmHg) after 20 weeks of gestation in a previously normotensive pregnant 
woman, which returns to normal by the end of the third month postpartum, 
together with properly documented proteinuria (≥300 mg in a 24 hour 
collection or ≥500mg/L on a spot urine collection or ≥30 mg protein/mmol 
creatinine in a spot urine collection or, failing other measurement, ≥1+ on 
dipstick testing) not associated with urinary tract infection or ruptured 
membranes (Brown, Lindheimer, de Swiet, Van Assche and Moutquin, 2001). 
The presence of oedema, which was used in the past as a necessary feature of 
the diagnosis of pre-eclampsia, has now been dropped from both clinical and 
research definitions because it is not specific to the condition. 
 
1.2.2. The differential diagnosis of pre-eclampsia 
The appearance of hypertension and proteinuria for the first time in pregnancy 
clearly presents a diagnostic dilemma. It may be pre-eclampsia per se; it may 
be a long term problem antedating pregnancy which may or may not have 
been aggravated during pregnancy; rarely, it may be a previously undiagnosed 
medical problem such as phaeochromocytoma (Schenker and Chowers, 1971) 
by chance coinciding with pregnancy; or much more rarely it may be a 
pregnancy specific condition such as hydatidiform mole (Page, 1939, Newman 
and Eddy, 1988) or Ballantyne syndrome (Carbillon, Oury, Guerin, Azancot 
and Blot, 1997) presenting as pre-eclampsia.  
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1.2.2.1. Hypertension 
Hypertension is a sine qua non of pre-eclampsia. It is also a common medical 
problem independent of pregnancy. Women with chronic hypertension and/or 
renal disease are three to seven times more likely to develop superimposed 
further hypertension and proteinuria in pregnancy (Chesley, 1980). In a 
population study of over a million people in America, 4.9% of women under 
the age of 40 years were hypertensive and among them the condition was 
previously undiagnosed in 39.7% (Stamler, Stamler, Riedlinger, Algera and 
Roberts, 1976). In England and Wales the prevalence of treated hypertension 
in women under the age of 44 years was 2.38% (Ryan and Majeed, 1999). In a 
Sri Lankan study, 13% of 2047 women aged between 20 to 40 years had a 
diastolic blood pressure of >90mmHg (Mendis, Ranasinghe and Dharmasena, 
1988). Data on variation of the prevalence of hypertension over time is scarce. 
In a small study of blood pressure and other cardiovascular parameters in 806 
adult women of Northern Sweden over the period 1986 to 1999, the 
prevalence of hypertension in those between the ages of 20 to 44 years ranged 
from 4.3% to 2.3% (Jansson, Boman and Messner, 2003). The number of 
women in this age group, however, is too small to draw broad conclusions 
from this data. 
 
Often the obstetrician is the only physician consulted by women during their 
reproductive years. As such, records of blood pressure measurements prior to 
pregnancy, a sure way of excluding chronic hypertension, are often not 
 17 
available. Records of normal blood pressure during early pregnancy may mask 
chronic hypertension due to the effect of the normal physiological reduction in 
blood pressure in the first half of pregnancy (MacGillivray, Rose and Rowe, 
1969, Ayala, Hermida, Mojon, Fernandez, Silva
 et al., 1997). In addition 
many women with chronic hypertension have an even greater physiological 
fall in blood pressure during the first half of pregnancy than do normotensive 
women (Sibai, Abdella and Anderson, 1983). Women with chronic 
hypertension therefore, may appear normotensive when they start antenatal 
care and then may show an increase in blood pressure in the third trimester 
resembling pre-eclampsia. Hypertension occurring before 20 weeks of 
pregnancy, however, is almost certainly chronic hypertension. It is usually 
essential hypertension with no identified underlying pathology (Sibai, 2002). 
Pre-eclampsia per se before 20 weeks of gestation has been described only in a 
handful of cases (Hazra, Waugh and Bosio, 2003). 
 
The only sure way of excluding chronic hypertension, in the absence of pre-
pregnancy blood pressure records, is to confirm its resolution postpartum. 
Davey and MacGillivray (1988) recommended the use of the traditional cut-
off of resolution of blood pressure within six weeks to confirm the diagnosis 
of pre-eclampsia. This recommendation was probably based on practicality 
rather than on scientific evidence since six weeks is the conventional time for 
the postnatal check-up in the UK. In more recent recommendations this period 
has been extended to three months (Brown
 et al., 2001). There is concern, 
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however, as to whether insisting on postpartum blood pressure normalisation 
would misclassify women with pre-eclampsia who may have developed 
chronic hypertension secondary to irreversible vascular damage caused by the 
pre-eclamptic state. If this were so, women who develop pre-eclampsia early 
in pregnancy, and are as a result more likely to have a prolonged illness with 
greater vascular damage; and women who have recurrent pre-eclampsia, 
resulting in repeated vascular damage, would be expected to take longer to 
normalise their blood pressure postpartum and/or develop chronic 
hypertension later in life. Several groups have reported such observations 
(Chesley
 et al., 1976, Sibai et al., 1986, Ferrazzani, De Carolis, Pomini, Testa, 
Mastromarino
 et al., 1994). It is difficult to determine how much time is 
adequate for normalisation of blood pressure due to the scarcity of systematic 
data on blood pressure in the immediate postpartum period. It is most likely, 
however, that the earlier recommendation that blood pressure should resolve 
by six weeks postpartum to confirm the diagnosis was not appropriate 
(Ferrazzani
 et al., 1994). It is also likely that there will also be a subgroup that 
will still be unnecessarily on antihypertensive therapy at this time. 
 
Blood pressure measurement is routine in antenatal care, but it is necessary to 
ensure that a standardised method is practised in pregnancy (Brown
 et al., 
2001). One area of controversy is the measurement of diastolic blood pressure 
(Higgins and de Swiet, 2001). The current ISSHP recommendation is to use 
Korotkoff phase V (K5) (sound disappearance) to record the diastolic blood 
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pressure, and to use Korotkoff phase IV (K4) (muffling) only when the sound 
does not disappear (Brown
 et al., 2001) because K5 is detected more reliably 
than K4 during pregnancy (Blank, Helseth, Pickering, West and August, 1994, 
Shennan, Gupta, Halligan, Taylor and de Swiet, 1996), because K5 reflects the 
true diastolic pressure in pregnancy than K4 (Brown, Reiter, Smith, Buddle, 
Morris
 et al., 1994), and because the change from K4 to K5 in hypertensive 
pregnant women does not alter the figures for the incidence of morbidity for 
the mother or the baby (Brown, Buddle, Farrell, Davis and Jones, 1998). 
 
1.2.2.2. Proteinuria 
De novo proteinuria is the second feature of the diagnosis of pre-eclampsia. A 
distinct renal lesion, glomerular endotheliosis, has been described and widely 
accepted as pathognomonic of pre-eclampsia (Spargo, Mc Cartney and 
Winemiller, 1959). It resolves postpartum. The severity of proteinuria in pre-
eclampsia correlates positively with the extent and the severity of the 
endothelial changes seen in the glomerulus (Fisher
 et al., 1981). Glomerular 
changes similar to that of pre-eclampsia, however, have also been reported in 
women with pregnancies complicated by hypertension alone. Moreover, in an 
ethically highly controversial study, control renal biopsies of normal pregnant 
women also show such changes, albeit of a milder degree (Strevens, Wide-
Swensson, Hansen, Horn, Ingemarsson
 et al., 2003). These observations 
suggest that it is possible that the severe glomerular changes seen in pre-
eclampsia may be one extreme of the adaptation process in pregnancy rather 
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than an abnormal condition specific to pre-eclampsia.  
 
In one of the early studies, glomerular endotheliosis was present in renal 
biopsies of 70% of primiparous women and 14% of multiparous women with 
pre-eclampsia diagnosed on the basis of de novo hypertension and proteinuria 
(McCartney, 1964). In another study renal biopsies of 84% of primiparous 
women with pre-eclampsia and 24% of multiparous women had glomerular 
endotheliosis (Fisher
 et al., 1981). These observations together with the 
observations on the prognostic significance of parity to the development of 
hypertension later in life (Chesley
 et al., 1976); and the reported impact of 
parity on the clinical presentation and on fetal growth and development 
(Gleicher, Boler, Norusis and Del Granado, 1986) are the basis for the widely 
accepted view that genetic studies of pre-eclampsia should be confined to 
primigravid women (Higgins
 et al., 2001). However, women in their second 
pregnancy who have experienced an early first trimester abortion in their first 
pregnancy could also be included in such studies as their uterine morphology 
essentially resembles that of primigravid women. In fact the risk of developing 
pre-eclampsia in nulliparous women with a previous abortion who conceive 
again with the same partner is half that of nulliparous women who do not have 
such a history (Saftlas, Levine, Klebanoff, Martz, Ewell
 et al., 2003). 
 
Renal protein excretion increases in normal pregnancy, and may reach levels 
of up to 300mg day in the third trimester of a normal pregnancy (Davison, 
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1985, Higby, Suiter, Phelps, Siler-Khodr and Langer, 1994). Proteinuria in 
excess of 300mg/day is extremely rare in uncomplicated pregnancies (Higby
 
et al., 1994, Waugh, Bell, Kilby, Lambert, Blackwell et al., 2003) and is 
usually associated with pre-eclampsia or renal disease. Rapid and reliable 
detection of significant proteinuria has always posed a challenge in clinical 
settings. Quantitative tests for proteinuria, although available in routine 
clinical practice in the West, are not widely available even in the best of 
centres in the developing world. What is available is the urine protein heat 
coagulation test (HCT) (Guidotti and Jobson, 1992). It is most often the only 
test available. The cut-off point for detecting significant proteinuria with the 
HCT, however, seems not to have been formally established. 
 
Pre-eclampsia is the most common cause of gross proteinuria in pregnancy.  
Other renal diseases that may give rise to a similar clinical picture, the 
diagnosis of which rely on a renal biopsy, include proliferative or 
membranoproliferative glomerulonephritis, minimal change nephrosis, lupus 
nephropathy, hereditary nephritis, diabetic nephropathy, renal vein 
thrombosis, and amyloidosis (Davison and Baylis, 1998). Non-glomerular 
renal disease such as reflux nephropathy and polycystic kidney disease can 
also give rise to significant proteinuria (Ihle, Long and Oats, 1987). A renal 
biopsy, however, is almost never indicated to resolve the differential diagnosis 
of de novo proteinuria in pregnancy (Lindheimer and Davison, 1987).  
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1.3. Investigating the genetics of pre-eclampsia 
1.3.1. Evidence for a genetic basis for pre-eclampsia 
Pre-eclampsia most certainly has a genetic basis because it occurs across the 
globe in all environmental conditions and because it runs in families (Adams 
and Finlayson, 1961, Chesley, Cosgrove and Annitto, 1961, 1962, Chesley, 
Annitto and Cosgrove, 1968, Sutherland, Cooper, Howie, Liston and 
MacGillivray, 1981, Arngrimsson, Bjornsson, Geirsson, Bjornsson, Walker
 et 
al., 1990, Lie, Rasmussen, Brunborg, Gjessing, Lie-Nielsen et al., 1998, 
Mogren, Hogberg, Winkvist and Stenlund, 1999, Esplin, Fausett, Fraser, 
Kerber, Mineau
 et al., 2001, Dawson, Parfrey, Hefferton, Dicks, Cooper et al., 
2002). Pre-eclampsia is nearly two and a half times more common in 
daughters of women with pre-eclampsia than in their daughters in law 
(Arngrimsson
 et al., 1990); twice as frequent in pregnancies fathered by men 
who are themselves the product of pregnancies complicated by pre-eclampsia 
compared to pregnancies fathered by men who were born of normotensive 
pregnancies (Esplin
 et al., 2001); and more frequent in pregnancies fathered 
by men who have previously fathered a pregnancy complicated by pre-
eclampsia in another woman compared to pregnancies in women whose 
partner does not have such a history (Lie
 et al., 1998).  
 
Several twin studies have examined the occurrence of pre-eclampsia in 
pregnancies of twins. The early studies were disappointing as they reported 
discordance for pre-eclampsia in pregnancies of monozygotic twins (MZ) 
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(Thornton and Onwude, 1991, Thornton and Macdonald, 1999, Treloar, 
Cooper, Brennecke, Grehan and Martin, 2001) These studies, however, lacked 
true population representation because they were based on volunteer twin 
registers and their sample size did not have sufficient power to arrive at 
definite conclusions. In contrast, in a recent population based study of 2116 
(917 MZ and 1119 dizygotic (DZ)) twin pairs in Sweden, pair wise 
concordance rates of 0.25 and 0.06 for pre-eclampsia were found in MZ and 
DZ twin pairs respectively. Furthermore, the estimates for heritability 
(influence of maternal genes) and non-shared environmental effect (including 
influence of fetal/paternal genes) were 0.54 and 0.46 respectively (Salone Ros, 
Lichtenstein, Lipworth and Cnattingius, 2000).  
 
1.3.2. Inheritance of pre-eclampsia 
The analysis of the mode of inheritance of pre-eclampsia, which does not 
show a clear pattern of inheritance, is made difficult by the nature of the 
condition itself  it is sex-limited and it occurs only during pregnancy. In 
addition susceptibility to pre-eclampsia could be controlled by the maternal 
genotype alone, or the fetal genotype alone, or by an interaction of the 
genotypes of the mother and her fetus.  Some of the fetal genes of course 
would be paternally derived. 
 
In one of the first attempts to answer this question, Cooper and Liston (1979) 
re-examined the data collected and previously reported by Chesley and 
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colleagues (Chesley
 et al., 1962, Chesley et al., 1968). The incidence of 
eclampsia in the sisters, daughters, and sisters in law of women with eclampsia 
proved to fit closely with homozygosity for a maternal recessive gene. When 
they extended their analysis to a further set of data from Aberdeen, however, 
they found instead evidence for the fetal-genotype hypothesis, as there was a 
significant deficit of eclampsia among sisters of affected women. In the 
absence of information about the patients in-laws in the latter group it was not 
possible for them to come to a final conclusion. The case for a single recessive 
gene acting on the mother was further strengthened by an analysis of data 
which compared the frequency of pre-eclampsia in mothers versus mothers in 
law of pre-eclamptic index cases (Sutherland
 et al., 1981) and in daughters 
versus daughters in law of eclamptic index cases (Chesley and Cooper, 1986) 
which showed that the maternal genotype alone is mainly responsible for 
susceptibility to pre-eclampsia. Both studies, however, could not rule out the 
possibility of multifactorial inheritance. Later the latter group modified their 
hypothesis to include the fetal genotype, and argued that the primary mode of 
action of the gene(s) involved is to affect the interaction between uterine and 
placental tissue (Cooper, Hill, Chesley and Bryans, 1988). They were 
supported by Liston and Kilpatrick (1991) who examined six simple 
Mendelian models of inheritance and rejected all except the one in which both 
the mother and the fetus expressed the same recessive gene to confer 
susceptibility. Arngrimsson and colleagues also supported the single maternal 
recessive gene hypothesis, however, their data could also fit a model of 
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dominant inheritance with incomplete penetrance (Arngrimsson
 et al., 1990). 
They analysed their data further on four models of Mendelian inheritance and 
concluded that a major maternal dominant gene model with reduced 
penetrance, or multifactorial inheritance (including the possible influence of 
fetal/paternal genes) could fit their data best (Arngrimsson, Bjornsson and 
Geirsson, 1995) .  
 
In practice, in the absence of any molecular or biochemical methods for carrier 
detection, it would be very difficult to prove that pre-eclampsia shows 
autosomal recessive inheritance. A high degree of parental consanguinity in 
association with pre-eclampsia, however, would provide strong supportive 
evidence for autosomal recessive inheritance. The available data on 
consanguinity and pre-eclampsia does not support such an association 
(Stevenson, Say, Ustaoglu and Durmus, 1976). Interestingly consanguineous 
marriages are favoured by at least 20% of the world population. It is widely 
practised in many parts of Asia, Middle East, Northern Africa, and South 
America. Prevalence in other parts of the world is believed to be low. 
Worldwide, it is estimated that at least 8.4% of children have related parents 
(World Health Organisation, 1996). Two Sri Lanka studies report 
consanguinity rates of 16% (Corea, 1982) and 10% (De Silva, 1998). While 
investigating the association of pre-eclampsia with consanguinity may be 
difficult in most parts of the world due to its rarity, proving such an 
association in parts of the world where consanguinity is common is made 
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difficult by the fact that some degree of consanguinity is the norm in many 
marriages. 
 
Apart from Mendelian modes of inheritance, it has also been proposed that 
pre-eclampsia could be caused by a mutated mitochondrial gene transmitted 
by the mother (mitochondrial inheritance) (Torbergsen, Oian, Mathiesen and 
Borud, 1989) or a mutation in a paternally imprinted, maternally active gene 
expressed by the fetus (genetic imprinting) (Graves, 1998). Li and colleagues, 
however, ruled out the possibility of mitochondrial inheritance as a common 
cause of pre-eclampsia because they found a similar risk for pre-eclampsia 
among maternal and paternal half sisters, when in fact they should have found 
a higher risk in the former group if pre-eclampsia were caused by a mutated 
mitochondrial gene (Lie
 et al., 1998).  
 
Pre-eclampsia therefore, like most other common disorders that are not 
inherited in a Mendelian fashion, is almost certainly a complex disorder 
involving both genetic and non-genetic/environmental factors.  
 
1.3.3. Pre-eclampsia genes 
1.3.3.1. Problems in identifying pre-eclampsia genes 
Research aimed at identifying genes contributing towards the risk of complex 
disorders are complicated by several major problems that are centred on 
phenotyping, genetic heterogeneity, reduced penetrance, and phenocopy. 
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Problems of phenotyping in pre-eclampsia, where the diagnostic signs of de 
novo hypertension and proteinuria depend on arbitrary cut off points on a 
continuous distribution of values, have already been discussed in previous 
sections. Furthermore, the severity of the disorder as well as the involvement 
of various organs is highly variable and the expression of the original 
phenotype is masked by medical care. Genetic heterogeneity refers to a 
situation where alleles at more than one locus can individually trigger the 
disease. Reduced penetrance results in an individual with a predisposing 
genotype not expressing the phenotype. In contrast, phenocopy refers to a 
situation where the disease is triggered by environmental factors in the 
absence of a predisposing genotype, as may be the case with pre-eclampsia 
occurring in women with chronic hypertension who develop gestational 
hypertension and on top of it proteinuria due to a urinary tract infection. Thus 
we may expect to encounter situations where a predisposing genotype does not 
result in the disease and, conversely, where the disease occurs without the 
predisposing genotype. This would make the correlation between genotype 
and the disease phenotype more difficult to establish. Furthermore, genetic 
heterogeneity also means that a gene implicated in the disease may be 
correctly identified in one population, but it may not be replicated in another 
(Lander and Schork, 1994).  
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1.3.3.2. Approaches to identifying pre-eclampsia genes and the current 
state of knowledge 
Linkage and association analysis, complementary methods of gene detection, 
are the two main approaches used to detect specific chromosome regions (loci) 
and genes that are involved in complex disorders such as pre-eclampsia (Risch 
and Merikangas, 1996). A third approach, which could be used in the not so 
distant future, would involve testing for association across the genome using a 
very dense map of markers (linkage disequilibrium genome screen).  
 
Linkage Analysis 
Many early linkage studies into pre-eclampsia that concentrated on candidate 
loci did not find linkage to any of the loci tested (Wilton, Cooper, Brennecke, 
Bishop and Marshall, 1990, Wilton, Barendse, Donald, Marshall, Trudinger
 et 
al., 1991, Arngrimsson, Geirsson, Cooke, Connor, Bjornsson et al., 1994, 
Wilton, Kaye, Guo, Brennecke and Cooper, 1995). Arngrimsson and 
colleagues found linkage to both the angiotensinogen gene on chromosome 
1q42-43 (Arngrimsson, Purandare, Connor, Walker, Bjornsson
 et al., 1993) 
and to the NOS3 gene on chromosome 7q36 encoding endothelial nitric oxide 
synthase (Arngrimsson, Hayward, Nadaud, Baldursdottir, Walker
 et al., 1997). 
Others, however, could not confirm the latter finding (Guo, Lade, Wilton, 
Moses, Grehan
 et al., 1999, Lade, Moses, Guo, Wilton, Grehan et al., 1999, 
Lewis, Lachmeijer, Downing, Dekker, Glazebrook
 et al., 1999).  
Hayward and colleagues investigated linkage across a small fraction of the 
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genome and constructed an exclusion map which indicated that the pre-
eclampsia gene may lie on one of chromosomes 1, 3, or 9; chromosome 18 
was not typed (Hayward, Livingstone, Holloway, Liston and Brock, 1992). 
Similarly, using a small number of marker loci, Harrison and colleagues, 
found evidence of linkage to chromosome 4q (Harrison, Humphrey, Jones, 
Badenhop, Guo
 et al., 1997). As technology advanced, other groups were able 
to search for linkage across the whole genome using large numbers of marker 
loci distributed on all chromosomes. These genome wide scans, when 
interpreted using the criteria suggested by Lander and Kruglyak (1995), 
revealed locations with significant linkage on chromosome 2p13 
(Arngrimsson, Sigurardottir, Frigge, Bjarnadottir, Jonsson
 et al., 1999), 2p25 
and 9p13 (Laivuori, Lahermo, Ollikainen, Widen, Haiva-Mallinen
 et al., 
2003); and locations with suggestive linkage on chromosome 2q, 3p and 15q 
(Arngrimsson
 et al., 1999); 2q23 and 11q23-24 (Moses, Lade, Guo, Wilton, 
Grehan
 et al., 2000); 3p,12q,15q, 10q,11,and 22q (Lachmeijer, Arngrimsson, 
Bastiaans, Frigge, Pals
 et al., 2001); and 4q32 (Laivuori et al., 2003). It has 
been suggested, taking into account the poor precision of estimates of map 
location of disease-predisposing loci for complex disorders, that the two loci 
identified by Arngrimsson et al. (1999) and Moses et al. (2000) represent the 
same location on chromosome 2p13. More support for the presence of a pre-
eclampsia susceptibility locus in this region comes from another report of the 
association between microsatellite marker D2S286, the same significant 
marker reported by Arngrimsson et al. (1999), on 2p13 with pre-eclampsia 
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(Laasanen, Hiltunen, Romppanen, Punnonen, Mannermaa
 et al., 2003). 
Laivuori et al. (2003), however, found what is definitely a separate pre-
eclampsia susceptibility locus on chromosome 2p25. Interestingly the 
statistical significance of the genome-wide scan by Arngrimsson et al. (1999) 
was attributed to two large multicase families. When the data was analysed 
excluding these families there was no linkage to chromosome 2. This 
observation and the poor overlap between these studies, in addition to 
highlighting the statistical contribution of large multicase families to such 
studies, also highlight the possibility of the existence of some families where 
pre-eclampsia may be caused by a major maternal susceptibility gene on 
chromosome 2, while a more complex mode of inheritance may be operative 
in other families.  
 
Association studies 
In contrast to family based linkage studies, association studies are based on 
populations and they search for associations between markers near or within 
known genes thought to be reasonable candidates for disease susceptibility. In 
these studies marker frequencies in unrelated cases and controls are compared.  
 
Selection of a suitable marker for analysis is an important consideration in 
association studies. Over the past few years Single Nucleotide Polymorphisms 
(SNPs) have emerged as the favoured genetic marker for association analysis 
(Gray, Campbell and Spurr, 2000, Schork, Fallin and Lanchbury, 2000). SNPs 
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that are known to be functionally significant based on previous work and/or 
SNPs in which the minor allele occurs relatively commonly (generally at a 
frequency of 5-10% or more), so that a study of adequate power could be 
carried out with a reasonable sample size of several hundred cases and 
controls, are usually chosen as markers for association analysis in common 
diseases such as pre-eclampsia. When available resources only permit the 
assay of a limited number of SNPs, as it usually happens, it seems appropriate 
to give the highest priority to SNPs in coding regions that lead to non-
synonymous and non-conservative variations, as they are most likely to be 
associated with functional effects and phenotypic outcomes; to SNPs in 5 
untranslated regions (UTRs); and to SNPs creating or deleting a splice site 
(Risch, 2000). SNPs selected for association analysis could either be directly 
contributory to the disease phenotype, or may be in linkage disequilibrium 
(LD) with a variation that is contributory. Theoretically, because 
recombination is less likely to occur between SNPs separated by short 
chromosomal distances, SNPs in LD with other SNPs contributory to a disease 
phenotype are expected to be close to each other. In actual fact, however, 
although generally LD decreases as the chromosomal distances increases 
(Salisbury, Pungliya, Choi, Jiang, Sun
 et al., 2003), LD can extend over much 
larger genomic regions than expected, and the patterns of LD differ markedly 
among populations (Reich, Cargill, Bolk, Ireland, Sabeti
 et al., 2001). 
 
When a SNP is in LD with a polymorphism contributing to the disease 
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phenotype, the power to detect an association decreases as the LD between the 
SNP and the disease-predisposing variation becomes weaker. This could be 
overcome by constructing haplotypes using SNPs on the same chromosome 
and testing association with haplotypes. Since haplotype based methods 
incorporate LD information, they are more powerful than methods based on 
single SNPs (Akey, Jin and Xiong, 2001, Zaykin, Westfall, Young, Karnoub, 
Wagner
 et al., 2002). Haplotype based association analysis is also more 
powerful than SNP based methods when multiple disease susceptibility 
variants occur within a gene (Joosten, Toepoel, Mariman and Van Zoelen, 
2001, Morris and Kaplan, 2002). It is best to use the maximally informative 
set of common SNPs (tagSNPs) that contribute to the maximum haplotype 
diversity in the gene or genomic region of interest when carrying out 
haplotype analysis of candidate genes (Huang, Fu and Boerwinkle, 2003). To 
do so information on the LD that exists between polymorphic sites in the 
region is required. 
 
LD is commonly measured using Lewontins disequilibrium coefficient (D') 
and the correlation coefficient (r
2; also referred to as Δ2) (Lewontin, 1964, 
Devlin and Risch, 1995). Complete LD is said to exist when D'=1. This 
occurs when neither site has experienced recurrent mutation or gene 
conversion and if there has been no recombination between sites. Perfect LD 
is said to exist when r
2
=1. This occurs when there is perfect correlation 
between the polymorphic sites, i.e. when both sites have the same minor allele 
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frequency. In case-control disease association analysis using a polymorphic 
marker, the statistical power to detect unassayed disease-associated 
polymorphisms depends on the correlation (r
2) between the unassayed sites 
and the assayed site. Such LD information can be made use of to select the 
tagSNPs for candidate gene disease association studies (Carlson, Eberle, 
Rieder, Yi, Kruglyak
 et al., 2004). 
 
Another factor that could undermine SNP base association analysis is 
genotyping error. It is necessary to take steps to minimise genotyping errors in 
any association study. It is especially important when polymorphisms with 
very low minor allele frequencies are genotyped, because otherwise infinitely 
large samples are required to account for genotyping errors and to maintain 
acceptable levels of power and significance (Gordon, Finch, Nothnagel and 
Ott, 2002, Kang, Gordon and Finch, 2004). Haplotype analysis is another way 
of minimising the impact of genotyping errors, as rare, possibly false, 
haplotypes generated due to their presence can be excluded from analysis. 
 
It is not always possible to determine haplotypes present in an individual 
unequivocally using genotype data unless genotype data is available for 
parents and/or other siblings in a family. Technically too, haplotyping is a 
laborious process (Eitan and Kashi, 2002). The alternative approach that has 
been widely employed therefore is to use the expectation-maximization (EM) 
algorithm (Dempster, Laird and Rubin, 1977) to infer maximum likelihood 
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haplotype frequencies from genotype data, in which the gametic phase is 
unknown in a proportion of subjects, under the assumption of Hardy-
Weinberg equilibrium (HWE) (Excoffier and Slatkin, 1995, Hawley and Kidd, 
1995, Long, Williams and Urbanek, 1995). The accuracy of the EM-based 
maximum likelihood method in estimating haplotype frequencies has been 
validated in a variety of simulated conditions (Schipper, D'Amaro, de Lange, 
Schreuder, van Rood
 et al., 1998, Fallin and Schork, 2000). These studies 
have shown that its accuracy is better with large sample size (>100 
chromosomes), more loci (>5 loci), and greater dispersion of haplotype 
frequency values (with some very common haplotypes and many rare 
haplotypes) (Fallin
 et al., 2000). 
 
Associations between disease and genetic markers, however, can also be due 
to factors other than LD such as unsuspected stratification of case and control 
groups (Cardon and Palmer, 2003). Stratification is a problem if the marker 
alleles have different frequencies in admixed racial groups and if one of them 
has a higher incidence of disease resulting in its over representation in cases 
and under representation in controls. There are clear differences in the pattern 
of variation in SNPs and haplotypes of genes in different populations 
(Salisbury
 et al., 2003). In association studies therefore, to avoid spurious 
genetic associations, it is essential that sufficient measures be taken to 
establish the correct racial origin of each individual in both case and control 
groups and to match the two groups for race. Taking extra care to ensure that 
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stratification is eliminated or minimised is particularly important when 
subjects are recruited for association analysis in racially diverse countries such 
as Sri Lanka. Sri Lanka has several major racial groups  Sinhalese (74%), Sri 
Lankan Tamils (11%), Indian Tamils (6%), Moors (7%), Malays (<1%) and 
Burghers (<1%) (Department of Census and Statistics, 2001).The Sinhalese 
are probably the descendents of the original inhabitants of the Island, but their 
origin is also traced to the Bengali region in Northern India. The Sri Lankan 
Tamils are the descendents of Tamils from Southern India who came to the 
Island and settled down at various times in the past when Sri Lanka was 
invaded by South Indian rulers. The Moors and the Malays are the 
descendents of Arab and Malay traders respectively. They came to the country 
in search of trade and settled down. Burghers are a hybrid population of Dutch 
and other Western Europeans who married mainly the Sinhalese during the 
colonial rule in the 16th to 20th centuries. 
 
Most genetic studies of pre-eclampsia to date have been case-control candidate 
gene pre-eclampsia association studies that examine the association between 
SNPs in candidate genes and the disease phenotype (see review by 
Lachmeijer, Dekker, Pals, Aarnoudse, ten Kate
 et al., (2002)). The results of 
these studies have not been consistent (see tables 1.3 and 1.4). There are many 
reasons why this may be so. The most obvious reason is differences in study 
design especially the sample size that makes many studies under powered to 
detect actual genetic effects leading to false negative results (Lalouel and 
 36 
Rohrwasser, 2002). In addition, pre-eclampsia is almost certainly a polygenic 
disorder, and as such although one gene may be responsible for causing the 
disorder in one population, it may not necessarily be so in another. Another 
reason is spurious association in admixed populations as discussed above. It is 
also possible that there are true differences between these populations such as 
the existence of modifier genes that may mask the effects of the gene being 
studied (epistatic gene-gene interactions) or environmental modifiers specific 
to the population. Additionally, it is also possible that what is important above 
is a specific haplotype, rather than any of the single loci that define the 
haplotype. In fact there are very few studies that have carried out haplotype 
analysis in candidate genes in pre-eclampsia (e.g. Kaiser, Brennecke and 
Moses, 2000, Plummer, 2001, Levesque, Moutquin, Lindsay, Roy and 
Rousseau, 2003).  
 
An issue that none of the association studies of pre-eclampsia have addressed 
adequately is the issue of correction for multiple testing to adjust the level of 
significance to determine a positive association. It is dealt with in the 
discussion (see section 4.4.1). Another concern is the selection of the control 
group. It is widely accepted that confining genetic studies of pre-eclampsia to 
nulliparous women would reduce the chance of those with underlying 
disorders, especially renal disease, being included among cases (Higgins
 et al., 
2001). However, there seems to be no such widely accepted consensus on 
what should constitute a suitable control group. Some of the control groups 
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that have been used in these studies include population-based controls, 
multiparous women in whom all pregnancies were normal, and nulliparous 
normotensive pregnant women (see tables 1.3 and 1.4). In addition there is 
also the question as to what factors they should be matched for. Matching for 
parity and age seems appropriate, but should they also be matched for body 
mass index (BMI) bearing in mind that there is a strong association with BMI 
and pre-eclampsia? These concerns have to be addressed when designing case-
control candidate gene pre-eclampsia association studies. 
  
Properly designed case-control candidate gene disease association studies are 
the most practical and powerful approach to identify genetic factors involved 
in complex diseases (Risch
 et al., 1996). In spite of this, however, the most 
persuasive test of association involves the use of family-based controls such as 
is the case in the transmission disequilibrium test (TDT) (Spielman, McGinnis 
and Ewens, 1993). In the TDT, if a given allele contributes to disease, then the 
probability that an affected person has inherited the allele from the 
heterozygous parent should vary from the expected probability under 
Mendelian segregation of 0.5; the association of a neutral polymorphism due 
to admixture displays no such deviation. Some authors believe that any 
association not confirmed by the TDT should be regarded as provisional 
pending proof of causality (Altshuler, Kruglyak and Lander, 1998). In addition 
the TDT has the added advantage that it is not subject to confounding due to 
racial stratification, and can distinguish between maternal and fetal 
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susceptibility genes (Zusterzeel, Visser, Peters, Merkus, Nelen
 et al., 2000, 
Zusterzeel, te Morsche, Raijmakers, Roes, Peters
 et al., 2002). 
 
1.3.3.3. Future direction of genetic studies of pre-eclampsia 
A major impediment to attempts at understanding the mode of inheritance and 
to establishing linkage in pre-eclampsia research has been the absence of any 
large-scale study in non-European populations other than in the Japanese 
population. It would be most appropriate therefore, to carry out a study to fill 
that void in a South Asian country such as Sri Lanka, an Island nation in the 
Indian Ocean with considerable genetic diversity between its five main racial 
groups that have by and large remained genetically heterogeneous, possibly 
due to cultural differences (Papiha, Mastana and Jayasekara, 1996a). 
It is evident from the study of Arngrimsson and colleagues (1999), where 
support for the susceptibility locus on chromosome 2p13 came mainly from 
two large multicase families, that the success in pinpointing pre-eclampsia 
susceptibility loci by linkage analysis would require the investigation of a 
large number of multicase families than has been possible so far. This will 
become increasingly difficult in view of the social trend towards smaller 
family size. In addition, there is ample epidemiological evidence for a 
fetal/paternal genetic contribution to pre-eclampsia (Lie
 et al., 1998, Esplin et 
al., 2001) that needs to be addressed adequately in future studies as most 
candidate gene studies and all genome-wide scans so far have focused mainly 
on maternal genetic factors.  Such studies of course would require the 
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mobilisation of huge amounts of financial and other resources and 
collaboration among teams of researchers as in the case of the UK Genetics of 
Pre-eclampsia Collaborative (GOPEC) study (http://www.gopec.org). In many 
populations including that of the Sri Lankan population therefore, candidate 
gene pre-eclampsia association studies will play an important role. Selection 
of candidate genes for such studies will depend on chromosome locations 
indicated by genome wide scans, the pathophysiological processes operative in 
pre-eclampsia, and the tissue expression pattern of the proposed candidate 
genes. 
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1.4. Some pathophysiological aspects of pre-eclampsia 
Pre-eclampsia has been termed the disease of theories due to the confusion 
surrounding its aetiology (Ness and Roberts, 1996, Dekker and Sibai, 1998, 
Redman, Sacks and Sargent, 1999). It is possible that the hypertension and 
proteinuria that are relied on to define the condition may simply be the final 
common pathway through which more than one type of pathology is being 
expressed. Pre-eclampsia is now widely accepted to be a two-stage disorder: 
reduced placental perfusion usually secondary to abnormal placentation and a 
consequent maternal disorder characterized by endothelial dysfunction and a 
systemic maternal disease (Roberts and Redman, 1993, Roberts, 2000).  
 
1.4.1. Stage 1: Reduced placental perfusion 
Pre-eclampsia only occurs in the presence of a placenta and its resolution 
begins with the removal of the placenta. More than 70 years ago Page 
proposed that decreased placental perfusion results in pre-eclampsia (Page, 
1939). This has subsequently been confirmed by direct measurements of 
intervillous blood flow (Kaar, Jouppila, Kuikka, Luotola, Toivanen
 et al., 
1980) and by animal experiments where it has been shown that reducing blood 
flow to the pregnant uterus and placenta results in a condition remarkably 
similar to pre-eclampsia, including glomerular endotheliosis (Aladjem, Lueck 
and Brewer, 1983, Combs, Katz, Kitzmiller and Brescia, 1993). 
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In many cases reduced perfusion is secondary to abnormal placentation. In 
addition conditions that are associated with microvascular disease such as 
chronic hypertension (Dekker, de Vries, Doelitzsch, Huijgens, von Blomberg
 
et al., 1995, Sibai, Ewell, Levine, Klebanoff, Esterlitz et al., 1997) and 
diabetes (Garner, D'Alton, Dudley, Huard and Hardie, 1990, Lao and Tam, 
2001, Xiong, Saunders, Wang and Demianczuk, 2001, Bryson, Ioannou, 
Rulyak and Critchlow, 2003, Ostlund, Haglund and Hanson, 2004); and 
conditions that are thrombophilic such as anticardiolipin antibody syndrome 
(Branch, Andres, Digre, Rote and Scott, 1989) may also decrease blood supply 
to the placenta and increase the pre-eclampsia risk. Moreover, obstetric 
conditions that increase placental mass such as multiple pregnancies 
(Coonrod, Hickok, Zhu, Easterling and Daling, 1995, Mastrobattista, Skupski, 
Monga, Blanco and August, 1997) and hydatidiform mole (Newman
 et al., 
1988, Soto-Wright, Bernstein, Goldstein and Berkowitz, 1995) can have the 
same effect, possibly due to a relative decrease of placental blood flow. 
 
1.4.1.1. Placentation: Morphological changes 
The process of human placentation is an invasive phenomenon in which 
embryo-derived cytotrophoblastic cells progressively integrate into maternal 
tissue. After implantation, specialised epithelial cells of the placenta that 
attach the fetus to the mother, cytotrophoblasts, differentiate along one of two 
pathways. In the first, cytotrophoblasts fuse to form the multinucleate 
syncytium that covers the floating chorionic villi. These villi, which are in 
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direct contact with maternal blood in the intervillous space, perform nutrient 
and gas exchange functions for the fetus. In the second pathway, extra villous 
cytotrophoblasts in the anchoring villi proliferate to form a shell lining the 
uterine cavity, and invade the uterine wall (interstitial invasion) and its blood 
vessels (endovascular invasion).  
 
Cytotrophoblasts that invade the uterine wall (interstitial cytotrophoblasts) 
reach the superficial myometrium by the eighth week of gestation (Pijnenborg, 
Bland, Robertson, Dixon and Brosens, 1981). Later, they invade deeper into 
the myometrium especially at the centre of the placental bed (Pijnenborg, 
Bland, Robertson and Brosens, 1983). When they reach the end of their 
invasion path they fuse to form multinuclear giant cells (Pijnenborg, Bland, 
Robertson and Brosens, 1996). Endovascular cytotrophoblasts invade the 
spiral arteries and migrate along the arteries to reach myometrial spiral arteries 
by the tenth week of gestation. This process, however, may continue for 
several more weeks (Pijnenborg
 et al., 1983). It has been hypothesised that 
endovascular invasion occurs in two waves  a first wave at the beginning of 
pregnancy following fecundation and a second deeper wave at the end of the 
first trimester around 14 to 16 weeks of gestation that involves the inner third 
of the myometrium (Robertson, Khong, Brosens, De Wolf, Sheppard
 et al., 
1986). There is also data, however, that suggest a progressive endovascular 
migration into myometrial arteries rather than it occurring in two stages 
(Robson, Ball, Lyall, Simpson, Ayis
 et al., 2001). 
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The process of trophoblast invasion, in addition to physically anchoring the 
fetal placenta to the uterus, transforms the small diameter muscular spiral 
arteries into large-diameter low resistance flaccid vessels that carry blood to 
the intervillous space (Pijnenborg
 et al., 1983). It is clear that this process, 
named physiological change, has to take place in both decidual and 
myometrial segments of spiral arteries as an essential prerequisite for the 
provision of an adequate blood supply to the rapidly growing fetus and 
placenta. The changes in myometrial arteries never return to a non-pregnant 
state, so that second and subsequent pregnancies begin with an advantage in 
terms of flow (Brosens, Robertson and Dixon, 1967, Khong, Adema and 
Erwich, 2003).  
 
Interstitial trophoblast invasion is deficient in pre-eclampsia, but endovascular 
invasion is greatly impaired and physiological changes do not take place in 
both decidual and myometrial spiral arteries. They remain low calibre high 
resistance vessels that are unable to provide an adequate blood supply to the 
intervillous space (Khong, De Wolf, Robertson and Brosens, 1986, Meekins, 
Pijnenborg, Hanssens, McFadyen and van Asshe, 1994, Naicker, Khedun, 
Moodley and Pijnenborg, 2003). Spiral artery remodelling in normal 
pregnancies and pregnancies complicated by pre-eclampsia is summarised in 
figure 1.1. 
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Figure 1.1. Spiral artery remodelling in normal pregnancies and pregnancies 
complicated by pre-eclampsia. The upper diagram shows normal adaptation 
of spiral arteries to pregnancy, whereas the lower one depicts this process in 
pre-eclampsia (adapted from Khong et al. (1986)). 
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1.4.1.2. Placentation: Molecular mechanisms 
At a molecular level, trophoblast invasion is a complex process. It has been 
studied using in vitro systems consisting of enzyme-dispersed cells, 
extravillous cytotrophoblast (EVT) growing out of first trimester explants, or 
EVT cell lines derived from first trimester explants maintained on matrices 
similar to either decidual extracellular matrix or basal lamina (MatrigelTM). 
These studies point to a complex interaction between EVT and its 
environment in regulating invasion. The downside to these elegant in vitro 
studies is that it is impossible to obtain trophoblast cells that have not been 
exposed to normal environmental levels of O2 in harvesting and preparation 
from placental tissue. It is not clear therefore whether such cells actually 
mimic cells in vivo.  
 
A comprehensive review of the large body of scientific literature in this field 
is beyond the scope of this introduction. A brief survey therefore is made 
below of the molecular mechanisms that are most relevant to the 
investigations undertaken in this study. 
 
The cytotrophoblast, which lies at the feto-maternal interface, is influenced by 
circulating and local factors from both compartments. Among them is 
Epidermal Growth Factor (EGF) (see section 1.5.1). The EGF gene, maps to 
chromosome 4q25-27 (Morton, Byers, Nakai, Bell and Shows, 1986) and is 
approximately 57cM away from the closest markers bordering the suggestive 
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locus for pre-eclampsia detected in the genome-wide scan of Finnish families 
by Laivuori et al. (2003). At four to five weeks of gestation EGF might act to 
induce proliferation, whereas, at six to 12 weeks and later, it induces 
differentiation (Maruo, Matsuo, Murata and Mochizuki, 1992). EGF has been 
shown to promote invasion of first trimester cytotrophoblasts on MatrigelTM 
assays and produce morphologic changes such as extension of pseudopodia 
and ruffling of the cell membrane, but not syncytium formation (Bass, 
Morrish, Roth, Bhardwaj, Taylor
 et al., 1994). This suggests that EGF may 
induce phenotype differentiation along the invasive pathway. In addition EGF 
has been shown to inhibit apoptosis in first trimester (Perkins, St John and 
Ahmed, 2002) and term cytotrophoblasts (Levy, Smith, Chandler, Sadovsky 
and Nelson, 2000). This can contribute to cytotrophoblast survival during 
placentation and throughout the pregnancy. Interestingly apoptosis occurs at a 
high rate in pre-eclampsia whereas little or no apoptosis is observed in 
placentae of normal pregnancies (DiFederico, Genbacev and Fisher, 1999, 
Allaire, Ballenger, Wells, McMahon and Lessey, 2000). What is not clear, 
however, is whether apoptosis occurs as a primary or secondary phenomenon.  
 
EGF receptors (EGFR) are found in most reproductive tissues. The placenta, 
however, has many times more EGFR than the uterus, endometrium or 
decidua (Hofmann, Rao, Barrows, Schultz and Sanfilippo, 1984, Hofmann, 
Rao, Carman and Siddiqi, 1988). In addition EGF can upregulate EGFR in the 
cytotrophoblast (DePalo and Das, 1988). EGF in the feto-maternal interface is 
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most likely to be of maternal origin (Haining, Schofield, Jones, Rajput-
Williams and Smith, 1991, Hofmann, Scott, Bergh and Deligdisch, 1991, Bass
 
et al., 1994). There is limited data on systemic levels of EGF in the maternal 
circulation, but EGF levels in maternal urine in the first trimester and maternal 
plasma at term is reduced in women who deliver small for gestation age 
(SGA) babies (Shigeta, Hiramatsu, Eguchi and Sekiba, 1992, Lindqvist, 
Grennert and Marsal, 1999). It is possible therefore, that genetic 
polymorphisms in the maternal EGF gene (see section 1.5.1.3) affecting its 
functional activity can cause defective placentation. The EGF gene therefore 
is a candidate gene for pre-eclampsia.  
 
The EGFR is the prototypal member of the super family of receptors with 
intrinsic protein tyrosine kinase activity. EGFR serves as the sole or 
overwhelmingly predominant receptor for multiple distinct ligands including 
EGF, Transforming Growth Factor Alpha (TGFA), Amphiregulin (AR), 
Heparin Binding EGF (HB-EGF), Betacellulin (BTC), Epiregulin, and Epigen 
(Harris, Chung and Coffey, 2003). Of these, TGFA
 
(see section 1.5.2) is of 
interest to pre-eclampsia because the gene encoding for TGFA maps to 
chromosome 2p13 (Tricoli, Nakai, Byers, Rall, Bell
 et al., 1986) within the 
boundary of the most likely location for a pre-eclampsia susceptibility gene 
identified in genome-wide scans (Arngrimsson
 et al., 1999, Moses et al., 
2000). TGFA can be localised in the endometrium during the proliferative and 
the secretory phase of the menstrual cycle, but its expression is particularly 
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high in decidual cells (Horowitz, Scott, Drews, Navot and Hofmann, 1993, 
Lysiak, Han and Lala, 1993). TGFA is reported to be present in all forms of 
trophoblast cells (Filla, Zhang and Kaul, 1993, Hofmann, Horowitz, Scott and 
Navot, 1993). This is probably an artefact brought on by the massive 
expression of EGFR in the cytotrophoblast because Bass et al. (1994) could 
not find TGFA
 
mRNA in cytotrophoblasts. TGFA in the feto-maternal 
interface like EGF is most likely to be of maternal origin (Haining
 et al., 1991, 
Bissonnette, Cook, Geoghegan, Steffen, Henry
 et al., 1992, Bass et al., 1994). 
Interestingly TGFA treatment of primary human cytotrophoblasts stimulates 
their proliferation in culture (Lysiak
 et al., 1993). The TGFA gene therefore is 
also a candidate gene for pre-eclampsia. 
 
In addition to molecules that bind directly to EGFR, there are others that can 
activate it without binding to it directly. Among them is angiotensin II (AngII) 
(Eguchi, Numaguchi, Iwasaki, Matsumoto, Yamakawa
 et al., 1998, Wang, Yu, 
Cohen and Brecher, 2000). AngII is a component of the renin-angiotensin 
system (RAS) that also includes prorenin, renin, angiotensinogen (AGT), 
angiotensin I (AngI), angiotensin-converting enzyme, and angiotensin 
receptors (AT1R and AT2R). All these are expressed in and around the 
remodelling spiral arteries forming a local RAS (Morgan, Craven and Ward, 
1998, Cooper, Robinson, Vinson, Cheung and Broughton Pipkin, 1999). AngII 
has two possible actions  acting via AT1R it is capable of promoting 
angiogenesis and cell growth; and acting via AT2R it is capable of exerting 
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anti-proliferative effects (Le Noble, Hekking, Van Straaten, Slaaf and Struyker 
Boudier, 1991, Yamada, Horiuchi and Dzau, 1996). Only the AT1R, however, 
has been proven to be present in the human placenta (Cooper
 et al., 1999). The 
important role that this local RAS, which has only been recently recognised, 
may play in remodelling of spiral arteries has been overshadowed by the long 
standing knowledge of the changes in the circulating RAS during pregnancy.  
 
The RAS in the circulating system, which is of critical importance in the 
regulation of blood pressure, is activated in normal pregnancy as evidenced by 
an increase in the concentration of plasma renin and angiotensinogen 
(Kalenga, de Gasparo, de Hertogh, Whitebread, Vankrieken
 et al., 1991). The 
resulting increase in AngII does not normally result in hypertension as 
normotensive pregnant women are resistant to the pressor effects of infused 
AngII (Abdul-Karim and Assalin, 1961). This appears to be due to the down-
regulation of the AT1R that mediate vasoconstriction (Baker, Broughton 
Pipkin and Symonds, 1992a) and increased secretion of vasodilator 
substances, among them placental and probably renal prostacyclin (Pedersen, 
Aalkjaer, Christensen, Christensen, Danielsen
 et al., 1984, Fitzgerald, Entman, 
Mulloy and Fitzgerald, 1987). AngII is one of the substances that stimulate 
placental prostacyclin production (Glance, Elder and Myatt, 1985). The 
changes observed in this system in women with established pre-eclampsia, 
however, differ markedly from that observed in normal pregnancies. Their 
plasma renin concentrations are significantly lower than in normotensive 
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pregnancies and it is often associated with low plasma AngII concentrations 
(Wier, Brown, Fraser, Lever, Logan
 et al., 1975). In addition, the AT1R 
density on platelets is increased (Baker, Broughton Pipkin and Symonds, 
1991), and pressor sensitivity to infused AngII is increased towards pre-
pregnancy values (Baker, Broughton Pipkin and Symonds, 1992b). The latter 
change is present even prior to the onset of clinically evident hypertension 
(Gant, Daley, Chand, Whalley and MacDonald, 1973). Other observations of 
note in women with pre-eclampsia, in relation to the RAS, include reduced 
placental secretion of prostacyclin (Fitzgerald
 et al., 1987) and an increase in 
the presence in the plasma of a high molecular weight form of AGT, which is 
believed to be of placental origin (Tewksbury and Dart, 1982). A recent 
finding sheds light on the possibility that agonistic autoantibodies directed 
against the AT1R in the plasma of women with pre-eclampsia could, through 
activation of Nicotinamide Adenine Dinucleotidephosphate (NADPH) 
oxidase, contribute to the production of reactive oxygen species and the 
inflammatory responses in pre-eclampsia (Dechend, Viedt, Muller, Ugele, 
Brandes
 et al., 2003). In addition to the above evidence for the role of 
angiotensinogen in blood pressure regulation, there is also evidence for a 
possible role for maternal AGT in determining fetal growth. In one study 
significant inverse correlations were found between the maternal plasma AGT 
level at 18 weeks of gestation and the birth weight and the head circumference 
of their babies (Broughton Pipkin, Sharif and Lal, 1995). This evidence 
supports the possibility that genes encoding components of the RAS are 
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candidates for pre-eclampsia; of them AGT (see section 1.5.3), being the 
precursor of AngII and the rate limiting factor in conversion of AGT to AngI 
in pregnancy, deserves particular consideration.  
 
1.4.2. Stage 2: The systemic disease 
The normal endothelium buffers response to circulating pressors, prevents 
activation of platelets, activates circulating anticoagulants, and maintains 
fluids in the intravascular compartment (Rubanyi, 1993). Injury to the 
endothelium sets in motion a dysfunctional cascade of vasoconstriction, 
coagulation, and intravascular fluid redistribution that is at the centre of the 
systemic disease of the clinical syndrome of pre-eclampsia (Roberts, Taylor, 
Musci, Rodgers, Hubel
 et al., 1989). 
 
There is morphologic evidence of endothelial cell injury in the kidney  
glomerular endotheliosis (see section 1.2.2.2), and in the placental bed and 
adjacent uterine vessels (Shanklin and Sibai, 1989) of women with pre-
eclampsia. In addition biochemical markers of endothelial cell activation 
appear in the circulation. Among these are: increased von Willebrand Factor 
(Redman, Denson, Beilin, Bolton and Stirrat, 1977), growth factor activity 
(Taylor, Heilbron and Roberts, 1990), cellular fibronectin (Friedman, de 
Groot, Taylor, Golditch and Roberts, 1994, Halligan, Bonnar, Sheppard, 
Darling and Walshe, 1994), plasminogen activation inhibitor -1 (Halligan
 et 
al., 1994), anticardiolipin antibodies (Scott, 1987, Branch et al., 1989), 
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endothelin (Taylor, Varma, Teng and Roberts, 1990, Florijn, Derkx, Visser, 
Hofman, Rosmalen
 et al., 1991), thromboxane (Kraayenbrink, Dekker, van 
Kamp and van Geijn, 1993), tissue plasminogen activator (Friedman, Schiff, 
Emeis, Dekker and Sibai, 1995), and vascular cell adhesion molecule 
concentration (Lyall, Greer, Boswell, Macara, Walker
 et al., 1994); and 
reduced prostacyclin metabolite excretion (Fitzgerald
 et al., 1987). Some of 
these changes have been demonstrated prior to clinically evident pre-
eclampsia supporting the central role of altered endothelial function in the 
pathophysiology of the disease. 
 
One of the features of an activated endothelium is a disturbance of the balance 
that is normally dominated by vasodilator autocoids, such as prostacyclin and 
nitric oxide, to a vasoconstrictor phenotype with the production of more 
endothelin, thromboxane, and adhesion molecules. The pathological changes 
present in various organs of women dying of eclampsia which show the 
widespread presence of haemorrhage and necrosis is also more consistent with 
reduced perfusion possibly secondary to vasoconstriction rather than 
mechanical disruption of blood vessels (Roberts
 et al., 1993).  
 
An activated endothelium can also activate the haemostatic system via 
platelets and the coagulation cascade. Activation of the coagulation cascade 
that creates a maternal hypercoagulable state is likely to further reduce organ 
perfusion by the formation of microthrombi. The maternal hypercoagulable 
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state in pre-eclampsia is characterised by increased platelet consumption and 
reduced platelet lifespan (Redman, Bonnar and Beilin, 1978), increased 
concentration of pro-coagulant factors like tissue plasminogen activator, 
plasminogen activator inhibitor 1, von-Willebrand factor, anticardiolipin 
antibodies, endothelin and fibronectin; and reduced expression of endothelial 
cell associated anticoagulant proteins including antithrombin III (Weenink, 
Borm, Ten Cate and Treffers, 1983) and protein C (Gilabert, Fernandez, 
Espana, Aznar and Estelles, 1988). Finally, fluid is lost from the vascular 
compartment secondary to vasoconstriction and to an endothelial leak (Brown, 
Zammit and Lowe, 1989). These changes further reduce organ perfusion. Here 
too the reduction in plasma volume antedates the clinical diagnosis of pre-
eclampsia. The significance of this last observation, however, is arguable 
because dry pre-eclampsia, without the movement of plasma from the 
vascular tree into the tissues, may sometimes be more dangerous than the 
oedematous form (Vosburgh, 1976, National High Blood Pressure Education 
Program Working Group, 2000). 
 
It has been proposed that a hypercoagulable state created by a hereditary 
predisposition to thrombophilia can increase the risk of pre-eclampsia 
(Kupferminc, Eldor, Steinman, Many, Bar-Am
 et al., 1999, van Pampus, 
Dekker, Wolf, Huijgens, Koopman
 et al., 1999, Kupferminc, Fait, Many, 
Gordon, Eldor
 et al., 2000). The 5,10-methylenetetrahydrofolate reductase 
(MTHFR), factor V, and prothrombin genes have been shown to have 
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polymorphisms that increase the thrombophilic tendency. Among these the 
MTHFR gene is the one that has received most attention (see section 1.5.4) 
because its 677C>T polymorphism is the commonest genetic cause of 
hyperhomocysteinaemia, which is an independent risk factor for vascular 
disease (Clarke, Daly, Robinson, Naughten, Cahalane
 et al., 1991, Boers, 
2000). Homocysteine is a metabolic intermediary. It is formed during the 
metabolism of methionine, a sulphur-containing essential amino acid, in the 
diet. Once formed homocysteine is either transulfurated by cystathionine β 
synthase into cystathionine or remethylated into methionine in the presence of 
5-methyltetrahydrofolate, which is formed from 5,10-methylene 
tetrahydrofolate by the action of MTHFR (see section 1.5.4.1). This process is 
impaired in 677TT homozygotes because their MTHFR gene encodes an 
enzyme that has reduced enzymatic activity.   
 
The mechanisms that underlie the relationship between homocysteine and 
vascular damage have been investigated extensively and various mechanisms 
involving platelets, endothelial cells and clotting factors have been proposed. 
Shortened platelet survival was suggested as a possible mechanism in a study 
on baboons (Harker, Harlan and Ross, 1983), but that has not been confirmed 
(Uhlemann, TenPas, Lucky, Schulman, Mudd
 et al., 1976, Hill-Zobel, Pyeritz, 
Scheffel, Malpica, Engin
 et al., 1982). Increased platelet adhesion (McDonald, 
Bray, Field, Love and Davies, 1964), inhibition of the expression of 
thrombomodulin and protein C activation on endothelial cells (Rodgers and 
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Conn, 1990, Lentz and Sadler, 1991), and an increase in factor V activity 
(Rodgers and Kane, 1986) have all been reported in different studies. All these 
could shift the haemostatic balance to coagulation. A direct toxic effect on 
endothelial cells has also been suggested (Harker, Slichter, Scott and Ross, 
1974, Harker, Ross, Slichter and Scott, 1976). In addition oxidized 
homocysteine could lead to an increased generation of hydrogen peroxide that 
could damage the endothelium, reduce prostacyclin synthesis, and increase 
atherogenic oxidised Low Density Lipoprotein (ox-LDL) in plasma 
(Starkebaum and Harlan, 1986). These studies, however, have been widely 
criticised as unrepresentative of the mechanisms in vivo because they have 
been conducted using extremely high concentrations of homocysteine (1 to 10 
mM). Interestingly in a group of patients with premature atherosclerosis, 
plasma levels of endothelium derived proteins, von Willebrand factor and 
thrombomodulin, that are markers of endothelial activation, decreased 
following homocysteine lowering treatment suggesting a reversible toxic 
effect of hyperhomocysteinaemia on the endothelium at concentrations found 
in vivo (Van den Berg, Boers, Franken, Blom, Van Kamp et al., 1995). 
 
Plasma homocysteine levels in normal pregnant women are almost 50% lower 
than in non-pregnant women (Andersson, Hultberg, Brattstrom and Isaksson, 
1992). In women who develop pre-eclampsia, however, mean plasma 
homocysteine levels are elevated in the first (Cotter, Molloy, Scott and Daly, 
2003) and second trimesters (Sorensen, Malinow, Williams, King and Luthy, 
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1999) of pregnancy prior to clinically evident disease, during the acute phase 
of the illness (Rajkovic, Catalano and Malinow, 1997, Rajkovic, Mahomed, 
Malinow, Sorenson, Woelk
 et al., 1999, Sanchez, Zhang, Rene Malinow, 
Ware-Jauregui, Larrabure
 et al., 2001) and postpartum (Dekker et al., 1995, 
van Pampus
 et al., 1999). Hyperhomocysteinaemia, as evidenced by the 
above-mentioned studies, is neither a feature of all pregnancies complicated 
by pre-eclampsia nor is its presence in pregnancy always associated with pre-
eclampsia, but plasma homocysteine levels, when elevated in pre-eclampsia, 
positively correlate with that of cellular fibronectin (Powers, Evans, Majors, 
Ojimba, Ness
 et al., 1998). This indicates that homocysteine may play a role 
in promoting endothelial dysfunction in susceptible women. The MTHFR gene 
therefore is a candidate gene for pre-eclampsia.  
 
1.4.3. The link between the two stages 
It has been hypothesised that women affected by pre-eclampsia have a 
circulating factor released by the hypoxic placenta that damages the 
endothelium. A serum factor that has selective affinity for endothelial cells 
found in the serum of women with pre-eclampsia has been shown to damage 
human endothelial cells (Rodgers, Taylor and Roberts, 1988, Tsukimori, 
Maeda, Shingu, Koyanagi, Nobunaga
 et al., 1992, 1994). Others have failed to 
confirm this (Kupferminc, Mullen, Russell and Silver, 1996), and instead 
found the plasma and not the serum of women with pre-eclampsia to be toxic 
to endothelial cells (Smarason, Sargent and Redman, 1996). This discrepancy 
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could be accounted for by the physiological differences between plasma and 
serum and the fact that different aspects of endothelial cell function were 
assayed by the two groups, i.e. endothelial cell proliferation compared to 
endothelial cell injury. 
 
It has been proposed that the possible explanation for the link between the two 
stages of the disease lies in observations made in relation to the pathogenesis 
of atherosclerosis and parallels to it that are seen in pre-eclampsia. In normal 
human pregnancy, plasma cholesterol and triglyceride concentrations rise by 
up to 50% to 300% respectively, with all major lipoproteins reflecting these 
changes (Potter and Nestel, 1979). These changes are accentuated in pre-
eclampsia resulting in pre-eclampsia sharing a common dyslipidaemia with 
atherosclerosis, which is characterised by increased triglyceride and fatty acid 
levels (Hubel, McLaughlin, Evans, Hauth, Sims
 et al., 1996), decreased high-
density lipoproteins (HDL) (Rosing, Samsioe, Olund, Johansson and Kallner, 
1989), and increased small dense low-density lipoproteins (LDL) (Sattar, 
Bendomir, Berry, Shepherd, Greer
 et al., 1997). In fact triglyceride and fatty 
acid levels in women with pre-eclampsia are elevated from early pregnancy 
(Lorentzen, Endresen, Clausen and Genriksen, 1994). This may be a feature of 
pregnancies that are destined to develop early-onset, but not-late onset pre-
eclampsia (Clausen, Djurovic and Henriksen, 2001). It is not known, however, 
whether these changes antedate pregnancy. 
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The small dense LDLs, which are a part of the atherogenic dyslipidaemia, are 
proposed to have preferential access to the subendothelial space, where they 
bind to proteoglycans and reside longer than other LDLs. Small dense LDLs 
are inherently more easily oxidisable. Protected from circulating antioxidants 
in the subendothelial space they form very reactive oxidized-LDL (ox-LDL). 
They damage endothelial cells as they are cytotoxic to them and attract 
monocytes, as they are also a potent chemo-attractant to circulating 
monocytes. Monocytes take up ox-LDL to form foam cells and eventually the 
fatty streak characteristic of atherosclerosis (Steinberg, Parthasarathy, Carew, 
Khoo and Witztum, 1989). This process that leads to an excess of free radicals 
and reactive oxygen species over antioxidant scavengers, termed oxidative 
stress, is thought to be responsible for the endothelial changes in 
atherosclerosis, and has been proposed as the link between decreased placental 
perfusion and the maternal syndrome in pre-eclampsia (Roberts and Hubel, 
1999).  
 
Changes in circulating lipids alone, however, are unlikely to be enough to 
bring about the widespread damage to endothelial cells that occur during a 
relatively short period of time during a pregnancy complicated by pre-
eclampsia. The answer to the link therefore, may perhaps lie in recent 
discoveries involving circulating factors that interfere with angiogenesis 
(Maynard, Min, Merchan, Lim, Li
 et al., 2003), engage AngII signalling 
(Dechend
 et al., 2003), and directly impair endothelial function (Savvidou, 
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Hingorani, Tsikas, Frolich, Vallance
 et al., 2003). Among them the study by 
Maynard et al. (2003) deserves special attention. They studied the gene 
expression profile of placental tissue in normotensive women and women with 
pre-eclampsia using microarray chips and discovered that the production of 
placental soluble fms-like tyrosine kinase 1 (sFlt1), an antagonist of vascular 
endothelial growth factor (VEGF) and placental growth factor (PlGF), is 
upregulated in pre-eclampsia, which could lead to increased systemic levels of 
sFlt1 that fall after delivery. They also found that the increased level of 
circulating sFlt1 in patients with pre-eclampsia is associated with decreased 
circulating levels of free VEGF and PlGF, which are necessary to maintain the 
integrity of the vascular endothelium. They were able to show that depleted 
levels of VEGF and PlGF result in endothelial dysfunction in vitro that can be 
rescued by exogenous VEGF and PlGF, and that the administration of sFlt1 to 
pregnant rats induces the classical features of pre-eclampsia  hypertension, 
proteinuria, and glomerular endotheliosis. The same group studied the 
gestational patterns of circulating sFlt1, free PlGF and, free VEGF in 
normotensive and pre-eclamptic pregnancies and concluded that increased 
levels of sFlt1 and reduced levels of PlGF, beginning five weeks before the 
clinical detection of the condition, predict the subsequent development of pre-
eclampsia (Levine, Maynard, Qian, Lim, England
 et al., 2004). These 
observations suggest strongly that sFlt1 may be a pre-eclampsia factor, but 
what upregulates sFlt1 is not known. 
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1.5. The candidate genes 
The pathophysiological evidence discussed above has suggested numerous 
candidate genes for pre-eclampsia. From the list of possible candidates EGF, 
TGFA, AGT, and MTHFR genes have been selected for the investigations 
described in this thesis.  
 
1.5.1. Epidermal Growth Factor 
1.5.1.1. Introduction 
EGF is a growth factor that has many biological functions, including 
proliferation of epidermal tissue (Groenen, Nice and Burgess, 1994). It is a 
globular protein of 6.4kDa consisting of 53 amino acids that is characterised 
by a consensus sequence consisting of six spatially conserved cysteine 
residues that form three intramolecular disulphide bonds. This consensus 
sequence, which is known as the EGF motif, present in all mammalian ligands 
that bind the EGFR, is crucial for EGFR binding. EGF proteins are closely 
conserved during evolution as indicated by approximately 70% similarity 
between the amino acid sequence of human and mouse EGF genes, and the 
conservation of the relative position of the cysteine residues. EGF is 
synthesized as a prepro-protein of 1207 amino acids. It exists as a membrane 
bound molecule from which EGF is released by proteolytic cleavage (Bell, 
Fong, Stempien, Wormsted, Caput
 et al., 1986).   
 
There have been numerous studies examining the properties of the EGFR, its 
 61 
ligands, and its signalling pathway. The following brief description is based on 
recent reviews by Wells (1999) and Harris et al. (2003): EGFR also referred to 
as HER (human EGF receptor) is the prototypal member of a family of 
transmembrane receptors with intrinsic protein tyrosine kinase activity. EGFR 
binding by its ligands, including EGF and TGFA, activates EGFR kinase and 
initiates numerous signalling pathways. The biological outcome of many of 
these pathways has not yet been determined. There are, however, two strongly 
activated pathways that interact with each other to bring about enhanced cell 
motility and cell proliferation. These pathways act via phospholipase C-γ 
(PLCγ) and ras. The PLCγ pathway enhances cell motility by hydrolysis of 
PIP2 (Phosphatidylinositol (4,5) bisphosphate) and mobilization/activation of 
actin modifying proteins (AMP) such as gelsolin, profilin, and cofilin, and 
possibly via protein kinase C (PKC) and calcium mediated events. Motility is 
blocked, however, if MEK (MAP kinase kinase) signalling is abrogated. The 
activation of the ras-MAP kinase (extracellular signal-regulated kinase, 
mitogen-activated protein kinase) pathway results in cell proliferation and 
motility. The phosphorylation of EGFR at threonine 654 by PKC, however, 
preferentially disrupts activation of the ras-MAP pathway, which is postulated 
to result in intermittent erk activity that favours cell motility over proliferation. 
These pathways are summarised in figure 1.2. 
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Figure 1.2. A general model of the cross-talk between downstream 
pathways activated by EGFR in different types of cells. See text for 
description. EGF: Epidermal Growth Factor, TGFA: transforming 
growth factor, EGFR: Epidermal growth factor receptor, MAPk: 
mitogen activated protein kinases, MEK: MAP kinase kinase, PLCγ: 
phospholipase C-γ, PIP2: Phosphatidylinositol (4,5) bisphosphate, 
AMP: Actin Modifying Protein, DAG: Diacylglycerol, IP3: Inositol-
1,4,5-triphosphate, PKC: Protein Kinase C (Adapted from Wells 
(1999)). 
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1.5.1.2. Genomic structure 
The gene encoding the EGF precursor maps to chromosome 4q22-25 
(Brissenden, Ullrich and Francke, 1984, Morton
 et al., 1986). It is located 
approximately 47.6cM and 67.3cM away from the suggestive locus for pre-
eclampsia identified by Laivuori et al. (2002) and Harrison et al. (1997) 
respectively (Figure 1.3). The genomic structure of the EGF gene was 
described by Bell et al. (1986). It has a length of approximately 110kb and 
consists of 24 exons. The introns interrupt the coding sequence of the gene 
such that many of the domains of the protein are the products of individual 
exons. Moreover, most of the protein (amino acids 43-952) is apparently the 
result of the tandem duplication of a block of eight to nine exons. This gene 
has been described as a mosaic because 15 of its 24 exons encode sequences 
that are homologous to exon-encoded regions in other proteins (eight of these 
exons encode the cysteine-rich EGF-like repeat motif). It is also a member of 
three gene families: one, which includes proteins that have EGF-like repeat 
motifs; a growth factor family which includes the TGFA precursor; and a 
receptor family which includes the LDL receptor (Figure 1.4).  
 
Bell et al. (1986) described some of the regulatory regions of the gene. There 
is a consensus cap site and TATA box 23 and 29 base pairs respectively, 
upstream of the transcription start site. The first 66 base pairs of the gene that 
encode the first 22 amino acids most likely represent the signal peptide. 
Mullhaupt, Feren, Jones and Fodor (2000) characterised the EGF promoter 
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further and showed that it is active during cell proliferation and negatively 
regulated in contact inhibited and quiescent cell cultures. They hypothesised, 
because of the link between EGF gene activity and growth induction, that the 
EGF promoter comprises a yet unidentified growth responsive regulatory 
domain. Other regulatory regions of this gene have not yet been characterised. 
 
1.5.1.3. Polymorphisms/haplotypes 
There are two studies that report on screening for EGF polymorphisms. 
Semina, Datson, Leysens, Zabel, Carey et al.(1996) screened all exons of the 
EGF gene and identified four SNPs in exons 7, 14, 15 and 19. They 
established the frequency of these polymorphisms in 50 white Caucasians 
(Table 1.1). Subsequently Shahbazi, Pravica, Nasreen, Fakhoury, Fryer et al. 
(2002) detected another SNP at position 61 in the 5 UTR (Table 1.1). They 
carried out in vitro studies to examine EGF production in peripheral blood 
mononuclear cells (PBMC) and found that cells of individuals homozygous 
for the 61A allele produced significantly less EGF than cells of heterozygous 
individuals and individuals homozygous for the 61G allele. The mechanism by 
which this polymorphism affects EGF production however, is not known. 
They also found that the 61G allele was associated with a significant risk of 
developing malignant melanoma (odds ratio (OR)=2.7, 95% Confidence 
Interval (CI), 1.9 to 4.0; P<0.0001). This finding, however, could not be 
replicated in another group of white Caucasians (McCarron, Bateman, 
Theaker and Howell, 2003). 
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In the two association studies mentioned above, in white Caucasian controls, 
the frequency of the 61A allele was 56.1% and 60.2% respectively. In the 
study by Semina et al. (1996) the frequency of the 67149A allele was 50%, 
and the variant allele of all other polymorphisms occurred in <10% of 
chromosomes. Thus the 61G>A and 67149G>A polymorphisms occur 
frequently enough in the population to justify their selection as markers for 
association analysis as it would be possible to carryout a study that has 80% 
statistical power at a significance level of 0.05 to detect a doubling of the risk 
of pre-eclampsia with the sample size of this study. In addition the 61G>A is 
the only EGF polymorphism that has been shown to have functional effects 
and to be implicated in the aetiology of a disease. The 67149G>A 
polymorphism that occurs in exon 14 of the gene results in a substitution of 
the amino acid methionine by isoleucine in the LDL receptor homology 
domain of the gene. These two polymorphisms were therefore selected for this 
study.
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Figure 1.3. A diagrammatic representation of the relative position of the EGF gene on a Sequence Tagged Site (STS) map of 
chromosome 4 in relation to markers that were associated with suggestive loci for pre-eclampsia in genome wide studies by 
Laivuori et al. (2002) and Harrison et al. (1997). Position of EGF and markers are from the STS map of chromosome 4 at the 
NCBI (see section 2.10). 
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Figure 1.4. A diagrammatic representation of the exon-intron organisation and the protein 
domains of the EGF gene and the location of SNPs used for association analysis in this 
study. Arrowheads indicate the positions at which introns interrupt the coding region. Exon 
numbers are shown between the arrowheads. The locations of the two SNPs are indicated. 
Modified and adapted from Bell et al.(1986)  
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Nucleotide
1
 Location Allele 
at SNP 
Amino 
Acid 
Frequency 
     
61 Exon 1 G -    0.44
 2
 
  A -    0.56 
     
48002 Exon 7 T His    0.99
 3
 
  C His    0.01 
     
67149 Exon 14 G Met    0.49
 3
 
  A Ile    0.50 
     
68062 Exon 15 T Leu    0.07
 3
 
  A Met    0.93 
     
80378 Exon 19 T Val    0.94
 3
 
  A Glu    0.06 
     
 
Table 1.1. SNPs reported in the EGF gene. 1 Nucleotides are 
numbered with respect to the transcription start site (see 
section 2.10 below). 
2
Shahbazi et al. (2002): frequencies are 
for 99 white Caucasians. 
3
Semina et al. (1996): frequencies 
are for 50 white Caucasians. 
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1.5.2. Transforming Growth Factor Alpha 
1.5.2.1. Introduction 
TGFA is a 50 amino acid protein that is synthesized as a prepro-protein of 160 
amino acids. It is a structural (shows 40% similarity in sequence) and 
functional homologue of EGF. It competes with EGF for binding to the EGFR. 
It too is believed to exist as a membrane bound molecule from which TGFA is 
released by proteolytic cleavage.  
 
1.5.2.2. Genomic structure 
The gene encoding TGFA precursor maps to chromosome 2p11-2p13 
(Brissenden, Derynck and Francke, 1985, Tricoli et al., 1986). It lies between 
the markers at 70.8cM and 79.4cM within the most likely location for a pre-
eclampsia susceptibility gene according to the genome wide scan of 
Arngrimsson et al. (1999) (Figure 1.5).  The gene is approximately 100kb long 
and consists of six exons, of which exon 1 encodes the 5 UTR and signal 
peptide, exon 2 is the N terminal precursor, exon 3 is the mature peptide 
through the first two disulphide loops of EGF motif, exon 4 is the third 
disulphide loop and transmembrane domain, exon 5 is the cytoplasmic 
domain, and exon 6 is the 3UTR (Figure 1.6) (Collin, Marshall, Naggert and 
Nishina, 1999, Machida, Yoshiura, Funkhauser, Natsume, Kawai et al., 1999). 
This exon organisation is similar to the genes of other EGFR ligands such as 
HB-EGF, AR, and BTC (Harris et al., 2003).
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Figure 1.5. A diagramtic representation of the relative position of the TGFA gene on a STS map of chromosome 2 in relation to 
markers that were associated with a suggestive locus for pre-eclampsia in genome wide studies by Arangrimmson et al. (1999) 
and Moses et al. (2000). The position of TGFA and microsatellite markers were obtained from the STS map of chromosome 2 at 
NCBI. The positions assigned to markers in this map differed from positions assigned to them on the radiation hybrid Marshfield 
map that were referred to in the report by Arangrimmson et al. (1999), but the order of markers on the two maps are the same. 
The most significant linkage under general criteria that included both women with gestational hypertension and pre-eclampsia 
was to marker D2S286, and under strict criteria including only women with pre-eclampsia and eclampsia it was between markers 
D2S211 and D2S1394. The markers bordering the area of distribution of the haplotypes shared by the members of the two large 
families (A&B) that contributed to the significant linkage to this region is also indicated. 
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Figure 1.6. A diagrammatic representation of the exon-intron organisation and the protein domains of the 
TGFA gene and the location of SNPs used for association analysis in this study. Arrowheads indicate the 
positions at which introns interrupt the coding region. Exon numbers are shown. The location of the SNPs in 
the 3UTR is indicated. 
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1.5.2.3. Polymorphisms/haplotypes 
There are several well-characterised polymorphisms in the TGFA gene that 
have been used in association analysis. A 4bp deletion/insertion polymorphism 
(DIP) in intron 5 of the gene, designated TaqI restriction length polymorphism 
(Hayward, Nancarrow and Bell, 1987), was among the first to be identified 
and has been found in less than 10% of chromosomes tested (Basart, Qian, 
May and Murray, 1994, Tanabe, Taketani, Endo-Ichikawa, Tokunaga, Ogawa 
et al., 2000). A second 4-bp DIP in the 3UTR of the gene is more common 
and it has been has been reported to be present in about 13% of white 
Caucasian chromosomes (Shiang, Lidral, Ardinger, Buetow, Romitti et al., 
1993) and 24% of Japanese chromosomes (Tanabe et al., 2000). There is also 
a cluster of SNPs at nucleotides 3822, 3827, and 3851 in the 3UTR of the 
gene. These three SNPs are in complete linkage disequilibrium and define four 
haplotypes (Table 1.2). They have been found to be associated with the 
development of two disorders involving tissue remodelling, viz. non 
syndromic cleft lip and palate (Ardinger, Buetow, Bell, Bardach, VanDemark 
et al., 1989) and cleft palate only (Shiang et al., 1993) in some populations, 
but not in others (Machida et al., 1999). Polymorphisms in 3UTR conserved 
regions of genes can play a role in mRNA stability or tissue specific targeting 
(Siomi and Dreyfuss, 1997). These three polymorphisms were therefore 
selected for this study. 
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Haplotype   Frequency 
3822G>A 3827T>C 3851T>C  
White 
Caucasian
1
 
Japanese
2
 
G T T  0.29 0.21 
G C T  0.50 0.50 
G C C  0.07 0.08 
A C T   0.14 0.20 
 
Table 1.2. Haplotypes defined by the three SNPs in the 3UTR 
of the TGFA gene and the reported frequency of the haplotypes 
in two distinct populations 
1
Shiang et al. (1993) 2Tanabe et al. 
(2000) 
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1.5.3. Angiotensinogen 
1.5.3.1. Introduction 
Angiotensinogen (AGT) is the precursor of AngII, which is a potent 
vasoconstrictor, a major determinant of salt and water homeostasis and a 
growth factor. AGT is mainly synthesised in the liver, but it is expressed in a 
wide range of tissues, including the placenta.  
 
 
1.5.3.2. Genomic structure and gene regulation 
The AGT gene maps to chromosome 1q42-43 (Isa, Boyd, Morrison, Harrap, 
Clauser et al., 1990). It is approximately 12kb in length and consists of five 
exons and four introns of which exon 1 encodes the 5 UTR, exon 2 encodes 
the signal peptide and AngI, and exons 3 to 5 encode the remainder of the 
coding sequence. A part of exon 5 also contains the 3UTR (Figure 1.7) 
(Gaillard, Clauser and Corvol, 1989, Fukamizu, Takahashi, Seo, Tada, 
Tanimoto et al., 1990). 
 
There are many studies that have examined the regulation of angiotensinogen 
gene expression. A brief survey is made here of the studies most relevant to 
the investigations undertaken in this thesis. Fukamizu et al. (1990) 
characterised the minimal promoter required for expression in HepG2 cells 
and other putative regulatory motifs in the 5 flanking region, including the 
TATA box, the oestrogen response element, the glucocorticoid responsive 
element, the acute phase response element, the cAMP response element, and 
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the heat shock response element. Later the same group identified other 
elements responsible for maintaining promoter activity. Among them is 
angiotensinogen core promoter element 1 (AGCE1), located between the 
TATA box and transcription initiation site, that interacts with an unidentified 
nuclear factor AGCF1 (AGCE-binding factor 1) (Yanai, Nibu, Murakami and 
Fukamizu, 1996), and AGCE2 and 5AGCE2, that interact with another 
unidentified nuclear factor AGCF2 (Yanai, Matsuyama, Murakami and 
Fukamizu, 1997). AGCF1 seems to play the major role in mediating the 
enhancer effects of the downstream enhancers of the AGT gene on gene 
expression. Two such enhancer elements spanning 80-bp (Nibu, Tanimoto, 
Takahashi, Ono, Murakami et al., 1994b) and 23-bp (Nibu, Takahashi, 
Tanimoto, Murakami and Fukamizu, 1994a) have been identified in exon 5 
and the 3 flanking region of the gene. Both these regions that bind HepG2 
specific nuclear factors are responsible for activating the AGT promoter in a 
cell type dependent manner, and are both necessary for full enhancer activity. 
Polymorphisms in the AGT minimal promoter have been shown to affect 
promoter activity (see section 1.5.3.3), but it is not known whether 
polymorphisms in the AGT 3UTR have any effects on enhancer activity. 
 
The regulation of the AGT gene is affected by many substances, among them 
AngII. AngII has been reported to stimulate the synthesis and secretion of 
AGT in primary cultures and on hepatocytes in suspension in rats (Ruiz, 
Jimenez, Montiel, Narvaez, Diego et al., 1987, Klett, Muller, Gierschik and 
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Hackenthal, 1990). Further work on rat hepatocytes show that this increase in 
AGT mRNA following stimulation with AngII is due to stabilisation of AGT 
mRNA by a 12-kD intracellular hepatic protein that selectively binds to the 
3UTR of the AGT mRNA rather than due to increased transcription 
(Hackenthal and Klett, 1993, Klett, Bader, Ganten and Hackenthal, 1994). No 
attempt to replicate these results in human cells has been reported. 
 
1.5.3.3. Polymorphisms/haplotypes 
Members of our pre-eclampsia research group and others have extensively 
investigated polymorphisms and the haplotype structure of the AGT gene and 
their prevalence in white Caucasian and Japanese populations. These studies 
show wide variation in both the prevalence of SNPs and the haplotype 
structure in these populations (Morgan, Broughton Pipkin and Kalsheker, 
1996, Jeunemaitre, Inoue, Williams, Charru, Tichet et al., 1997, Nakajima, 
Jorde, Ishigami, Umemura, Emi et al., 2002, Plummer, Morgan and 
Kalsheker, 2002).  
 
Of the many polymorphisms in the AGT gene Ward and colleagues 
investigated the 235Met>Thr polymorphism in exon 2 for its possible role in 
pre-eclampsia. It was selected because it had been found to be associated with 
essential hypertension (Jeunemaitre, Soubrier, Kotelevtsev, Lifton, Williams 
et al., 1992). They found that in their population pre-eclampsia was associated 
with the 235Thr allele (Ward, Hata, Jeunemaitre, Helin, Nelson et al., 1993). 
77 
Then they extended their investigations to functional studies and found that 
235Met/Thr heterozygotes exhibited significantly elevated expression of the 
235Thr allele compared to the 235Met allele, suggesting that the elevated 
expression of the 235Thr allele in decidual spiral arteries may cause first 
trimester atherotic changes leading to pre-eclampsia (Morgan, Craven, Nelson, 
Lalouel and Ward, 1997). Subsequently they found evidence in support of 
their hypothesis when 235Thr/Thr homozygous women were found to have a 
greater media area/external diameter ratio than 235Met/Met homozygous 
women (Morgan, Craven, Lalouel and Ward, 1999b). Results of studies that 
have examined the association of the 235Met>Thr polymorphism with pre-
eclampsia are summarised in table 1.3. The initial positive result has not been 
replicated in all populations. In one recent study, the 174Met allele of the 
174Thr>Met polymorphism and the 1035A/174Met/235Thr haplotype of the 
AGT gene are reported to confer a two-fold increased risk of pre-eclampsia in 
a French Canadian population (Levesque et al., 2003). The same study failed 
to find any significant increased risk associated with the 235Thr allele alone. 
 
The 235Thr allele is in linkage disequilibrium with the 20C, 6A and 174Met 
alleles of the 20A>C, 6G>A and 174Thr>Met polymorphisms of the AGT 
gene (Morgan et al., 1996, Jeunemaitre et al., 1997). Reporter gene constructs 
containing the AGT minimal promoter with the nucleotide A at 6 and C at  
20 have increased promoter activity upon transient transfection in human 
liver derived HepG2 cells compared with reporter constructs containing 
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nucleotide G at 6 and A at 20 respectively (Inoue, Nakajima, Williams, 
Quackenbush, Puryear et al., 1997, Zhao, Zhou, Narayanan, Cui and Kumar, 
1999). This may account for the reported association of high levels of plasma 
AGT with the 235Thr allele (Jeunemaitre et al., 1992). In contrast, in 
normotensive pregnant women the 235Thr allele seems to be associated with 
lower plasma angiotensinogen concentrations (Morgan, Crawshaw, Baker, 
Broughton Pipkin and Kalsheker, 1999a). It is possible therefore, that complex 
mechanisms are operative in regulating angiotensinogen expression in 
pregnancy.   
 
The above-mentioned SNPs are situated 5 to the 235Met>Thr polymorphism. 
Recently members of our group screened the 3UTR/flanking region of the 
AGT gene, and described the presence of six novel SNPs in this region 
(11535C>A, 11608C>A, 12058G>A, 12194A>C, 12429C>T, 12822T>C) that 
together with the 235Met>Thr polymorphism define five common AGT 
haplotypes that are found in 91% of white Caucasian chromosomes (Plummer 
et al., 2002). Interestingly two of these SNPs, 11535C>A and 11608C>T, are 
in linkage disequilibrium with each other, and split the common haplotype 
bearing 235Met; all other haplotypes have been described in association with 
the 235Thr allele (Plummer et al., 2002). The 174Thr>Met, 235Met>Thr and 
11535C>A polymorphism of the AGT gene were therefore selected for this 
study. 
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All the 3UTR/flanking region SNPs are located outside the two regions that 
have been showed to be responsible for the 3 enhancer activity under basal 
conditions in HepG2 cells (Nibu et al., 1994a). What effect, if any, that the 
SNPs have on enhancer activity and enhancer activity in HepG2 cells under 
stimulated conditions has not been studied so far. A further study was 
undertaken therefore, to investigate the functional significance of the 
3UTR/flanking region SNPS on AGT gene expression using reporter gene 
constructs containing enhancer elements harbouring the three common 
haplotypes defined by the 3UTR/flanking region SNPs (see table 2.12) under 
basal and AngII stimulated conditions in HepG2 cells.  
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Figure 1.7. Genomic structure of the AGT gene. The exons and introns are numbered. The protein 
domains are indicated. The positions of the three polymorphisms used in these investigations are 
indicated. 
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T allele frequency 
Population Cases Controls 
Primi/
Multi 
Exclusion criteria 
Cases Controls P 
White Caucasian,USA
1
 45 PE 571 normal pregnant women Both CHT, RD, MP 0.60 0.41 <0.001 
Japanese
1
 18 PE 80 normal pregnant women Both DM, CHT, RD, MP. 0.90 0.71 0.041 
Indonesian
2
 20 E 100 non eclamptic women ? ? 0.65 0.62 NS 
White Caucasian,Australia
3
 106 PE/E 81 normal pregnant women ? ? 0.47 0.38 NS 
Chinese
3
 72 PE/E 48 normal pregnant women ? ? 0.78 0.75 NS 
Japanese
4
 33 GH/PE 280 normal pregnant women Both CHT, DM, RD, MP 0.79 0.80 NS 
White Caucasian, UK
5,6
 43 PE 84 normal pregnant women Both CHT 0.48 0.48 NS 
Japanese
7
 115 GH/PE/E 381 normal pregnant women Both CHT, DM, RD, FA, HELLP 0.91 0.76 <0.001 
Japanese
8
 58 PE 164 normal pregnant women Primi CHT, DM, RD, MP, FA 0.78 0.59 0.01 
Hispanic
9
 87 PE 53 women with at least 2 normal 
pregnancies 
Both CHT, DM, RD, PlatD, AID 0.72 0.70 NS 
Romanian
10
 11PE 6 normal pregnant women ? ? 0.42 0.33 NS 
Hellenic (north west 
Greece)
11
 
41 PE 102 normal with at least 2 
normal pregnancies 
Both MP 0.59 0.40 0.005 
French Canadian
12
 203 PE 357 normal pregnant women Primi MP, CHT 0.44 0.40 NS 
 
Table 1.3. A summary of the case-control AGT 235Met>Thr pre-eclampsia association studies with some studies reporting 
an association. *The frequency of the AGT 235Thr/Thr genotype. 
Abbreviations: 
?-Information not available 
AID-Auto Immune Disorders 
CHT-Chronic Hypertension 
DM-Diabetes Mellitus 
FA-Fetal and amniotic fluid  
       volume abnormalities 
GH-Gestational Hypertension 
HELLP-HELLP Syndrome 
MP-Multiple Pregnancies 
PE-Pre-eclampsia 
PlatD-Platelet Disorders 
RD-Renal Disease 
Primi-Primiparous 
Multi-Multiparous 
References: 
1. (Ward et al., 1993) 
2. (Romi, Patria and Matsuo, 1997)  
3. (Guo, Wilton, Fu, Qiu, Brennecke et 
al., 1997) 
4. (Suzuki, Tanemura, Murakami and 
Suzumori, 1999) 
5. (Morgan, Baker, Broughton Pipkin 
and Kalsheker, 1995) 
6. (Morgan et al., 1999a) 
7. (Kobashi, Hata, Shido, Kato, 
Yamada et al., 1999) 
8. (Kobashi, Shido, Hata, Yamada, 
Kato et al., 2001) 
9.   (Bashford, Hefler, Vertrees, Roa 
and Gregg, 2001) 
10. (Procopciuc, Jebeleanu, Surcel and 
Puscas, 2002) 
11. (Bouba, Makrydimas, Kalaitzidis, 
Lolis, Siamopoulos et al., 2003) 
12. (Levesque et al., 2003) 
 
* * 
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1.5.4. 5,10-Methylenetetrahydrofolate Reductase 
1.5.4.1. Introduction 
MTHFR (Enzyme Commission 1.5.1.20) is the enzyme that catalyses the 
conversion of 5,10-methylenetetrahydrofolate to 5- Methyl tetrahydrofolate, 
the major form of folate in plasma, that is a cosubstrate for remethylation of 
homocysteine to methionine (Figure 1.8). Thus normal biological activity of 
MTHFR is important for the regulation of methionine and homocysteine 
concentrations in the circulation.  
 
Severe forms of MTHFR deficiency (residual enzyme activity that correspond 
to 0-20% of control values) caused by rare mutations in the MTHFR gene 
result in homocysteinuria as well as severe neurological and vascular 
complications (Sibani, Christensen, O'Ferrall, Saadi, Hiou-Tim et al., 2000). 
Milder forms of MTHFR deficiency (residual enzyme activity 35-50% of 
control values) caused by other common polymorphisms in the MTHFR gene 
result in mild hyperhomocysteinaemia (Frosst, Blom, Milos, Goyette, 
Sheppard et al., 1995, van der Put, Gabreels, Stevens, Smeitink, Trijbels et al., 
1998, Weisberg, Tran, Christensen, Sibani and Rozen, 1998). These common 
polymorphisms have been associated with complications in pregnancy such as 
recurrent pregnancy loss (Nelen, Steegers, Eskes and Blom, 1997) and pre-
eclampsia. The latter association, however, has not been replicated in most of 
the studies (Table 1.4). 
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1.5.4.2. Genomic structure 
The MTHFR gene maps to chromosome 1p36.3 (Goyette, Sumner, Milos, 
Duncan, Rosenblatt et al., 1994). It consists of 11 exons with lengths ranging 
from 102-bp to 432-bp and introns with lengths ranging from 250-bp to 1.5-
kb, except for one large intron of 4.2-kb (Figure 1.9). There is approximately 
90% similarity between the nucleotide sequences of the human and mouse 
MTHFR genes. Both genes have 11 exons of similar sizes and similar exon-
intron boundaries (Goyette, Pai, Milos, Frosst, Tran et al., 1998). 
 
The promoter region of the MTHFR gene contains numerous consensus 
sequences for transcription factor binding sites, but lack a TATA box. This 
points to complex regulation of the MTHFR gene at transcriptional level. 
Three MTHFR transcript variants, predicted to give rise to 74.5, 78.9 and 76.8 
kDa molecular weight MTHFR polypeptides, have been identified in cultured 
human fibroblasts (Homberger, Linnebank, Winter, Willenbring, Marquardt et 
al., 2000). However, the major MTHFR isoform that has been identified in 
most human tissues so far appears to have a molecular weight of 77 kDa. In 
addition a smaller isoform with a molecular weight of 70 kDa has also been 
found in the human fetal liver (Frosst et al., 1995). Interestingly the human 
and mouse MTHFR genes are in head to head orientation in close proximity to 
the CLCN6 (a putative chloride channel) gene with only 3.1-kb and 2.5-kb 
respectively in each species between the translation initiation codons of each 
gene (Gaughan, Barbaux, Kluijtmans and Whitehead, 2000). 
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Figure 1.8. Pathways of folate metabolism relating to MTHFR.  
MS  Methionine Synthase, CBS  Cystathionine β Synthase,  
THF  Tetrahydrofolate. 
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1.5.4.3. Polymorphisms/haplotypes 
There are many variations described in the MTHFR gene. Most of them are 
rare mutations found in patients with homocysteinuria (Goyette, Frosst, 
Rosenblatt and Rozen, 1995, Goyette, Christensen, Rosenblatt and Rozen, 
1996, Sibani et al., 2000). It also has several common polymorphisms. The 
677C>T and 1298A>C polymorphisms are the most well characterised of the 
common MTHFR polymorphisms (Frosst et al., 1995, van der Put et al., 1998, 
Weisberg et al., 1998). In addition to these, other polymorphisms have also 
been described, but their functional relevance has not yet been investigated. 
They are the 1317C>T polymorphism that does not result in a change in the 
amino acid sequence that has been reported in a frequency of 5% in a small 
group of African-American women (Weisberg et al., 1998), and the 1793G>A 
polymorphism that results in an arginine to glutamine substitution at codon 
594 that has been reported in frequencies of less than 10% in different racial 
groups from among a clinic population in Texas and New York (Rady, Szucs, 
Grady, Hudnall, Kellner et al., 2002). 
 
The 677C>T polymorphism is characterized by a point mutation at nucleotide 
677 in exon 4 of the gene. It results in the substitution of the amino acid 
alanine by valine in the folate-binding site of the N-terminal catalytic domain 
of the enzyme in an evolutionary conserved region (Frosst et al., 1995). The 
MTHFR variant found in 677TT homozygous individuals that has reduced 
enzyme activity had been characterised biochemically as a thermolabile 
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variant of MTHFR before its genetic characterisation (Kang, Zhou, Wong, 
Kowalisyn and Strokosch, 1988). The enzyme activity of MTHFR in 677TT 
homozygotes is 50-60% lower at 37
o
C and approximately 65% lower at 46
o
C 
than in 677CC homozygotes under similar conditions. 677CT heterozygotes 
are in the intermediate range. Reduced activity of the mutated allele has been 
demonstrated in both lymphocytes obtained from peripheral blood (Frosst et 
al., 1995) and placental tissue (Daly, Molloy, Mills, Lee, Conley et al., 1999) 
These variations in MTHFR activity appear to correlate with biochemical 
abnormalities. 677TT homozygotes have higher total levels of homocysteine 
in their plasma than 677CC homozygotes. The homocysteine levels, however, 
depend in part on folate levels, in that homocysteine is increased among those 
who have an inadequate intake of folate (indicated by low serum folate levels) 
while it is normal in others who have an adequate intake of folate (Jacques, 
Bostom, Williams, Ellison, Eckfeldt et al., 1996, Ma, Stampfer, Hennekens, 
Frosst, Selhub et al., 1996). Thus it should be possible to overcome 
hyperhomocysteinaemia caused by the 677T allele by folate supplementation 
(Litynski, Loehrer, Linder, Todesco and Fowler, 2002). 
 
There are many studies examining the prevalence of the 677T allele in many 
parts of the world. They show a wide variation of the frequency of the allele 
between geographical areas and between different racial groups within 
geographical areas.  These variations may reflect the ancestral origin of these 
populations. In these studies the prevalence was highest among Hispanic 
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groups in Italy, Spain and Mexico; and lowest among Africans. White 
Western Europeans and Chinese had frequencies intermediate between these 
two groups. The prevalence among Asian populations varied widely (Pepe, 
Camacho Vanegas, Giusti, Brunelli, Marcucci et al., 1998, Schneider, Rees, 
Liu and Clegg, 1998, Wilcken, Bamforth, Li, Zhu, Ritvanen et al., 2003). The 
prevalence of the 677T allele among the white Caucasians in Britain is 
reported to range from 33 to 38% (Botto and Yang, 2000) and among the Sri 
Lankans it is reported to range from 4.5% (Schneider et al., 1998) to 10% 
(Alagratnam, Wierzbicki, Swaminathan, Turner and Wickramasinghe, 2000). 
 
There are two hypotheses to explain the high frequency of the 677T allele in 
some populations, which attribute it to a selection advantage in the past (Blom, 
1998). First, in times of famine, reduced MTHFR activity would have lead to 
decreased remethylation of homocysteine and thus preserved the available 
one-carbon moieties of the tetrahydrofolate metabolism for the vital synthesis 
of purines and thymidine. Secondly, those who carry the mutated allele have a 
lower risk of colon cancer. As a consequence the frequency of the 677T allele 
would have increased gradually. The unexpectedly high prevalence of the 
677T allele in Mexico, northern China, and southern Italy has suggested the 
possibility of heterozygote advantage with respect to the risk of neural tube 
defects (NTD) because of the reported excess of 677CT heterozygotes among 
first degree relatives of patients with NTD (Weitkamp, Tackels, Hunter, 
Holmes and Schwartz, 1998). These hypotheses, however, are unconfirmed. 
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The 677C>T polymorphism is in partial linkage disequilibrium with the 
1298A>C polymorphism that is characterized by a point mutation at 
nucleotide 1298 in exon 7 of the gene. It results in an amino acid substitution 
(glutamine to alanine) within the c-terminal regulatory domain of the enzyme, 
and is believed to affect the regulation of the enzyme by  
S-adenosylmethionine, an allosteric inhibitor of MTHFR that is known to bind 
in the c-terminal region (Weisberg et al., 1998).  
 
In all studies thus far, almost all subjects with the 677TT genotype and most 
subjects with the 677CC genotype have had the 1298AA genotype and the 
haplotype with both substitutions, 677T/1298C, have been extremely rare 
(<1% or absent). These findings suggest that each substitution would have 
evolved on a separate wild-type allele. (Adjalla, Amouzou, Sanni, 
Abdelmouttaleb, Chabi et al., 2003, Ogino and Wilson, 2003).  The activity of 
the enzyme encoded by the 677CC/1298CC haplotype is approximately 60% 
of that of the enzyme encoded by the 677CC/1298AA haplotype. This is not as 
low as the activity of the enzyme encoded by the 677TT genotype. In addition 
individuals with the 677CC/1298CC haplotype do not appear to have higher 
serum homocysteine levels than controls. Subjects who harbour the 
667TT/1298AA haplotype, however, have reduced enzyme activity and 
elevated homocysteine levels similar to that seen in individuals with the 
677TT genotype (van der Put et al., 1998, Weisberg et al., 1998, Adjalla et al., 
2003).  
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It would appear therefore, given the pathophysiological basis for the selection 
of the MTHFR gene as a candidate gene for pre-eclampsia, that it would be 
sufficient to carry out association analysis using the 677C>T polymorphism, 
as it is the polymorphism that has the predominant functional effect. The 
677C>T polymorphism was therefore selected for this study.
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Figure 1.9. Genomic structure of the MTHFR gene. The exons are numbered. Arrowheads indicate 
the position of the introns. The positions of the two common polymorphisms are indicated.  
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T allele frequency 
Population Cases Controls 
Primi/ 
Multi Exclusion criteria Cases Controls P 
Japanese
1
 67 PE 98 healthy pregnant delivering >22 weeks 
& 260 healthy adults 
? ? 0.48 0.37 <0.02 
Italian
2
 45PE/51GH 129 healthy parous women Both CHT, RD, DM, PD 0.43 0.52 0.057 
Black South African
3
 150 PE 110 healthy pregnant, >37 Weeks Both ED, MD. 0.10 0.06 NS 
Jewish
4
 34 PE 110 healthy pregnant Both ? 0.22 0.08 0.005 
White northern European
5
 283 PE 100 healthy pregnant women at delivery & 
100 healthy non pregnant women with 
no history of PE 
Both 
 
CHT, RD, DM, MP 0.31 0.31 NS 
White
6
 99 PE 114 healthy pregnant women Primi CHT, RD, MD 0.34 0.40 NS 
Black Zimbabwian
7
 171 PE 185 healthy pregnant at delivery Both CHT 0.09 0.09 NS 
Japanese
8
 73 PE 215 healthy pregnant at 1 month 
postpartum 
Both HELLP, CHT, RD, DM, 
MP, FA 
0.38 0.38 NS 
Jewish
9
 63 PE 126 pregnant women with at least 1 normal 
pregnancy immediately postpartum 
Both CHT, MP, TE 0.24 0.10 0.008 
Hungarian
10
 120 PE 101 healthy pregnant women Both CHT, DM, RD, MP 0.34 0.32 NS 
Japanese
11
 133 PE 224 healthy pregnant women ? CHT, RD 0.48 0.37 0.007 
White
12
 281 PE 360 women who have had 2 normal 
pregnancies 
Both ? 0.33 0.33 NS 
White & African American 
13
 
100 PE 97 health pregnant women immediately 
postpartum 
Both CHT, DM, RD, MP, TE, 
FA 
0.22 0.25 NS 
Italian
14
 54 PE 74 health pregnant women  ? CHT, DM, RD 0.10 0.12 NS 
Mexican
15
 13 PE/E 15 healthy pregnant women ? CHT, DM, RD  0.58 0.33 0.059 
German
16
 15 PE 34 healthy pregnant at delivery Both 0.30 0.43 NS 
Croat
16
 25 PE 28 healthy pregnant at delivery Both 0.32 0.33 NS 
Indonesian
16
 41 PE 27 healthy pregnant at delivery Both 
HELLP, CHT, DM, RD, 
VD, HD 
0.10 0.09 NS 
French Canadian
17
 203 PE 357 healthy pregnant women Primi MP, CHT 0.16 0.13 NS 
Table 1.4. Continued in next page. 
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T allele frequency 
Population Cases Controls 
Primi/ 
Multi Exclusion criteria Cases Controls P 
Chinese
18
 57 PE 120 normal women ? ? 0.58 0.39 0.001 
Finnish
19
 113 PE 103 healthy pregnant women postpartum Both CHT, RD, AID 0.23 0.26 NS 
Dutch
20
 176 PE 403 population based controls Both CHT, RD, HD, MP 0.33 0.29 NS 
Dutch
21
 174 PE 120 healthy blood donors ? ? 0.30 0.34 NS 
Australian (White Anglo-
Saxon)
22 
include cases in
23
 
156 PE 79 healthy pregnant women Primi CHT, RD, MD 0.33 0.34 NS 
Scottish
24
 164 PE Primi MP 0.28 0.30 NS 
 303 GH 
103 non pregnant women who have had a 
uncomplicated first singleton pregnancy   0.37 0.30 NS 
Black South African
25
 204 PE 338 normotensive pregnant women Both ? 0.07 0.06 NS 
Table 1.4. A summary of case-control MTHFR 677C>T pre-eclampsia association studies with most studies failing to show an 
association. *The frequency of the MTHFR 677TT genotype. 
Abbreviations: 
?-Information not available 
CHT-Chronic Hypertension 
DM-Diabetes Mellitus 
ED-Endocrine Disease 
FA-Fetal Anomaly 
GH-Gestational Hypertension 
HELLP-HELLP Syndrome 
HD-Hepatic Disease 
MD-Metabolic Disease 
MP-Multiple Pregnancies 
PD-Pulmonary Disease 
PE-Pre-eclampsia 
RD-Renal Disease 
TE-Thromboembolism 
VD-Vascular Disease 
Primi-Primiparous 
Multi-Multiparous 
References: 
1. (Sohda, Arinami, Hamada, Yamada, Hamaguchi et al., 1997) 
2. (Grandone, Margaglione, Colaizzo, Cappucci, Paladini et al., 
1997) 
3. (Chikosi, Moodley, Pegoraro, Lanning and Rom, 1999) 
4. (Kupferminc et al., 1999) 
5. (O'Shaughnessy, Fu, Ferraro, Lewis, Downing et al., 1999) 
6. (Powers, Minich, Lykins, Ness, Crombleholme et al., 1999) 
7. (Rajkovic, Mahomed, Rozen, Malinow, King et al., 2000) 
8. (Kobashi, Yamada, Asano, Nagano, Hata et al., 2000) 
9. (Kupferminc et al., 2000) 
10. (Rigo, Nagy, Fintor, Tanyi, Beke et al., 2000) 
11. (Watanabe, Hamada, Yamakawa-Kobayashi, Yoshikawa 
and Arinami, 2001) 
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2001) 
13. (Livingston, Barton, Park, Haddad, Phillips et al., 2001) 
14. (D'Elia, Driul, Giacomello, Colaone, Fabbro et al., 2002) 
15. (Perales Davila, Martinez de Villarreal, Triana 
Saldana, Saldivar Rodriguez, Barrera Saldana et al., 
2001) 
16. (Prasmusinto, Skrablin, Hofstaetter, Fimmers and 
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17. (Levesque et al., 2003) 
18. (Li, Zheng, Xue, Sun, Chen et al., 2000) 
19. (Laivuori, Kaaja, Ylikorkala, Hiltunen and Kontula, 
2000) 
20. (Zusterzeel, Visser, Blom, Peters, Heil et al., 2000) 
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et al., 2001) 
22. (Kaiser, Brennecke and Moses, 2001) 
23. (Kaiser et al., 2000) 
24. (Morrison, Miedzybrodzka, Campbell, Haites, 
Wilson et al., 2002) 
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1.6. Objectives 
As elaborated above EGF 61G>A, EGF 67149G>A, TGFA 3822G>A, TGFA 
3827T>C, TGFA 3851T>C, AGT 174Thr>Met, AGT 235Met>Thr, AGT 
11535C>A and MTHFR 677C>T polymorphisms and the haplotypes defined 
by them were selected as markers for pre-eclampsia to test the hypothesis that 
EGF, TGFA, AGT and MTHFR are candidate genes for pre-eclampsia in a 
racially distinct South Asian Sinhalese population in Sri Lanka and in a white 
Caucasian population in Nottingham, UK using the case-control candidate 
gene disease association model. The objective of the cases-control candidate 
gene pre-eclampsia association study was: 
1. to compare allele/haplotype frequencies stated above in normotensive 
pregnant women and in women with pre-eclampsia to determine whether 
they are associated with the susceptibility to pre-eclampsia among 
Sinhalese women in the Sri Lankan population; and in white Caucasian 
women in Nottingham, UK. 
 
Since results of such studies would have to be interpreted in relation to the 
population frequencies of these alleles/haplotypes, it was necessary to 
supplement these investigations by examining the allele/haplotype frequencies 
in the Sri Lankan and UK populations. The objective of the population genetic 
study was: 
2. to compare allele/haplotype frequencies stated above in the Sinhalese, the 
Sri Lankan Tamil and the Moor racial groups in the Sri Lankan population 
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and the white Caucasians in Nottingham, UK. 
 
As evidenced by the pathophysiological roles played by them, described in 
previous sections of this chapter, the above mentioned candidate genes may 
also play a role in determining the phenotypic expression of quantitative traits. 
EGF; because of its similarity with EGF, TGFA; and AGT may all play a role 
in determining the birth weight of babies. In addition AGT may determine the 
blood pressure of pregnant women. It was decided therefore, to investigate 
them by examining candidate gene quantitative trait associations in 
normotensive pregnant women and their babies using the above-mentioned 
polymorphic markers. The objectives of the candidate gene quantitative trait 
association study were: 
3. to determine whether haplotypes of the EGF, TGFA and AGT genes in 
normotensive pregnant women are associated with the birth weight of their 
babies among Sinhalese women in the Sri Lankan population; and in white 
Caucasian women in Nottingham, UK. 
4. to determine whether haplotypes of the AGT gene in normotensive 
pregnant women are associated with their antenatal booking blood 
pressure among Sinhalese women in the Sri Lankan population; and in 
white Caucasian women in Nottingham, UK. 
 
As mentioned above in 1.5.3.3, the AGT gene has been a long-standing interest 
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to further understand the regulation of the AGT gene by characterising the 
functional effects of the three common haplotypes in the 3UTR/flanking 
region of the gene defined by the AGT 3UTR/flanking region SNPs on gene 
expression using reporter gene constructs under basal and AngII stimulated 
conditions. The objectives of the reporter gene expression study was: 
5. to study the effects of the three common haplotypes of the 3UTR/flanking 
region of the AGT gene on reporter gene expression in HepG2 cells under 
basal and AngII stimulated conditions. 
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2. METHODS 
All the methods used in these investigations are described in this chapter. 
Since there were no pre-existing DNA resources for Sri Lankans, subjects had 
to be recruited in Sri Lanka afresh. Obtaining ethical clearance to conduct 
these investigations was therefore, the first consideration and it is described at 
the outset. The validation of the heat coagulation test (HCT), which was 
central to establishing the diagnosis of pre-eclampsia in Sri Lanka, is 
described in the second part of the chapter. It is followed by a description of 
the recruitment of subjects for population genetic and case-control candidate 
gene disease association studies and their phenotyping. The generic molecular 
genetic methods are in the fourth part of the chapter. It is followed by a 
detailed description of specific genotyping and functional assays that were 
used for these investigations. The constitution of the buffers and culture media 
prepared in house is in appendix 2. The constitution of the buffers that were 
purchased from outside suppliers is given when it is first mentioned in the text 
if the manufacturer had disclosed it. A list of suppliers is in appendix 3. The 
chapter concludes with a description of the statistical methods, databases and 
software tools used for these investigations and a special note on 
polymorphism nomenclature. 
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2.1. Ethical considerations 
The Ethical Review Committee of the Faculty of Medicine, University of 
Colombo, Sri Lanka, approved these studies. All Sri Lankan volunteers were 
recruited after obtaining written informed consent using consent forms in 
Sinhala and Tamil languages. Some Moors are literate in Sinhala and Tamil 
while others are literate in Tamil only. In addition the Sri Lankan studies were 
also approved by the Department of Health Services, Sri Lanka. 
 
The recruitment of subjects for the white Caucasian DNA resources at the 
University of Nottingham was done with the approval of the Hospital Ethics 
Committee of the Queens Medical Centre, Nottingham, UK. All these 
subjects had been recruited after obtaining written informed consent. 
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2.2. Validation of the urine protein heat coagulation test 
It was necessary to establish that women classified as having pre-eclampsia by 
the clinicians had actually satisfied the research definition for pre-eclampsia 
before recruiting them for the case-control candidate gene disease association 
study. How this was done is described in section 2.4.1. An important 
consideration in the research definition of pre-eclampsia was the use of a 
stringent cut off for the detection of significant proteinuria as has been done in 
the GOPEC study to ensure recruitment of women with strictly defined pre-
eclampsia. In the GOPEC study the following were used as being indicative of 
significant proteinuria: proteinuria of ≥500 mg/day on a 24 hour collection, 
≥300mg/L on a 24 hour collection, ≥50 mg protein/mmol creatinine in a spot 
urine collection, ≥2+ on dipstick testing.  
 
In the two recruiting hospitals in Sri Lanka none of these tests were available 
routinely. What was available was the HCT that was performed in the wards 
by midwives and nurses (Guidotti et al., 1992). The sulphosalycilic acid test 
(SAT) for urinary protein (Gyure, 1977) and in exceptional circumstances 24-
hour urine protein estimations were also available on request from the 
laboratory when false negative HCT results were suspected on clinical 
grounds, but it was the HCT that was usually relied upon by the clinicians to 
detect significant proteinuria. ≥2+ on the SAT had been recommended as the 
cut-off for significant proteinuria in a previous version of the ISSHP 
recommendations (Davey et al., 1988), but it does not appear in the current 
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one (Brown et al., 2001). The threshold for significant proteinuria using the 
HCT, however, seems not to have been determined before.  
 
In a Sri Lankan study, ≥1+ on the HCT had been found to correspond on 
average to >300 mg of protein on a 24 hour collection (Kudalugoda Arachchi, 
Malalasekara, Premaratne, Lanerolle and Sheriff, 1998). This article, however, 
did not report the sensitivity, the specificity, the positive predictive value 
(PPV), or the negative predictive value (NPV) of the test. Although the 
authors were contacted with the view to obtaining the raw data to carry out 
this analysis, they were unable to trace the original data. Another drawback in 
that study was that a research assistant had performed the HCT once the 
sample reached the laboratory. In actual practice, however, it is a midwife or 
nurse who performs it in a busy ward setting.  
 
It was decided to adopt the cut-off of ≥1+ on the HCT as the definition for 
significant proteinuria for the purpose of recruiting women with pre-eclampsia 
in Sri Lanka, but at the same time the need to validate the use of this cut-off to 
detect significant proteinuria was recognised. To do so, a study was carried out 
with the aim of determining whether ≥1+ on a standardised HCT reliably 
detects significant proteinuria defined as ≥500 mg/day on a 24-hour urine 
collection and to compare it with the Roche Combur
10
 Test
® 
dipstick test for 
protein (Roche Diagnostics Ltd.). 
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2.2.1. Recruitment of subjects and the study protocol 
The recruitment was conducted in the De Soysa Hospital for Women (DSHW) 
and the Castle Street Hospital for Women (CSHW), the two main teaching 
hospitals of the University of Colombo, Sri Lanka, between August 2002 and 
April 2003. The aim of recruitment was to recruit as many women as possible 
during this period. 107 hospitalised pregnant women of >20 weeks of 
gestation whose proteinuria status was known based on a HCT result within 
the preceding 24 hours as a part of routine inpatient clinical care were 
recruited after obtaining written informed consent. At recruitment they passed 
a sample of urine and immediately thereafter began a 24-hour urine collection 
under supervision. A midwife or nurse performed a HCT and a dipstick test on 
separate aliquots of the initial sample. Midwives and nurses were trained on 
performing the HCT according to a standard protocol (see appendix 4) and the 
dipstick test according to manufacturers instructions. This dipstick test is 
based on the principle of the protein error of pH indicators. The 24-hour urine 
protein estimations were made in the laboratory using the pyrogallol red 
method (Randox Laboratories Ltd, UK) by a technician who was blinded to 
the results of the tests done in the ward. A third aliquot of the initial sample 
was sent to the laboratory for a SAT. The SAT is used routinely in Sri Lanka 
as a backup test if the HCT is negative when there is strong clinical suspicion 
of significant proteinuria.  Briefly the SAT involved acidifying urine by 
adding 10% acetic acid, centrifugation of the sample for 5 minutes at 3000 
rpm, placing 2ml of urine in a test tube, adding 2ml of 5-sulphosalicylic acid, 
101 
and making a qualitative assessment of turbidity to report the result. The 
coefficient of variance for 24-hour proteinuria estimations in this lab between 
different runs was 3%. 
 
2.2.2. Results 
Five women were excluded because their 24-hour urine collections were not 
completed. The dipstick test results of 31 women were not available because 
the midwife or nurse performing the HCT had either not performed the 
dipstick test or having performed it, had not recorded the result. SAT results 
were available for 88 women. 
 
The results of the women for whom results of both the HCT and dipstick test 
were available are summarised in Table 2.1. ≥1+ on the HCT was comparable 
with ≥2+ on the dipstick test in detecting proteinuria of ≥300mg/day or 
≥500mg/day. ≥1+ on the dipstick test had the highest sensitivity for detecting 
proteinuria of ≥300mg/day, but lacked specificity at ≥500mg/day. 
 
2.2.3. Discussion 
≥1+ on the HCT is as good as ≥2+ on the dipstick test in detecting proteinuria 
of ≥500mg/day. The HCT, however, is less sensitive than ≥1+ on the dipstick 
test in detecting lesser degrees of proteinuria. In the West, where dipstick 
testing is routine in clinical practice, its sensitivity is perceived to be much 
higher than evidence from this and other studies would suggest (Kuo, 
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Koumantakis and Gallery, 1992, Brown and Buddle, 1995, Bell, Halligan, 
Martin, Ashmore, Shennan et al., 1999). Induced diuresis is often cited as a 
reason for false negative dipstick results. This may be true of the HCT as well. 
The practice in Sri Lanka, to overcome the problem of false negative HCT 
results, is to test another aliquot of the urine sample using a more sensitive 
laboratory test such as the SAT when significant proteinuria is clinically 
suspected. In this study, of the false negatives on the HCT, 70% with 
proteinuria of ≥500mg/day and 50% with ≥300mg/day were picked up by the 
SAT. The sensitivity of the combined HCT and SAT based on the results of 
the 88 women for whom results of both tests were available was 0.90 for 
proteinuria of ≥500mg/day and 0.73 for proteinuria of ≥300mg/day. It is clear 
therefore that having a backup test for HCT such as the SAT would be useful 
in clinical settings where access to 24-hour urine protein estimations is not 
readily available. The prevalence of significant proteinuria in this hospitalised 
series of women was high. It was 0.59 for significant proteinuria of 
≥300mg/day and 0.37 for significant proteinuria of ≥500mg/day. The positive 
and negative predictive values may be distorted because of this high 
prevalence. These values were tested therefore across a prevalence range from 
0.05 to 0.60. These results showed that the results of the HCT and the dipstick 
test are comparable across this range (Table 2.2). 
 
In conclusion therefore, ≥1+ on the HCT is a suitable cut off point for 
detecting proteinuria of ≥500mg/day. 
103 
24hr Urine Protein 
 Heat Coagulation Test    Dipstick Test   Sulphosalycilic Acid Test 
Estimation 
 Negative   ≥1+   Total    Negative ≥1+ Total   Negative/1+ ≥2+ Total   Negative ≥1+ Total 
 <300 mg/day  25  1  26   24 2 26  25 1 26  24 2 26 
 ≥300mg/day  15  30  45  9 36 45  23 22 45  7 29 36 
 Total  40  31  71  33 38 71  48 23 71  31 31 62
*
 
                
 Sensitivity    0.67    0.80    0.49    0.81 
 Specificity    0.96    0.92    0.96    0.92 
 PPV  0.97    0.95    0.96    0.94 
 NPV  0.63    0.73    0.52    0.77 
                                
                
 <500 mg/day  59 6 65  28 12 40  37 3 40  30 8 38 
 ≥500mg/day  11 26 37  5 26 31  11 20 31  1 23 24 
 Total  70 32 102  33 38 71  48 23 71  31 31 62
*
 
                
 Sensitivity    0.70    0.84    0.65    0.96 
 Specificity    0.91    0.70    0.93    0.79 
 PPV  0.81    0.68    0.87    0.74 
 NPV  0.84    0.85    0.77    0.97 
                                
 
Table 2.1. Comparison of the results of the HCT, dipstick test and SAT. Results are from data of women who had both the HCT and 
dipstick test result. 
*
Nine women did not have the SAT result. All figures, except the sensitivity, specificity, PPV, and NPV, refer to 
number of women. PPV: Positive Predictive Value. NPV: Negative Predictive Value. 
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ence 0.05 0.10 0.15 0.20 0.25 0.30 0.35 0.40 0.45 0.50 
                    
        
        
0.52 0.70 0.79 0.84 0.87 0.90 0.92 0.93 0.94 0.95 
0.97 0.95 0.92 0.89 0.86 0.82 0.79 0.75 0.71 0.66 
         
0.35 0.54 0.65 0.72 0.78 0.82 0.85 0.87 0.89 0.91 
0.99 0.98 0.96 0.95 0.93 0.92 0.90 0.87 0.85 0.82 
         
0.40 0.59 0.69 0.76 0.81 0.84 0.87 0.89 0.91 0.93 
0.97 0.94 0.91 0.88 0.85 0.81 0.78 0.74 0.70 0.65 
          
gative (NPV) predictive values of the heat coagulation test and the dipstick test across a proteinuria prevalence range from 0.05 to 0.60. Based on PPV and NPV of all 102 wom
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2.3. Recruitment of population volunteers 
2.3.1. Sri Lankan subjects 
The genetic epidemiological component of this study was designed to identify 
gross differences in allele frequencies between racial groups. 80 Sinhalese, 80 Sri 
Lankan Tamil, and 81 Moor subjects were recruited for this study in Colombo, 
Sri Lanka (50% male). They were recruited from among women attending 
antenatal clinics at the DSHW, staff and students of the University of Colombo, 
and accompanying persons of patients attending General Practice clinics. With a 
sample of 80 subjects it was possible to detect a minimum difference of 0.07 or 
+0.11 in the frequency of an allele, between two populations, when that allele 
occurs in a frequency of ≥0.10 in one of them, at a significance level of P=0.05 
with 80% power (Table 2.3). All subjects were assigned to the correct racial 
group by inquiring from them about the race and country of origin (to identify 
and exclude Indian Tamils) of their parents and all four grandparents. Those of 
mixed race were excluded. The medical history of all volunteers was recorded. 
1.5 ml of venous blood was obtained from each volunteer. 
 
2.3.2. British subjects 
The white Caucasian population in Nottingham, UK was studied using an 
already existing DNA resource at the University of Nottingham (Morgan et 
al., 1996, Plummer et al., 2002). Samples in this resource had been collected 
from volunteers attending a blood donor clinic in Nottingham. 80 subjects 
(50% male) were selected randomly from this resource. 
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Allele frequency in 
population 1 
Minimum difference in 
allele frequency 
detectable in population 2 
0.10  0.07 , + 0.11 
0.25  0.12 , + 0.14 
0.50  0.15 , + 0.15 
 
Table 2.3. Population frequencies of polymorphic 
variants detectable at significance level P=0.05, with 
Power = 80% with a sample size of 80. Power calculation 
was done with Sample Size Software, SPSS Inc., USA. 
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2.4. Recruitment of women with pre-eclampsia and normotensive 
pregnant women 
2.4.1. Sri Lankan subjects 
Recruitment of women with pre-eclampsia and normotensive pregnant women 
in the Sri Lankan population was done from the DSHW and the CSHW from 
August 2001 to January 2003. The nine consultant obstetrics units in these two 
hospitals account for approximately 25 000 deliveries per year. 
 
Pre-eclampsia, for the purpose of recruitment, was defined as hypertension of 
≥140/90 mmHg on two occasions six hours apart occurring after 20 weeks of 
gestation in a previously normotensive woman, together with proteinuria of 
≥1+ on the HCT (see section 2.2) not associated with urinary tract infection or 
ruptured membranes.  
 
Potential recruits were identified by doctors, midwives, and nurses in the 
referring units and referred for recruitment. A total of 324 gravida 1 para 0 
(G1P0) and 32 gravida 2 para 0 (G2P0) women were referred for recruitment. 
All multigravid women had conceived again with the same partner. On the basis 
of the referral 228 (64%) women were deemed to fulfil recruitment criteria. Four 
of them had left the hospital prior to being approached for recruitment. The rest 
were approached for recruitment; of them eight declined. The balance, 216 
women, were recruited after obtaining written informed consent; of them six 
were subsequently withdrawn from the study either because they were deemed 
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not to have actually fulfilled the recruitment criteria or because they were 
subsequently found to have one or more exclusion criteria information about 
which had come to light after recruitment. Therefore only 210 (59%) of the 356 
women were recruited. A much higher exclusion rate is reported in the GOPEC 
study where similar rigorous inclusion criteria were applied (OMalley, Personal 
Communication). It is interesting to note that in both studies the main reason for 
non-participation was the failure to fulfil the criteria for significant proteinuria 
(Table 2.4). 
 
Almost all women with pre-eclampsia were recruited before delivery. Two 
Sinhalese women who developed postpartum eclampsia following delivery at 
term were found to have blood pressure and proteinuria that fulfilled the 
diagnostic criteria and were recruited. Women were not approached for 
recruitment or were withdrawn from the study following recruitment for the 
following reasons: mixed race or current pregnancy fathered by a man of a race 
other than that of the woman; renal disease, chronic hypertension, or persistent 
proteinuria (defined as ≥1+ on the HCT in the first three urine samples tested in 
pregnancy with or without urinary tract infection); ischaemic heart disease, 
cerebrovascular accidents, or insulin or non-insulin dependent diabetes mellitus; 
BMI ≥30kg/m
2 
based on height and weight measured at the antenatal booking 
visit or, in case of unbooked pregnancies, postpartum; hydatidiform mole, 
multiple fetuses, or gestational diabetes in the current pregnancy; and pregnancy 
conceived as a result of in-vitro fertilisation where such information was 
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volunteered by the woman. Race was established as in section 2.3.1. When 
recording the family history, information regarding consanguinity was also 
recorded. However, consanguinity was reported only in one family. 
 
A summary of recruitment is given in table 2.4. It also includes an analysis of 
the reasons for non-participation and/or withdrawal. An analysis of the race of 
the recruited women is given in table 2.5. 10ml of venous blood was obtained 
at the time of recruitment from all recruits.  
 
Recruitment of normotensive pregnant women was conducted from May 2002 
to January 2003. The normotensive pregnant women were matched for race, 
parity, age, and BMI with the women with pre-eclampsia. In June 2002, a 
preliminary analysis of the racial breakdown of women with pre-eclampsia 
recruited up to then indicated that by the end of the recruitment period it 
would not be possible to recruit sufficient numbers of Tamil and Moor women 
with pre-eclampsia to carry out any meaningful genetic analysis. It was 
decided therefore, to confine the genetic studies to Sinhalese women. As such 
recruitment of normotensive controls was confined to primigravid Sinhalese 
women. In addition to ensuring that they were normotensive and non-
proteinuric throughout the pregnancy, all other exclusion criteria applied to 
women with pre-eclampsia were also applied to normotensive pregnant 
women. Moreover, normotensive pregnant women delivering before the 37
th
 
week of gestation and women delivering babies weighing <2.0 kg were not 
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recruited. This was an arbitrary cut-off; however, the mean weight of 
Sinhalese babies delivering at term in Sri Lanka is reported to be 2824g 
(standard deviation (SD) 413g; Male 2911g (SD 427g), Female 2820g (SD 
440g)) (Nanayakkara, 1998).These women were excluded because it is 
possible that pre-eclampsia and low birth weight may have common 
aetiological factors as evidenced by the changes seen in the placenta in both 
conditions (Khong et al., 1986). Normotensive pregnant women were 
identified by midwives and nurses on the first postpartum day while in 
postnatal wards and referred for recruitment. A total of 180 Sinhalese 
normotensive pregnant women were recruited as controls. During the 
recruitment period weekly comparisons were made between case and control 
groups to determine the inter group variability in age and BMI, and based on 
that, appropriate controls were recruited to match the two groups as closely as 
possible. 
 
The phenotyping booklet for women with pre-eclampsia of the GOPEC study 
was modified and adopted to collect the phenotyping data of the Sri Lankan 
women. Data were stored in a SPSS database. Data relating to severity of 
disease, delivery, and the baby of one Sinhalese woman with pre-eclampsia 
who was transferred to a district hospital for delivery were not available. It 
was possible, however, to confirm that the mother and baby were safe and 
well after delivery, and that she had made a complete recovery postpartum. 
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 No 
Total Referred 356 
Could not be approached for recruitment 4 
Consent not given 8 
Excluded or withdrawn  
Failed proteinuria criteria 64 
Chronic hypertension 18 
Twin pregnancy 12 
Diabetes mellitus/Gestational diabetes 11 
Failed blood pressure criteria 10 
Body Mass Index ≥30 kg/m
2
 8 
Mixed race marriage 7 
G1 abortion at a period of gestation > 12 weeks 3 
Blood sampling could not be done 1 
Total Recruited 210 
 
Table 2.4. Summary of recruitment of Sri Lankan women with pre-
eclampsia. 
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Total 
Race 
No % 
Population
%
1
 
Sinhalese 180 86% 76% 
Sri Lankan Tamil 17 8% 11% 
Indian Tamil 1 0% 1% 
Moor 12 6% 9% 
Total 210 100%  
 
Table 2.5. The racial breakdown of the Sri Lankan 
women with pre-eclampsia. 
1
As a % of the total 
population of each race in the district of Colombo 
(Department of Census and Statistics, 2001). 
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2.4.2. British subjects 
The white Caucasian women with pre-eclampsia and normotensive pregnant 
women in Nottingham, UK were studied using an already existing DNA 
resource in the University of Nottingham. Samples in this resource were 
collected from volunteers delivering in obstetric units at the Queens Medical 
Centre and the City Hospital in Nottingham between 1988 and 1999. All 
subjects had given written informed consent to participate. This collection had 
been made by Morgan and colleagues for preliminary investigations into 
genetics of pre-eclampsia (Morgan et al., 1995, Morgan, Crawshaw, Baker, 
Edwards, Broughton Pipkin et al., 1997, Morgan, Crawshaw, Baker, 
Brookfield, Broughton Pipkin et al., 1998, Morgan et al., 1999a). It contained 
both primiparous and multiparous samples. 74 primiparous pre-eclamptic and 
81 primiparous normotensive samples from this collection were selected for 
the study. Some samples in this collection were not selected because there was 
insufficient DNA left for analysis. A SPSS phenotyping database of these 
women had been maintained. It was however, not as comprehensive or 
complete as the phenotyping database of the Sri Lankan women. At the time 
this collection was made, since the emphasis was on genetic studies, the 
samples were coded as pre-eclamptic or normotensive and anonymised. It was 
not possible therefore, to identify the subjects for whom data was missing to 
retrieve their case notes to complete the missing data. 
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2.5. Generic molecular genetic methods 
2.5.1. DNA extraction 
Venous blood obtained from Sri Lankan population volunteers, women with 
pre-eclampsia and normotensive pregnant women were collected into EDTA 
containing tubes and stored at 20
o
C prior to DNA extraction. DNA extraction 
was done using QIAamp
®
 DNA mini kits (Qiagen Ltd., UK) according to the 
manufacturers protocol. This protocol involves lysis of leukocytes, adsorption 
of DNA on to a silica membrane, washing of membrane to ensure the removal 
of proteins and other possible contaminants, and the elution of DNA from the 
column.  
 
The QIAamp
®
 DNA Blood Mini Kit DNA extraction procedure was carried 
out as follows: 20μl of protease (or proteinase K), 200μl of venous blood, and 
200μl of lysis buffer AL were added to a 1.5 ml microcentrifuge tube in that 
order and mixed by pulse vortexing for 15 seconds. Then the reaction was 
incubated at 56
o
C for 10 minutes. Following incubation the tube was 
centrifuged briefly to remove drops from the inside of the lid. Then 200μl of 
ethanol was added to the reaction, mixed by pulse vortexing for 15 seconds, 
and the tube briefly centrifuged again to remove drops from the inside of the 
lid. This reaction mix was then applied to a QIAamp spin column that was 
placed on a 2ml collection tube and the column was centrifuged at 8000 rpm 
for 1 minute. Next 500μl of wash buffer AW1 was applied to the spin column. 
This was followed by centrifugation at 8000 rpm for 1 minute. Lastly 500μl of 
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wash buffer AW2 was applied to the spin column. This was followed by 
centrifugation at 14 000 rpm for 1 minute. After each centrifugation step the 
flow-through was discarded.  Finally the spin column was placed in a 1.5ml 
collection tube and 200μl of elution buffer AE was added to the spin column. 
After incubating the column for 5 minutes at room temperature, DNA was 
eluted from the column by centrifugation at 8000 rpm for 1 minute. The eluted 
DNA samples were labelled and stored at 20
o
C. 
 
2.5.2. Polymerase Chain Reaction 
Amplification of DNA segments of interest was the starting point for almost 
all the experiments described in this thesis. This was done using the 
polymerase chain reaction (PCR). PCR amplification involves simultaneous 
primer extension on complementary strands of DNA with two oligonucleotide 
primers, specific to each strand that flank the genomic region to be amplified, 
using thermostable Taq DNA polymerase enzyme in the presence of 
deoxynucleotides and a reaction buffer containing Mg
2+
 (Saiki, Scharf, 
Faloona, Mullis, Horn et al., 1985, Mullis and Faloona, 1987, Saiki, Gelfand, 
Stoffel, Scharf, Higuchi et al., 1988). PCRs were performed on Techne Genius 
(Techne, UK) or DNA Engine: Tetrad  PTC225 (Genetic Research 
Instrumentation, UK) programmable thermal cyclers without the need for oil 
overlay. All PCR buffers and enzymes used in these investigations were from 
Roche Diagnostics GmbH, Germany and MBI Fermentas, Lithuania (Helena 
Biosciences, UK). 
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PCR primers were designed using Primer3 software (see section 2.8). PCR 
were conducted in a reaction mix containing 100-200ng of template genomic 
DNA, 200μM deoxynucleotides (dNTPs: dATP, dCTP, dGTP and dTTP), 
PCR reaction buffer (10mM Tris-HCL, 50mM KCl, 1.5 mM MgCl2, pH 
8.3,20
o
C), and 1U Taq DNA polymerase. PCR amplification involved 
repeated cycles of heat denaturation of the genomic DNA at 94
o
C for 30 
seconds, annealing of the primers to their complementary sequences at an 
annealing temperature depending on the melting temperature of the two 
primers, which was determined empirically, for 1 minute, and extension of the 
annealed primers at 72
o
C for 1 minute.  The temperature cycles were preceded 
by 2 minutes at 94
o
C and concluded with 10 minutes at 72
o
C followed by 
cooling at 4
o
C. The presence of PCR amplified products was confirmed by 
electrophoresing a fraction of the reaction mix on an agarose gel (see section 
2.5.3) 
 
2.5.2.1. Multiplex PCR 
Multiplex PCR is a variant of PCR in which two or more genomic regions are 
simultaneously amplified in the same reaction using multiple sets of 
oligonucleotide primers (Chamberlain, Gibbs, Ranier, Nguyen and Caskey, 
1988, Henegariu, Heerema, Dlouhy, Vance and Vogt, 1997). It is described in 
section 2.6.5. 
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2.5.2.2. Mutagenically Separated PCR 
Mutagenically separated PCR (MS-PCR) is a variant of PCR that is used for 
genotyping biallelic polymorphisms. It enables genotyping by examining PCR 
products on an agarose gel without the need for further downstream 
processing. It is described in section 2.5.5.2. 
 
2.5.3. Agarose gel electrophoresis 
Electrophoresis through agarose is the standard method used to separate and 
identify DNA fragments. During electrophoresis negatively charged DNA 
molecules migrate towards the anode with smaller fragments having greater 
mobility. The location of DNA within the gel can be determined directly by 
staining with low concentrations of the dye ethidium bromide that intercalates 
with DNA as it migrates and fluoresces when examined over ultra violet (UV) 
light on a UV transilluminator. 
 
Agarose gels were prepared by mixing an appropriate amount of molecular 
biology grade agarose (Helena Biosciences, UK) in an appropriate volume of 
1 × TAE buffer to obtain the correct percentage gel (weight/volume). 0.5μg/ml 
of ethidium bromide (Sigma-Aldrich, UK) was added to each gel. Gels were 
poured into gel casting trays fixed with combs with the desired number of 
wells and allowed to set at room temperature. After that the gels were 
submerged in 1 × TAE buffer. Next approximately 5μl of each sample of 
DNA to be resolved mixed with 5μl of gel loading buffer (15% (w/v) Ficol; 
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Sigma-Aldrich, UK) were placed in separate wells and a 50 volt current was 
applied. The pattern created by different size DNA fragments was visualised 
by examining the gel on a UV transilluminator. The size of the DNA 
fragments can be confirmed by electrophoresing in the presence of a size 
marker in one of the wells. 100bp DNA ladder and ΦX 174 size markers 
(Promega, UK) were used as the size marker in the investigations described in 
this thesis. 
 
2.5.4. Automated sequencing 
Automated sequencing was done to confirm the genotype of control samples 
used in genotyping assays, as well as to confirm the insert sequence of plasmid 
constructs used in the reporter gene expression investigations. PCR amplified 
products of genomic regions flanking polymorphic sites were sequenced to 
confirm the genotype while miniprep plasmid DNA were sequenced to 
confirm the insert sequence.  
 
PCR mixes contain various impurities such as excess primers and 
deoxynucleotides in addition to the PCR products. Excess primers can be 
removed by treatment with Exonuclease I (ExoI). Excess deoxynucleotides 
can be removed by treatment with Shrimp Alkaline Phosphatase (SAP). This 
was done by incubating 5μl of a PCR reaction mix in a final volume of 10μl 
containing 5U ExoI and 1U SAP (Amersham Biosciences, UK) at 37
o
C for 15 
minutes. The reaction was stopped by inactivating the enzymes by further 
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incubation for 15 minutes at 80
o
C. The reaction was then cooled on ice and 
spun down before being subjected to the cycle sequencing reaction. 
 
Cycle sequencing was done using the ABI PRISM
®
 BigDye
®
 Primer v3.0 
Cycle Sequencing Ready Reaction Kit (Applied Biosystems, UK). This 
system works on the basis of the Sanger dideoxy chain termination principle 
(Sanger, Nicklen and Coulson, 1977). It contains four ddNTPs with different 
fluorescence labels and AmpliTaq
®
 DNA polymerase. At the end of the 
reaction PCR products of varying sizes all terminating with a fluorescent-
labelled dideoxy nucleotide are generated. The sequence is then read out 
automatically by capillary electrophoresis of cycle sequencing products 
through an automated sequencing machine. 
 
Cycle sequencing reactions were set up in a final volume of 10μl, containing 
3μl enzyme treated PCR products, 4μl big dye ready reaction mix, and 
approximately 5pmol of the sequencing primer in a final volume of 10μl. All 
reactions were set up and run in the dark (samples covered with aluminium 
foil) to prevent degeneration of light sensitive dyes. The reactions were subject 
to 25 cycles of denaturation at 96
o
C for 30 seconds, primer annealing at 50
o
C 
for 15 seconds and primer extension at 60
o
C for 4 minutes. The temperature 
cycles were concluded with 28
o
C for 1 minute followed by cooling. Following 
cycling, products were cleaned by loading them on to a Centriflex
®
 gel 
filtration cartridge (Edge Biosystems, USA) and subjecting it to centrifugation 
120 
at 3600 rpm for 2 minutes. The filtrate was evaporated to dryness at 90
o
C and 
then stored at 20
o
C prior to automated sequencing.  
 
2.5.5. Genotyping methods 
2.5.5.1. Restriction Fragment Length Polymorphism 
Polymorphisms sometimes create or abolish recognition sites for restriction 
enzymes. This can be made use of for genotyping as follows: Firstly genomic 
DNA flanking the polymorphic site is amplified by PCR. Then the PCR 
amplified products are digested with the appropriate restriction enzyme. 
Finally the genotype is determined by inspecting the pattern created by 
resolving the restriction-digested PCR fragments by electrophoresis on an 
agarose gel. This is termed restriction fragment length polymorphism (RFLP).  
 
All restriction enzymes and buffers used in these investigations were from 
Roche Diagnostics GmbH, Germany or MBI Fermentas, Lithuania (Helena 
Biosciences, UK). Restriction digestion was carried out in a reaction mix 
containing 10μl PCR products, 2U appropriate restriction enzyme and 1 × 
appropriate restriction digestion buffer in a final volume of 15μl. The reaction 
was incubated overnight at 37
o
C. The digested products were resolved by 
electrophoresing a fraction of the reaction mix by agarose gel electrophoresis 
(see section 2.5.3) to identify the genotype. 
 
It is useful to build in an internal quality control to any RFLP assay to 
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distinguish truly undigested samples from those in which the restriction 
enzyme fails to digest a recognition site that is actually present in the sample. 
One way to do this is to locate a naturally occurring non-polymorphic constant 
recognition site for the same restriction enzyme close to the polymorphic site 
and design PCR primers so that the constant restriction site is also 
incorporated into the amplified PCR product. When such a PCR product is 
digested, the constant site should be digested in all reaction tubes. If it has 
failed to digest, then that sample has to be repeated. This method was used for 
internal quality control in all PCR/RFLP assays described in this thesis. When 
a constant restriction site is not found near the polymorphism of interest a 
multiplex PCR could be set up to co-amplify a different genomic region 
containing a constant restriction site or a PCR primer could be designed 
incorporating a constant restriction site within the primer sequence. The use of 
both these strategies in PCR/RFLP genotyping assays, for example, to 
genotype the MTHFR 677C>T polymorphism has been described before (Van 
Amerongen, Mathonnet, Boucly, Mathieu, Vinatier et al., 1998, Bravo-Osorio 
and Bydlowski, 2000). 
 
2.5.5.2. Mutagenically Separated PCR 
In this method genomic DNA is amplified by PCR using two primers of 
different lengths specific to each allele of a biallelic polymorphism and a 
common reverse primer. Then the genotype is determined by inspecting the 
pattern created by resolving the PCR products by electrophoresis on an 
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agarose gel.  
 
This method makes use of the inherent amplification refraction property of 
primers mismatched at their 3 end (Kwok, Kellogg, McKinney, Spasic, Goda 
et al., 1990) and the inability of Taq DNA polymerase to perform 3 to 5 
proofreading to correct and amplify such mismatched primers. As a result, 
only the primer(s) specific for the allele(s) present in a sample of genomic 
DNA are amplified under appropriate conditions (Rust, Funke and Assmann, 
1993). As such, designing primers for a MS-PCR assay required special 
consideration. The 3 end of the each primer should contain a nucleotide 
specific for one allele of the polymorphism. One or more nucleotide 
mismatches should be incorporated near the 3 end to improve the allele 
specificity of the primer and two mismatches should be incorporated into the 
longer primer at two positions corresponding to the 5 end of the shorter 
primer to inhibit filling up of heteroduplex molecules that may be formed 
between long and short PCR products during the final cycles of the PCR. The 
effects of the incorporation of such mismatches on primer extension have been 
studied extensively (Newton, Graham, Heptinstall, Powell, Summers et al., 
1989, Kwok et al., 1990, Rust et al., 1993).  
 
2.5.5.3. Competitive Allele Specific Oligonucleotide Hybridisation 
Under certain conditions short oligonucleotide probes bind to a single stranded 
DNA target only when perfectly matched  a difference in even a single base 
123 
is adequate to prevent binding. This property is made use of in allele specific 
oligonucleotide (ASO) hybridisation assays to genotype biallelic 
polymorphisms. In this method genomic regions of interest are first amplified 
by PCR. Then PCR products are spotted on duplicate sets of nylon 
membranes. Next each membrane is incubated with a radiolabelled 
oligonucleotide probe specific for either the wild type or the variant allele of 
the polymorphism. Then hybridisation of labelled probes is revealed by 
autoradiography to determine the genotype.  
 
Oligonucleotide probes can vary from 15 to 25 bases in size and the 
polymorphic site is usually located towards their centre. This method can be 
improved by reducing non-specific binding of probes to target DNA by pre-
hybridisation of each filter with a 10 fold molar excess of the unlabelled 
alternative oligonucleotide prior to hybridisation with the labelled probe. This 
improved competitive method increases the accuracy of ASO hybridisation by 
enhancing the specificity of probe binding and reducing background noise 
(Gunneberg, Scobie, Hayes and Kalsheker, 1993).  
 
In preparation for competitive ASO hybridisation, genomic regions flanking 
the polymorphism of interest were amplified by PCR. Then 2μl of the PCR 
product were denatured in 200μl of 0.2N NaOH/2 × SSC and spotted onto 
duplicate nylon membranes (Hybond N+, Amersham Biosciences, UK). In 
addition, two oligonucleotides, each specific for one of the alleles of the 
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polymorphism were radiolabelled in a 10μl reaction containing 3pmol 
oligonucleotide, 5U T4 polynucleotide kinase (PNK), 1 × PNK buffer (70mM 
Tris-HCl; pH 7.6 at 25ºC, 10mM MgCl2, 5mM DTT) (Promega, UK), and 
6pmol γ
32
P-dATP. The reaction was incubated at 37ºC for 1 hour and 
terminated by incubation at 80ºC for 10 minutes. Un-incorporated 
radiolabelled nucleotides were removed by size exclusion chromatography 
through Sephadex
®
 G-50 (Amersham Biosciences, UK) spin columns. 
 
Competitive ASO hybridisation consisted of two steps. First each membrane 
was prehybridised at 52
o
C for 1 hour in 10ml 5 × SSPE/1% SDS containing 
30pmol of unlabelled oligonucleotide corresponding to each allele, and then 
they were hybridised at 52
o
C for 1 hour in 10ml 5 × SSPE/1% SDS containing 
3pmol of the alternative 
32
P end labelled ASO. Following hybridisation 
membranes were washed in 2 × SSPE/0.1% SDS for two 30 minute periods at 
room temperature, then twice for 15 minutes in 5 × SSPE/0.1% SDS at 52°C, 
and autoradiographed at 80°C overnight. Once the genotypes were 
determined the probes were removed from the filter by placing them on a tray 
containing boiled 0.1% SDS on a shaker for 30 minutes. As a result filters 
could be reused to determine the genotype at multiple sites within the same 
PCR product. 
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2.5.5.4. Quality control considerations 
Quality control was an important consideration in all genotyping assays. In 
PCR before RFLP and competitive ASO hybridisation assays, and in MS-PCR 
assays DNA-free controls were used. If any of these negative controls were 
found to have PCR amplified products on gel electrophoresis, then the entire 
PCR batch was repeated. In MS-PCR and in RFLP assays sequenced positive 
controls were also used. If they gave a wrong genotype the entire batch was 
repeated. In addition in PCR/RFLP assays as described in section 2.5.5.1 
constant restriction sites were used for internal quality control of each 
restriction digestion reaction. In competitive ASO hybridisation assays, at 
least one sample of each genotype was sequenced to confirm the genotype. 
 
Two independent observers read all gels and autoradiographs. Samples were 
re-genotyped when the observers did not agree on the genotype. Genotype 
frequencies of all polymorphisms were examined to confirm that they were in 
HWE. If the genotypes of samples of normotensive pregnant women or 
samples of population volunteers were not in HWE then they were re-
genotyped. In the investigations described in this thesis this had to be done 
once (see section 2.6.2). The final level of quality control was applied 
statistically when haplotype analysis was done. Rare haplotypes occurring in 
frequencies of ≤0.05% could represent either actual rare haplotypes or false 
haplotypes created as a result of genotyping errors. Such haplotypes were 
therefore excluded from the analysis.  
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2.5.5.5. Selection of genotyping methods 
Nine polymorphisms were genotyped in the investigations described in this 
thesis. When a genotyping method had already been described for a particular 
polymorphism that method was used for genotyping; however, modifications 
were made to such methods to improve quality control when appropriate. New 
genotyping methods had to be developed to genotype several polymorphisms. 
Different genotyping strategies were employed for each one of them so that 
the author gained experience with different methods. The amount of time 
taken up for genotyping, workload, and cost are important considerations in 
selecting a genotyping method. In terms of time and the amount of work 
involved MS-PCR was the quickest and least labour intensive. In terms of cost 
PCR/RFLP methods were the most expensive because of the additional cost of 
restriction enzymes, but the relative cost of the genotyping methods employed 
in the investigations described in this thesis did not differ greatly.  
 
2.5.6. Mammalian cell culture 
Cells from a human hepatoma cell line (HepG2) obtained from the European 
Collection of Cell Cultures (ECACC) were used in the reporter gene 
expression investigations described in this thesis (Aden, Fogel, Plotkin, 
Damjanov and Knowles, 1979, Knowles, Howe and Aden, 1980). Cell culture 
procedures were carried out under sterile conditions in a Class I flow cabinet. 
All culture media and reagents used in these investigations were from Sigma-
Aldrich, UK or Gibco BRL (Invitrogen, UK).  
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Stocks of HepG2 cells were maintained in a cryopreserved state in liquid 
nitrogen. They were rapidly thawed and grown in 25ml or 75ml flasks in 
complete Eagle Minimal Essential Medium (EMEM) at 37ºC in a humidified 
atmosphere containing 5% carbon dioxide. The complete EMEM contained 
84% EMEM, 10% heat-treated fetal bovine serum, 2% l-glutamine, 1% 
penicillin/streptomycin, 1% amphotericine B, 1% non essential amino acids, 
and 1% sodium pyruvate. 
 
2.5.6.1. Feeding cells 
The culture medium in the flask was replaced every 2-3 days to provide the 
cells with a continuous supply of nutrition. This entailed the removal of the 
old culture medium, washing the cells with phosphate buffered saline (PBS), 
pipetting out all the PBS, and replenishing the flask with complete EMEM. 
 
2.5.6.2. Passaging 
Once the cells reached 90-100% confluence they were harvested and 
subcultured into new flasks. Cell harvesting entailed removal of the old culture 
medium, washing the cells with PBS, discarding the PBS, trypsinising the 
cells with trypsin-EDTA and incubation for 5 minutes at 37ºC in a humidified 
atmosphere containing 5% CO2. 5ml or 10 ml of trypsin-EDTA was used for 
25ml or 75ml flasks respectively. At the end of the incubation period the flask 
was struck firmly to dislodge any adherent cells and the medium was agitated 
by pipetting to break down cell clumps. Cell clump formation is a recognised 
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feature of HepG2 cells. Once cells were resuspended, an equal volume of 
complete EMEM was added to inactivate trypsin. Thereafter more complete 
EMEM was added to the flask to make up the volume necessary to seed new 
flasks. Finally 5ml or 15ml of complete EMEM containing suspended HepG2 
cells was transferred into new 25ml or 75ml flasks respectively. 
 
2.5.6.3. Maintaining cell stocks 
Stocks of frozen HepG2 cells were maintained in liquid nitrogen. In 
preparation for freezing down, cells were harvested as in section 2.5.6.2 and 
transferred into a 15ml centrifuge tube. This was followed by making the 
volume in the tube up to 15ml with complete EMEM, centrifuging the tube at 
500 rpm at 4
o
C for 5 minutes, discarding the supernatant and resuspending the 
cell pellet in 5ml of complete EMEM and an equal volume of freezing 
medium (2:2:1 complete EMEM: Bovine calf serum: Dimethylsulfoxide 
(DMSO)). 1.5ml aliquots of the mixture were then transferred into 2ml vials. 
The vials were frozen at 80
o
C overnight before being transferred to the liquid 
nitrogen storage tank. 
 
2.5.7. Study of gene expression and regulation 
Genetic reporter systems are used to study eukaryotic gene expression and 
regulation. They are most frequently used as indicators of transcriptional 
activity in cells. These systems have an expression vector containing a reporter 
gene that can be transferred into cells. DNA sequences of interest are cloned 
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into the expression vector either upstream (promoter elements) or downstream 
(enhancer elements) of an enzyme reporter gene to create a recombinant 
molecule. Following transfer, the cells are assayed for the presence of the 
reporter by measuring the enzymatic activity of the reporter protein. This 
enables the study of the effects of the insert on reporter gene expression, 
which serve as an indicator of the effect of the insert on the transcriptional 
activity of the gene of interest in vivo. An ideal reporter gene is not 
endogenously expressed in the cell type of interest and is amenable to assays 
that are sensitive, quantitative, rapid, easy, reproducible and safe.  
 
There are many genetic reporters and assay systems designed for analysis of 
transcriptional regulation in mammalian cells. The pGL3 series of expression 
vectors (Figure 2.1) containing the firefly luciferase reporter gene (Promega, 
UK) were used for the investigations described in this thesis. Following co-
transfection of the pGL3 reporter gene construct and the control pRenilla 
plasmid into HepG2 cells transcriptional activity was assessed using the 
Promega dual-luciferase
®
 reporter assay system (Promega, UK). Dual reporter 
systems are used to improve experimental accuracy. They involve the 
simultaneous expression and measurement of two individual reporter enzymes 
within a single system. Normalisation of the effect minimises the experimental 
variability seen due to differences in cell transfection efficiency, pipetting 
differences, cell lysis variability, and assay efficiency. 
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The following account of the Promega dual-luciferase
®
 reporter assay system 
is based on information provided by the manufacturer. In this system the 
activity of firefly (Photinus pyralis) and sea pansy (Renilla reniformis) 
luciferase are measured sequentially from a single sample containing cell 
lysates or cell free translation systems. The firefly and Renilla luciferase are of 
distinct evolutionary origins. They have dissimilar enzyme structures and 
substrate requirements. That makes it possible to selectively discriminate 
between their respective bioluminescent reactions. Thus, the luminescence 
from the firefly luciferase reaction (the experimental reporter) may be 
quenched while simultaneously activating the luminescent reaction of Renilla 
luciferase (the control reporter). In this system the firefly luciferase is 
quantified by the addition of Luciferase Assay Reagent II (LARII). Then Stop 
and Glow solution
®
 is added to simultaneously quench the firefly luciferase 
activity and activate Renilla luciferase. Both systems generate full activity 
within two seconds and remain consistently raised during the 10 second period 
used for measuring activity.  
 
2.5.7.1. Expression vectors 
The pGL3Promoter expression vectors (pGL3P) were the base vectors used to 
create the recombinant experimental reporter vectors used for the AGT 
reporter gene expression investigations described in this thesis. The 
pGL3Control (pGL3C) and pGL3P vectors were also used as positive controls 
in these investigations. The pGL3P vector had the simian virus 40 (SV40) 
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promoter 5 of the firefly luciferase gene while the pGL3C vector had the 
SV40 promoter and SV40 enhancer, 5 and 3 of the firefly luciferase gene 
respectively (Figure 2.1). 
 
2.5.7.2. The construction of recombinant experimental reporter vectors 
The traditional method used for constructing recombinant experimental 
reporter vectors using the pGL3P base vector is restriction digestion of pGL3P 
and ligation of the insert. In this series of experiments, however, the Gateway
®
 
cloning system (Invitrogen, UK) was used for this purpose (see below). To 
facilitate Gateway
®
 cloning, the pGL3P vectors had the Gateway
®
 
modifications at the multiple cloning site downstream of the luciferase 
reporter gene (pGL3P3GW).  
 
The following account of the Gateway
®
 cloning system is based on the 
technical information provided by the manufacturer. This system is based on a 
site-specific recombination mechanism found in phage λ (Landy, 1989, 
Hartley, Temple and Brasch, 2000). It uses the key DNA recombination 
sequences involved in the recombination reactions and the proteins that 
mediate the recombination reactions in a two-step process to generate 
recombinant experimental vectors starting with the Gateway® modified base 
vector and the insert. The DNA recombination sequences are referred to as the 
att sites. In preparation for Gateway® cloning an insert is generated by PCR 
amplification of genomic DNA. This PCR is carried out with two 
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oligonucleotide primers that have attB1 and attB2 sequences at the 5 end of 
the forward and reverse primer respectively. These two attB sequences 
therefore flank the PCR amplified insert. The first step of the recombination 
reaction is called the BP recombination reaction. In the BP recombination 
reaction the attB sites of the insert recombines with the attP sites of the donor 
plasmid (pDONR
®
 201) in a reaction mediated by BP Clonase® enzyme 
resulting in a recombinant plasmid, referred to as the entry clone that now has 
attL sites flanking the insert. These recombinant plasmids are then chemically 
transformed into 5DHα competent cells and grown in culture containing 
kanamycin to obtain a plentiful supply of the entry clone. In the second step, 
which is called the LR recombination reaction, attL sites recombine with the 
attR sites on the destination vector (pGL3P3GW) in a reaction mediated by 
LR Clonase® enzyme resulting in a recombinant experimental vector. These 
recombinant experimental vectors are also chemically transformed into 5DHα 
competent cells and grown in culture containing ampicillin to obtain a 
plentiful supply of the expression clone. This is the experimental reporter gene 
construct that is used to study the effects of the insert on reporter gene 
expression. The Gateway® cloning system is illustrated in figure 2.2. 
 
When compared with cloning by restriction digestion and ligation, one of the 
main advantages of the Gateway
®
 cloning system is that the time consuming 
and sometimes unreliable restriction digestion and ligation steps are not 
required for cloning. In addition once an entry clone containing an inset of 
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interest is made, it can be easily sub cloned into a wide variety of destination 
vectors using the LR Reaction. The system is also designed to make selection 
of colonies containing either the entry clone or the expression clone easy, 
because the plasmids that they are derived from, in addition to having an 
antibiotic resistant gene (donor vector has a kanamycin resistant gene and the 
destination vector has an ampicillin resistant gene) have a selection marker, 
the ccdB gene, which inhibits growth of E.Coli. Transformants selected for 
antibiotic resistance therefore, will have either the entry clone or the 
expression clone only. The use of two different antibiotic resistant genes for 
each step ensures that following the LR recombination reaction transformants 
selected for ampicillin resistance will only contain the expression clone. A few 
background colonies may also be seen in culture. They contain inactive or 
deleted ccdB genes. 
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Figure 2.1. Circle maps of pGL3Control and pGL3Promoter vectors. 
pGL3P3GW has Gateway
®
 modification at the multiple cloning site 
downstream of the luciferase gene as indicated in the figure. Source: 
Promega Protocols and Applications Guide. Catalogue No. P1610. 
 
Site of Gateway® 
modifications 
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BP recombination reaction 
 
 
LR recombination reaction 
 
 
Figure 2.2. A schematic diagram of the two steps in the Gateway® cloning system. Source: Invitrogen Gateway® 
Technology Manual. Catalogue Nos:12535-019, 12535-027. 
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2.5.7.3. Purification of vector DNA from bacterial cells 
It is necessary to obtain pure samples of intact vector (plasmid) DNA from 
transformed 5αDH cell cultures. Two procedures were used for this purpose. 
Minipreps were performed to obtain plasmid DNA to carry out sequencing 
and restriction digestion to confirm the presence of the insert sequence. 
Endotoxin free midipreps were performed to obtain plasmid DNA for 
transfection. Endotoxins are proficient inducers of the acute phase response 
process. If present in plasmid preparations they can interfere with reporter 
gene assays. When endotoxin free preparations are made, endotoxins present 
in bacterial cells contaminating plasmid DNA are removed from the final 
preparation. All buffers and kits used for plasmid DNA purification in these 
investigations were from Qiagen, UK. 
 
Miniprep 
The QIAprep
®
 spin miniprep plasmid purification kit was used for minipreps. 
This protocol involved pelleting of bacterial cells, resuspension of cells, 
alkaline lysis, cleaning of the bacterial lysate, adsorption of plasmid DNA 
onto a silica membrane in the presence of salt, washing the membrane and 
eluting plasmid DNA. The protocol is used to purify of up to 20μg/ml of high 
copy plasmid DNA from 1-5ml of overnight bacterial culture.  
 
The miniprep procedure was carried out as follows: Transformed bacterial 
cells were grown overnight in 5ml of Luria-Bertani (LB) medium containing 
the appropriate selective antibiotic in a 20ml universal container at 37
o
C with 
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horizontal shaking at 225 rpm. 1.5 ml of the overnight bacterial culture was 
applied to a 1.5ml microcentrifuge tube. Cells were then pelleted by 
centrifugation at 14 000 rpm for 10 minute and the supernatant was discarded. 
Then the cells were resuspended in 250μl of chilled buffer P1 (50mM Tris-Cl, 
pH 8.0; 10mM EDTA; 100μg/ml RNase). Next 250μl of the lysis buffer P2 
(200mM NaOH; 1% SDS) were added to the resuspended cells. It was mixed 
by gently inverting 6 times to prevent sheering of plasmid DNA. The lysis 
reaction was allowed to continue at room temperature for up to but not 
exceeding 5 minutes by which time a viscous slightly clear mixture was seen. 
Then 350μl of the neutralisation buffer N3 (3.0M Potassium Acetate, pH5.5) 
were added to the reaction and mixed immediately by gently inverting the tube 
6 times. The reaction was then centrifuged at 14 000 rpm for 10 minutes and 
the resulting supernatant was applied to a QIAprep spin column. The column 
was then centrifuged at 14 000 rpm for 1 minute. Next the column was washed 
by adding 750μl of buffer PE (1M NaCl; 50mM MOPS, pH 7.0; 15% 
isopropanol) followed by centrifugation at 14 000 rpm for 1 minute. Any 
residual wash buffer was removed by a further centrifugation at 14 000 rpm 
for 1 minute. After each of these centrifugation steps the flow-through was 
discarded. Finally the column was placed in a 1.5ml collection tube and 50μl 
of buffer EB (10 mM Tris.Cl, pH8.0; 1mM EDTA) was added to the centre of 
the column membrane. After allowing the column to stand for 1 minute, the 
plasmid DNA was eluted from the column by centrifugation at 14 000 rpm for 
1 minute. The DNA concentration of the eluted sample was measured 
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spectrophotometrically on a GeneQuant RNA/DNA calculator (Amersham 
Biosciences, UK) and the sample was stored at 20
o
C. 
 
Endotoxin free midi preparation 
Endotoxin free midipreps were made using a Qiagen Endofree
®
 plasmid maxi 
kit using the QIAfilter
®
 midiprep protocol. The protocol involves procedures 
that are similar to that of the miniprep procedures except for an additional step 
to remove endotoxins and the use of endotoxin free buffers. The protocol is 
used to purify up to 100μg of high copy plasmid DNA from 25ml overnight 
bacterial cultures. 
 
Transformed bacterial cells were grown overnight in 25ml of LB medium 
containing the appropriate selective antibiotic in a 50ml centrifuge tube at 
37
o
C with horizontal shaking at 225 rpm. Bacterial cells in this tube were 
pelleted by centrifugation at 4600 rpm for 15 minutes and the supernatant was 
discarded. Then the cells were resuspended in 4ml of chilled buffer P1. Next 
4ml of the lysis buffer P2 were added to the resuspended cells. It was mixed 
by gently inverting 6 times to prevent sheering of plasmid DNA. The lysis 
reaction was allowed to continue at room temperature for up to but not 
exceeding 5 minutes by which time a viscous slightly clear mixture was seen. 
Then 4ml of the chilled neutralisation buffer P3 (3.0M Potassium Acetate; pH 
5.5) was added to the reaction and mixed immediately by gently inverting the 
tube 6 times. The lysate was then poured into a QIAfilter cartridge and filtered 
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into a 15ml centrifuge tube and the volume noted. Next a volume equal to 
1/10
th
 the volume noted before, was pipetted from the endotoxin removal 
buffer ER and added to the tube. The tube was inverted 10 times, and allowed 
to incubate on ice for 30 minutes. While the reaction was incubating, 5ml of 
buffer QBT (750mM NaCl; 50mM MOPS, pH 7.0; 15% isopropanol, 0.15% 
Triton
®
) was added to a QIAGEN-tip100 and the filter in the tip was allowed 
to equilibrate by gravity. At the end of 30 minutes of incubation, the lysate in 
the 15 ml tube was applied to the equilibrated tip and it too was allowed to 
enter the tip aided by gravity. The tip was then washed twice with 10ml of 
endotoxin free buffer QC (1.0M NaCl; 50mM MOPS, pH 7.0; 15% 
isopropanol). The flow through was discarded at the end of each step 
mentioned above. Next the tip was placed on a 50ml centrifuge tube and the 
DNA was eluted by applying 5ml of endotoxin free buffer QN (1.6M NaCl; 
50mM MOPS, pH 7.0; 15% isopropanol) and allowing it to flow through by 
gravity. After that 3.5ml of isopropanol was added to it to precipitate the 
DNA. The precipitated DNA was pelleted to the bottom of the tube by 
centrifuging at 4600 rpm for 90 minutes at 4
o
C. At the end of centrifugation 
the pellet was washed with endotoxin free ethanol and again centrifuged at 
4600 rpm for 30 minutes at 4
o
C. Finally ethanol was carefully removed and 
the pellet was air dried before being resuspended in 100μl of endotoxin free 
TE (10mM Tris, pH8.0; 1mM EDTA). The DNA concentration of the eluted 
sample was measured spectrophotometrically on a GeneQuant RNA/DNA 
calculator (Amersham Biosciences, UK) and the sample was stored at 20
o
C. 
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2.5.7.4. Strategy for transferring expression vectors into mammalian cells 
Transfection is the process of introducing expression vectors into mammalian 
cells. The Promega Tfx
®
 systems was used for this purpose.  
 
The following brief account of this system is based on the technical 
information provided by the manufacturer. This system uses artificial 
liposomes to deliver the plasmid DNA into mammalian cells. The liposome 
has an overall positive charge at physiological pH and the cationic portion of 
the liposome associates with the negatively charged plasmid DNA, resulting in 
the formation of a complex. An overall positive charge tends to improve 
transfection efficiency, probably due to the combination of the positive 
complex with the negatively charged cell membrane. Following endocytosis 
through the membrane the complexes initially appear in endosomes and finally 
in the nucleus. 
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2.6. Genotyping the samples of population volunteers, women with pre-
eclampsia, and normotensive pregnant women 
2.6.1. Epidermal Growth Factor 61G>A genotyping 
The substitution of G by A at nucleotide 61 creates a restriction site for the 
AluI restriction enzyme. This polymorphism therefore, was genotyped using a 
PCR/RFLP assay described previously (Shahbazi et al., 2002).  
 
The genomic region flanking the polymorphic site was amplified by PCR 
using primers EGF-61F and EGF-61R (Table 2.6) as described in section 
2.5.2. These primers were used to generate PCR products for both genotyping 
and sequencing. EGF-61F was the sequencing primer for cycle sequencing 
reactions that were conducted as described in section 2.5.4. Restriction 
digestion was carried out as described in section 2.5.5.1 with the restriction 
enzyme AluI and restriction digestion buffer H (5mM Tris-HCl, 10mM NaCl, 
1mM MgCl2, 0.1mM dithioerythritol, pH 7.5 at 37
o
C). Digested PCR 
fragments were then resolved by agarose gel electrophoresis as described in 
section 2.5.3 by electrophoresing for 1 hour at 50 volts on a 3% agarose gel. A 
summary of the sizes of the digested products is in figure 2.3. The pattern 
created by them on a 3% agarose gel and the DNA sequence of the genomic 
region flanking the polymorphic site is figure 2.4. 
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Prime 
Name 
Sequence  (5→3) Orientation Annealing 
Temperature 
(
o
C) 
Product 
Size 
(bp) 
 
EGF-61F 
 
EGF-61R 
 
TGT CAC TAA AGG AAA GGA GGT 
 
TTC ACA GAG TTT AAC AGC CC 
 
 
Sense 
 
Antisense 
 
51
o
C 
 
242 
 
Table 2.6. The PCR primers used to amplify the genomic region flanking the EGF 61G>A 
polymorphic site for the PCR/RFLP genotyping assay and for sequencing. (Shahbazi et al., 2002). 
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Figure 2.3. A diagrammatic representation of the location of AluI restriction sites on PCR products 
generated using primers EGF-61F and EGF-61R and the size of the fragments created by restriction 
digestion of the PCR products with AluI. The expected banding patterns are: 61GG: 193-bp; 61AA: 91-
bp and 102-bp; 61GA: 91-bp, 102-bp and 193-bp. 15-bp and 34-bp products were not visible following 
agarose gel electrophoresis and the 91-bp and 102-bp products appeared together as a single band. 
AluI site created by 61A
34bp 15bp
Constant Alu I sites
242bp
34bp 15bp
61G
61A
193bp
91bp 102bp
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A                              U             AA         GG          GA           M 
 
 
B GG AA GA 
 
  
 
Figure 2.4. EGF 61G>A genotyping: A) The pattern created by electrophoresing 
the AluI digested products of samples of the three genotypes on a 3% agarose gel. 
U: Uncut Products. M:100bp size marker. B) The sequence of the three genotypes 
on the sense strand. Arrowheads indicate the polymorphic site. 
 
 
 
 
 
 
 
 
242-bp !
193-bp !
93-bp and 106-bp !
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2.6.2. Epidermal Growth Factor 67149G>A genotyping 
A new MS-PCR assay was developed to genotype this polymorphism. Two 
allele specific forward primers EGF-G and EGF-A and a common reverse 
primer EGF-R were designed for this assay (Table 2.7). Principles discussed 
in section 2.5.5.2 with regard to incorporation of mismatched nucleotides into 
allele specific primers were made use of in designing EGF-G and EGF-A.  
 
A fourth primer, EGF-F was designed and used together with EGF-R to 
produce PCR fragments to confirm the genotype by sequencing (Table 2.7). 
These PCR were conducted as described in section 2.5.2. EGF-R was used as 
the sequencing primer for cycle sequencing reactions that were conducted as 
described in section 2.5.4.  
 
In addition to optimising the MS-PCR assay by repeating it at different 
annealing temperatures, the assay was further optimised by carrying out the 
reactions varying the number of allele specific primers used in each reaction 
mix, and by varying the dNTP concentration in the reaction mix. When 
samples homozygous for the A allele were amplified with only the primer 
specific for the G allele in the reaction mix, non-specific amplification of the 
A allele giving a G band on electrophoresis was observed. The same samples 
were correctly amplified however, when both primers were present in the 
reaction mix. It is possible that this is a result of competition for templates and 
other reaction components (Figure 2.5.A). When the same reaction was 
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repeated at a dNTP concentration of 20μM non-specific amplification of 
primers did not occur (Figure 2.5.B). Others have also reported similar 
observations with allele specific primers (Newton et al. (1989), Kwok et al. 
(1990), Rust et al, (1993)).  
 
The MS-PCR assay was conducted in a final volume of 15μl containing 
genomic DNA, 0.08μM EGF-G, 0.08μM EGF-A, 0.1μM EGF-R, 20μM of 
dNTP, PCR buffer; and 1U of Taq Polymerase. The reactions were subjected 
to 35 cycles of denaturation at 94
o
C for 30 seconds, annealing at 60
o
C for 1 
minute, and extension at 72
o
C for 5 minute. The temperature cycles were 
preceded by 2 minutes at 94
o
C and concluded with 5 minutes at 72
o
C followed 
by cooling at 4
o
C.  
 
The 67149G specific primer was 20 nucleotides longer than the 67149A 
specific primers. Thus when the PCR was carried out a 182-bp product was 
generated with 67149GG homozygotes, a 162-bp product was generated with 
67149AA homozygotes, and both 182-bp and 162-bp products were generated 
with 67149GA heterozygotes.  
 
MS-PCR products were then resolved by agarose gel electrophoresis as 
described in section 2.5.3 by electrophoresing for 1 hour at 50 volts on a 3.5% 
agarose gel. The pattern created by MS-PCR products and the DNA sequence 
of the genomic region flanking the polymorphic site is in figure 2.6. 
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Primer 
Name 
Sequence  (5→3) Orientation Annealing 
Temperature 
(
o
C) 
Product 
Size 
(bp) 
 
EGF-G 
 
 
EGF-A 
 
 
EGF-F 
 
EGF-R 
 
TTATGTGTGGTTCTCAGATTCCGCTATGCCATCAGTAAGG 
                                                     CC                                           A 
 
                                                     GGGCTATGCCATCAGGAATA 
                                                                                              A                 
    
TGT TTC CAG GTC ACC CAT TT 
 
CAG ATT CCA GCC AAG GAA AG 
 
 
Sense 
 
 
Sense 
 
 
Sense 
 
Antisense 
 
60 
 
 
 
 
 
51
o
C 
 
182 
 
 
162 
 
 
242 
 
Table 2.7. The PCR primers used for the MS-PCR genotyping assay of the EGF 67149G>A polymorphism and the PCR primers 
used to amplify the genomic region flanking the EGF 67149G>A polymorphic site for sequencing. The positions where 
mismatches have been introduced to allele specific primers EGF-G and EGF-A are in bold and the corresponding mismatch on the 
antisense strand is indicated. 
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Lane          1         2         3     Marker    4         5          6         7        8         9      Marker  
Primer(s)         G         A      G,A    G        A       G,A      G       A       G,A 
 
  
 A B 
Figure 2.5. A) Non-specific amplification of the 67149A allele by a 67149G specific primer when a 
67149AA homozygous sample was amplified only with the 67149G specific primer (lane 1). The 
same sample amplified with a 67149A specific primer (lane 2) and with both primers (lane 3) show 
the amplification of the 67149A specific primer only. The dNTP concentration in this reaction was 
200μM. B) When the same experiment was carried out with the dNTP concentration at 20μM (lanes 
4 to 6), non-specific extension of the 67149G specific primer did not occur (lane 4). In a similar 
experiment with a 67149GG homozygous sample (lane 7-9) the 67149G specific primer was 
amplified while the 67149A specific primer was not amplified. 
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A 
 
B GG AA GA 
 
   
 
Figure 2.6. EGF 67149G>A genotyping. A) The pattern created by 
electrophoresing the MS-PCR products of samples of the three genotypes on a 
3.5% agarose gel. B) The sequence of the three genotypes on the antisense strand. 
Arrowheads indicate the polymorphic site. 
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2.6.3. Transforming Growth Factor Alpha 3827T>C & 3851T>C 
genotyping 
The TGFA 3827T>C and 3851T>C polymorphisms were genotyped using a 
PCR/RFLP assay. The recognition site for HinfI that is present in the wild type 
3827T allele is abolished when it is substituted by the 3827C allele. Similarly 
the recognition site for NCoI that is present in the wild type 3851T allele is 
abolished when it is substituted by the 3851C allele. It was possible therefore, 
to genotype these two polymorphisms using a PCR/RFLP assay as described 
before (Shiang et al., 1993). This assay however, lacked an internal control. 
Two new primers, TGFA-F2 and TGFA-R2 were designed therefore, to 
amplify a 645-bp fragment flanking the polymorphic region incorporating 
constant restriction sites for both enzymes (Table 2.8). PCR were conducted as 
described in section 2.5.2 using primers TGFA-F2 and TGFA-R2. These 
primers were also used to generate PCR products for sequencing. TGFA-R2 
was also used as the sequencing primer in cycle sequencing reactions that 
were conducted as described in section 2.5.4. 
 
Restriction digestion was carried out as described in section 2.5.5.1 with 
restriction enzyme HinfI or NCoI and 1 × restriction digestion buffer H. 
Digested PCR fragments were then resolved by agarose gel electrophoresis as 
described in section 2.5.3 by electrophoresing for 1 hour at 50 volts on a 3% 
agarose gel. A summary of the sizes of the digested products is in figure 2.7. 
The pattern created by them on a 3% agarose gel and the DNA sequence of the 
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genomic region flanking the polymorphic site is figure 2.8. 
 
2.6.4. Transforming Growth Factor Alpha 3822G>A genotyping 
A new competitive ASO hybridisation assay was developed to genotype the 
3822G>A polymorphism. It was carried out using oligonucleotide probes 
TGFA-A, TGFA-G1 and TGFA-G2 (Table 2.8). The 3822G>A polymorphism 
was just 5-bp away from the 3827T>C polymorphism. If only one probe was 
used for the 3822G allele with a C corresponding to a 3827C allele, then in the 
presence of a 3827T allele it would either hybridise inadequately or not at all 
leading to erroneous genotyping. Two 3822G allele specific probes were used 
therefore, for hybridisation. One had T at the position corresponding to 3827 
and the other had C (Table 2.8). The competitive ASO hybridisation assay was 
carried out according to the procedure described in section 2.5.5.3. The only 
modification to that procedure was that nylon filters were blotted in triplicate 
for each sample to hybridise with the three probes and as such during pre-
hybridisation each filter was hybridised with two unlabeled oligonucleotides. 
For example if hybridisation was with TGFA-A, then pre-hybridisation was 
with TGFA-G1 and TGFA-G2.  
 
According to previous reports the combination of alleles 3822A and 3827T 
did not occur together in any chromosome. An oligonucleotide probe for this 
combination of alleles was not used therefore in the TGFA 3822G>A 
genotyping assay. However, to further verify that such a combination did not 
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exist, an ASO hybridisation assay was carried out on 92 samples with a probe 
containing nucleotides A and T at positions corresponding to 3822 and 3827 
(5-CTA ACC ACA AGA CTC TCA AC-3) and the TGFA-A probe. No 
hybridisation was observed with the former probe in any sample.
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Primer 
Name 
Sequence  (5→3) Orientation Annealing 
Temperature 
(
o
C) 
Product  
Size 
(bp) 
PCR Primers    
TGFAF2 
 
TGFAR2 
CGG ACC ACG ATT TCA AGA CT 
 
GCT TCA ATG GCA CCA TTT CT 
Sense 
 
Antisense 
 
55 645 
ASO Probes 
TGFAA 
 
TGFAG1 
 
TGFAG2 
 
CTA ACC ACA AGA CCC TCA AC 
 
CTA ACC ACG AGA CCC TCA AC 
 
CTA ACC ACG AGA CTC TCA AC 
 
Sense 
 
Sense 
 
Sense 
  
 
 
Table 2.8. The PCR primers used to amplify the genomic region flanking the TGFA 3UTR polymorphic site for the 
PCR/RFLP genotyping assay, for sequencing, and the allele specific oligonucleotides used for the competitive ASO 
hybridisation assay; and the oligonucleotide probes used for the competitive ASO hybridisation genotyping assay of the 
3822G>A polymorphism. The allele specific nucleotides corresponding to the polymorphic sites 3822 and 3827 in the 
ASO probes are in bold. 
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Figure 2.7. A diagrammatic representation of the location of HinfI and NCoI restriction sites on PCR products generated 
using primers TGFA-F2 and TGFA-R2 and the size of fragments created by restriction digestion of the PCR products with 
NCoI and HinfI. The expected banding patterns are: When digested with NCoI  3851TT: 123-bp, 216-bp and 306-bp; 
3851CC: 123-bp, and 522-bp; 3851TC: 123-bp, 216-bp, 306-bp, and 522-bp. When digested with HinfI  3827TT: 187-bp 
and 330-bp; 3827CC: 517-bp; 3827TC: 187-bp and 330-bp, 517-bp. The 37-bp, 44-bp, and 47-bp products were not 
visible following agarose gel electrophoresis. 
3827C
37bp
37bp
3851T
3851C
3827T
Constant Hinf I sites Hinf I site created by 3827T
123bp 216bp
47bp 44bp 517bp
Constant NCo I site NCo I site created by 3851T
645bp               
47bp 44bp 187bp 330bp
306bp
123bp 522bp
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  A                                             NCoI                 Hinf1 
                                                   3851                  3827 
                                    U     TT   CT   CC   CC   CT  TT   
 
B 
 
 
Figure 2.8. TGFA 3827T>C and 3851T>C genotyping: A) The pattern created 
by electrophoresing PCR products of samples of the three genotypes at each 
polymorphic site digested with NCoI and HinfI on a 3% agarose gel. Images 
from two gels have been merged for illustration. U: Undigested PCR products. 
The sizes of the products digested with NCoI and the undigested product are 
on the left; and the sizes of the products digested with HinfI are of the right.  
B) The sequence of a sample with the genotype 3822GG, 3827TC and 
3851TT at the polymorphic sites. Sequence is on the anti-sense strand. 
 
 
 
 
 
 
645-bp !
522-bp !
306-bp !
216-bp !
123-bp !
 
 
 
 
 
 
 
 
∀ 517-bp 
 
∀ 330-bp 
 
∀ 187-bp 
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2.6.5. Angiotensinogen 174Thr>Met, 235Met>Thr and 11535C>A 
genotyping 
These polymorphisms were genotyped using a competitive ASO hybridisation 
assay previously developed and used in our laboratory (Morgan et al., 1996). 
  
The genomic region flanking the 174Thr>Met and 235Met>Thr 
polymorphisms were amplified with primers A21 and A22. The genomic 
region flanking the 11535C>A polymorphism was amplified with primers 
H2651 and H2654 (Table 2.9). A multiplex PCR was conducted to generate 
PCR products of both genomic regions in the same reaction. It was conducted 
in a reaction mix containing 100-200ng template genomic DNA, 200μM 
deoxynucleotides, PCR buffer, 0.4μM A21, 0.4μM A22, 0.8μM H2651, 
0.8μM H2654 and 1U Taq DNA polymerase. PCR amplification involved 
repeated cycles of heat denaturation of the genomic DNA at 94
o
C for 1 
minute, annealing at 60
o
C for 1 minute, and extension of the annealed primers 
at 65
o
C for 5 minutes. The temperature cycles were preceded by 2 minutes at 
94
o
C and concluded with 3 minutes at 65
o
C followed by cooling at 4
0
C. The 
presence of PCR amplified products was confirmed by agarose gel 
electrophoresis as in section 2.5.3. 
 
The oligonucleotide probes used for competitive ASO hybridisation are listed 
in table 2.9.  The hybridisation reactions were conducted according to the 
protocol described in section 2.5.5.3. The only exception was that when 
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genotyping the 11535C>A polymorphism, the filters had to be pre-hybridised 
with 300pmols of the competing primer, before hybridisation with 3pmols of 
the labelled primer, to eliminate a high level of background signal.  
 
Separate PCRs were conducted with primer sets A21 and A22, and H2651 and 
H2654 to generate PCR products for sequencing as described in section 2.5.2. 
A21 and H2651 were used as sequencing primers for the cycle sequencing 
reactions that were conducted as described in section 2.5.4. 
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Primer 
Name 
Sequence  (5  3) Orientation Polymorphism
/ Allele 
PCR 
product size 
    
PCR Primers    
A21 AAG GAC AAG AAC TGC ACC TCC CGG CT Sense 
A22 GCCAGA GCC AGC AGA GAG GTT TGC CT Antisense 
174Thr>Met & 
235Met>Thr 
365 
     
H2651 AAC CCG CTG AGC ACA GCA TG Sense 
H2654 TGG AGG CTT AGT GTG GCA AGA Antisense 
11535C>A 634 
     
ASO Probes    
G6745 CTG CTG TCC ATG GTG GT Sense 174Met  
G8041 CTG CTG TCC ACG GTG GT Sense 174Thr  
F016 TCC CTG ACG GGA GCC AG Sense 235Thr  
F017 TCC CTG ATG GGA GCC AG Sense 235Met  
N8804 TGC GGA ACA ATA GCT GGT Sense 11535A  
N8805 TGC GGA ACC ATA GCT GGT Sense 11535C  
     
 
Table 2.9. The PCR primers used to amplify the genomic regions flanking the AGT polymorphic sites for the 
competitive ASO hybridisation assay and for sequencing; and the allele specific oligonucleotides used for the 
competitive ASO hybridisation assay at each polymorphic site. The allele specific nucleotides corresponding to the 
polymorphic sites in the ASO probes are in bold. 
159 
2.6.6. 5,10-Methylenetetrahydrofolate reductase 677C>T genotyping 
The MTHFR 677C>T polymorphism creates a HinfI recognition site. It was 
possible therefore, to genotype this polymorphism using an already described 
genotyping assay (Frosst et al., 1995), which, however, lacked an internal 
control. A new set of PCR primers incorporating a constant restriction site was 
therefore designed and used for genotyping the Sri Lankan samples as 
described below. A MS-PCR assay was also developed to genotype this 
polymorphism with a view to designing a faster genotyping assay. As the MS-
PCR assay was developed prior to the collection of Sri Lankan samples, the 
white Caucasian women with pre-eclampsia and normotensive pregnant 
women were genotyped using the MS-PCR assay as described below.  
 
PCR/RFLP assay 
The genomic region flanking the polymorphic site was amplified by PCR 
using primers VAJ-1 and VAJ-2 (Table 2.10).  These primers were used to 
generate PCR products for both genotyping and sequencing. VAJ-2 was also 
used as the sequencing primer in cycle sequencing reactions that were 
conducted as described in section 2.5.4. Restriction digestion was carried out 
as described in section 2.5.5.1 with the restriction enzyme HinfI and 1 × 
restriction digestion buffer H. Digested PCR fragments were then resolved by 
agarose gel electrophoresis as described in section 2.5.3 by electrophoresing 
for 1 hour at 50 volts on a 3% agarose gel. A summary of the sizes of the 
digested products is in figure 2.9. The pattern created by them on a 3% 
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agarose gel and the DNA sequence of the genomic region flanking the 
polymorphic site is in figure 2.10A and 2.10C respectively. 
 
MS-PCR assay 
Two allele specific forward primers and a common reverse primer were used 
for this assay. Primers described previously for a capillary electrophoresis 
assay to genotype this polymorphism was modified and used (Ulvik, Ren, 
Refsum and Ueland, 1998). The only modification made was the addition of a 
20-bp CT tail to the 677C allele specific primer (Table 2.10).  
 
MS-PCRs were conducted in a final volume of 25μl containing genomic 
DNA; 0.18μM MTHFR-C, 0.25μM MTHFR-T, 0.23μM MTHFR-R; 200μM 
of dNTP; PCR buffer; and 1U of Taq Polymerase. The reactions were 
subjected to 35 cycles of denaturation at 94
o
C for 30 seconds, annealing at 
62
o
C for 1 minute, and extension at 72
o
C for 1 minute. The temperature cycles 
were preceded by 2 minutes at 94
o
C and concluded with 30 minutes at 72
o
C 
followed by cooling at 4
0
C.  
 
The 677C specific primer was 20 nucleotides longer than the 677T specific 
primer. Thus when the PCR was carried out a 137-bp product was generated 
with 677CC homozygotes, a 117-bp product was generated with 677TT 
homozygotes, and both 137-bp and 117-bp products were generated with 
677CT heterozygotes.  
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MS-PCR products were then resolved by agarose gel electrophoresis as 
described in section 2.5.3 by electrophoresing for 1 hour at 50 volts on a 3.5% 
agarose gel. A summary of the pattern created by MS-PCR products is in 
figures 2.10B.  
 
One drawback in this assay was heteroduplex formation as a result of the 
failure to introduce nucleotide mismatches to the longer MS-PCR primer to 
correspond to the 5 end of the shorter primer. It did not however, interfere 
with genotyping (Figure 2.10.B).
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Primer 
Name 
Sequence  (5  3) Orientation Annealing 
Temperature 
(
o
C) 
Product 
Size (bp) 
 
VAJ-1 
 
TAT TGG CAG GTT ACC CCA AA 
 
Sense 
 
55 
 
557 
 
VAJ-2 
 
GGG ACC TGG AGA TCC ACT TT 
 
Antisense 
  
     
MTHFR-C CTCTCTCTCTCTCTCTCTCTGAAGGAGAAGGTGTCTGCGGTAGC 
                                                                                                           G 
 
Sense 62 137 
MTHFR-T                                                    GAAGGAGAAGGTGTCTGCGGAAGT 
                                                                                                           G 
Sense  117 
 
MTHFR-R 
 
ACG ATG GGG CAA GTG ATG 
 
 
Antisense 
  
 
Table 2.10. PCR primers used for the PCR/RFLP and MS-PCR genotyping assays to genotype the MTHFR 677C>T polymorphism. 
The positions where mismatches have been introduced to allele specific primers MTHFR-C and MTHFR-T are indicated in bold and 
the corresponding mismatch on the antisense strand is indicated. 
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Figure 2.9. A diagrammatic representation of the location of HinfI restriction sites 
on PCR products generated using primers VAJ1 and VAJ2 and the size of the 
fragments created by restriction digestion of the PCR products with HinfI. The 
expected banding patterns are: 677CC: 104-bp and 453-bp; 677TT: 104-bp, 368-bp, 
and 85-bp; 677CT: 85-bp, 104-bp, 368-bp and 453-bp. The 85-bp and 104-bp 
products appeared together as a single band on agarose gel electrophoresis. 
677C
677T
Constant Hinf I siteHinf I site created by 677T
557bp
453bp 104bp
85bp 368bp 104bp
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A 
 
B 
 
C TT CT CC 
 
   
Figure 2.10. MTHFR 677C>T genotyping: A) The pattern created by 
electrophoresing the HinfI digested PCR products of samples of the three 
genotypes on a 3% agarose gel. Visualising the 368-bp and 453-bp fragments was 
sufficient to assign the genotype. U: Undigested PCR product. B) The pattern 
created by electrophoresing the MS-PCR products on a 3.5% agarose gel. A faint 
larger heteroduplex band is seen in the CT sample. C) The sequence of the three 
genotypes on the antisense strand. Arrowheads indicate the polymorphic site. 
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2.7. Angiotensinogen reporter gene expression studies 
The three common haplotypes defined by the 3UTR/flanking region SNPs in 
the AGT gene were examined in this study with relation to their functional 
effects. The AGT 3UTR/flanking region inserts, which were from a putative 
enhancer region, were designated E1, E2 and E3. They were cloned into 
pGL3P3GW vectors to create the recombinant experimental reporter vectors 
necessary for these investigations. 
 
2.7.1. Generation of recombinant experimental reporter gene constructs 
2.7.1.1. PCR amplification of the AGT 3UTR inserts 
The three inserts with attB1 and attB2 modifications at their 5 and 3 ends 
respectively were generated by PCR of genomic DNA using primers AGTEF 
and AGTER (Table 2.11). AGTEF and AGTER had an attB1 or attB2 
sequence at their 5 ends respectively.  
 
Three samples, which had been genotyped for the 3UTR /flanking region 
SNPs, were used for these PCRs. Each sample was known to be homozygous 
for one of the three common haplotypes in the 3UTR/flanking region. A 
1660-bp genomic region from 11259-bp to 12919-bp in the published 
sequence was amplified. PCR was carried out as described in section 2.5.2.  
The presence of PCR products was confirmed by agarose gel electrophoresis 
as described in section 2.5.3 by electrophoresing for 30 minutes at 50 volts on 
a 1% agarose gel. The haplotype structure of the inserts is listed in table 2.12.  
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Primer 
Name 
Sequence  (5  3) Orientation Annealing 
Temperature 
(C
o
) 
Product 
Size 
(bp) 
PCR Primers    
AGTEF GGGG ACA AGT TTG TAC AAA AAA GCA GGC TTT 
TAG CGC GGG ACT ACT GTT 
Sense 58 1660 
AGTER GGGG AC CAC TTT GTA CAA GAA AGC TGG GTG 
AAT GTT CGT ATT TTG TAT CCT TG 
Anti-sense   
    
Sequencing Primers Orientation Position on 
Sequence* 
 
FRS3 ATT GCC TTC GGT TTC TAT Sense 11383-11400  
SDEN3 CAT CTG TGT GAT GGA CAG G Sense 11573-11591  
SSP2 GTT CGG AAT CTT GGG GAG GA Sense 11781-11800  
SSP1 CAC GGG GAT TAC AAA TCT CG Sense 12027-12046  
SDEN6 TCA GAA TCT GCA GTT TTA CA Sense 12218-12237  
H2654 TGG AGG CTT AGT GTG GCA AGA Antisense 12623-12643  
ASP4 GGA CAG CAT CAC CAT TGC TA Antisense 12093-12112  
DEN2 CTT CCC TGT CAC CCT CTT Antisense 11807-11824  
RV4 GAC GAT AGT CAT GCC CCG CG Antisense on vector**  
     
 
Table 2.11. PCR primers used to amplify the AGT exon 5 and 3UTR/flanking region and the sequencing primers 
used to confirm the sequence of the enhancer insert in destination vectors. Gateway
®
 modifications in the 5 ends 
of PCR primers are in italics. * Position of primer relative to transcription start site on AGT gene. The insert spans 
from 11259 to 12919. ** downstream of insert. 
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Construct 
Polymorphisms 
Name 
11535C>A 11608C>A 12058G>A 12194A>C 12429C>T 12822T>C 
 
E1 
 
C C G A C C 
 
E2 
 
C C G A C T 
 
E3 
 
A T G A C T 
 
Table 2.12. A summary of the haplotype structure of the three AGT 3UTR/flanking region inserts. 
 
 168 
2.7.1.2. BP recombination reaction 
The inserts were cloned into pGL3Promoter vectors using the Gateway
®
 
cloning system. The BP recombination reaction was set up with 100fmol of 
PCR products, 2μl of 150ng/μl of the pDONR
®
 201 vector, and 4μl of the 5 × 
BP Clonase
®
 reaction buffer, and 1 × TE to make up a final volume of 16μl. 
BP Clonase
®
 enzyme was removed from 70
o
C, vortexed briefly and added to 
the above reaction mix. This reaction mix was vortexed briefly twice and then 
incubated at 25
o
C for 1 hour. Then 2μl proteinase K was added to the reaction 
mix and the reaction was incubated for 37
o
C for 10 minutes. 
 
2.7.1.3. Transformation of 5αDH competent cells 
The entry clone that was generated by the BP recombination reaction was 
transformed into 5αDH competent cells. To do so 1μl from the BP 
recombination reaction mix was applied to a 50μl aliquot of 5αDH competent 
cells and mixed gently. Then it was incubated on ice for 30 minutes and 
maintained for 30 seconds at 42
o
C in a water bath before being immediately 
transferred on to ice. 450μl of SOC medium was then added to the reaction 
mix and it was incubated at 37
o
C for 1 hour with horizontal shaking at 225 
rpm. 20μl and 100μl aliquots of transformed 5αDH competent cells were then 
plated on culture plates with LB medium and incubated overnight at 37
o
C. The 
plates had kanamycin as the selective antibiotic. The next morning the plates 
were transferred into a refrigerator. In the afternoon five single colonies were 
picked up and applied separately to 20ml universal tubes containing 5ml LB 
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medium with kanamycin. These tubes were incubated overnight at 37
o
C with 
horizontal shaking at 225 rpm.  
 
2.7.1.4. Confirmation of the presence of the insert by PCR 
The following morning, to confirm the presence of the inset in entry clones in 
the 5αDH cells growing in each tube, a PCR reaction was set up with 1μ of the 
culture and AGTEF and AGTER primers as described in section 2.5.2. The 
initial denaturation of this PCR, however, was conducted for 12 minutes and 
Taq DNA polymerase was added to the reactions at the end of the initial 
denaturation step. The presence of a 1660-bp PCR products was confirmed by 
agarose gel electrophoresis as described in section 2.5.2 by electrophoresing 
for 30 minutes at 50 volts on a 1% agarose. This confirmed the presence of the 
inset in entry clones growing in the transformed 5αDH cells in culture. 
 
2.7.1.5. Confirmation of the presence of the insert by restriction digestion 
2ml of culture medium that had been confirmed to contain 5αDH cells with 
the insert were next subjected to miniprep as described in section 2.5.7.3. The 
presence of the insert sequence in the entry clones in this miniprep was 
confirmed again using a restriction digestion assay. There were two 
recognition sites for the restriction enzyme SspI in the entry clone. One was 
within the insert sequence and the other was in the vector sequence. It was 
predicted that digestion of miniprep entry clone DNA with SspI would result 
in two restriction fragments of 2517-bp and 1664-bp. The results of restriction 
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digestion confirmed this. 
 
2.7.1.6. LR recombination reaction 
The LR recombination reaction was set up with 300ng of entry clone miniprep 
DNA, 300ng of pGL3P3GW, 4μl of the 5 × LR Clonase® reaction buffer, and 
1 × TE to make up a final volume of 16μl. LR Clonase® enzyme was removed 
from 70
o
C, vortexed briefly and added to the above reaction mix. This 
reaction mix was vortexed briefly twice and then incubated at 25
o
C for 1 hour. 
Then 2μl of proteinase K was added to the reaction mix and the reaction was 
incubated for 37
o
C for 10 minutes. 
 
The expression clone that resulted from the LR recombination reaction was 
transformed into to 5αDH competent cells as described in section 2.7.1.3 
above. The only exception was that the cells were grown in culture medium 
containing ampicillin instead of kanamycin. Following this procedure the 
presence of the insert sequence was confirmed by PCR as described in section 
2.7.1.4. Next a miniprep of the expression clone was made as described in 
section 2.5.7.3 and the entire sequence of the insert was confirmed by 
sequencing. The sequencing primers are listed in table 2.11. 
 
2.7.1.7. Endotoxin free midi prep of expression vector 
5αDH cells containing expression vector plasmids were cultured overnight in 
20ml of LB medium containing ampicillin in a 50ml centrifuge tube at 37
o
C 
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with horizontal shaking at 225 rpm. An endotoxin free midiprep was made 
using this culture as described in section 2.5.7.3. The endotoxin free midi 
preparations of these plasmids were then used for the transfection 
experiments. 
 
2.7.2. Transfection of experimental plasmid constructs into HepG2 cells 
and reporter gene assay 
2.7.2.1. Transfection assay 
In preparation for the assay, HepG2 cells were trypsinised from flasks and 
then diluted in an appropriate volume of EMEM sufficient to plate on either 
one or two 12 well plates depending on the requirement. 1.2ml of this HepG2 
suspension was then aliquoted into each well. The cells were grown in these 
plates until they had reached 60-70% confluence. 
 
The transfection mix for each well consisted of 200ng of vector DNA, 20ng 
pRenilla, and 1μl Tfx20 reagent suspended in 400μl of serum free EMEM. 
The vector DNA was one of either the recombinant experimental vector 
(pGL3Promoter with 3 AGT enhancer insert) or pGL3Promoter containing 
SV40 promoter or pGL3Control containing both SV40 promoter and 
enhancer. The latter two were the positive controls of the assay. All assays 
were performed in triplicate and each experiment was performed at least three 
times. Serum free EMEM contained all components of complete EMEM listed 
above except for fetal bovine serum. The sum of the total serum free medium 
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for each experiment was aliquoted and the required pRenilla was added to the 
total volume. This ensured that the pRenilla concentration was uniform in all 
wells for each experiment. A 1.2ml aliquot of the solution was prepared for 
each triplicate experiment. To these 1.2 ml aliquots the total vector DNA 
requirement (600ng of each vector DNA) was added. The transfection reagent 
(Tfx20) was added to create a 3:1 ratio of DNA to Tfx reagent. This ratio can 
be varied with most transfection occurring most efficiently at ratios from 2:1 
to 4:1. The ratio of 3:1 had been determined as optimum for the HepG2 cell 
line previously in our laboratory (Marsters, 2000). The mixture was vortexed 
and incubated at room temperature for 15 minutes. Whilst this incubation 
proceeded, the cells were washed twice with PBS. After incubation, 400μl of 
each transfection mix was added to the appropriate well. The transfection 
reaction was incubated at 37
o
C with 5% CO2 for 1 hour. Following this, 800μl 
of complete EMEM was added, and the cells incubated at 37
o
C in a 
humidified incubator with 5% CO2 for 24 hours. 
 
2.7.2.2. Stimulation 
After 24 hours, the cells were either maintained under basal conditions or 
stimulated with AngII. To maintain cells in a basal state, the overnight culture 
medium was removed; cells were washed with PBS, and 1.2 ml of serum free 
EMEM was added to each well. To stimulate cells, the same procedure was 
followed, but AngII was added to the serum free EMEM. HepG2 cells were 
stimulation with AngII at concentrations of 10
-13
, 10
-11
, and 10
-9
M. The 
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rationale for using these concentrations of AngII was that they span the 
physiological range of AngII, and it has been shown that, at least in the 
chorionic plate vasculature, such concentrations are physiologically active in 
vitro (Semple, 1977, Odum and Broughton Pipkin, 1987). 
 
2.7.2.3. Harvesting of cells 
After 24 hours, both non-stimulated and stimulated cells were washed twice 
with PBS ensuring that all PBS was removed, and then 200μl of 1 × passive 
lysis buffer was added to each well. Following this, the cells were incubated 
for 15 minutes at room temperature. The cells were then scraped off the base 
of the well. The solution from each well was collected into a separate 1.5ml 
microcentrifuge tube. The tubes were centrifuged briefly before the reporter 
gene assay to sediment any cell debris. 
 
2.7.2.4. Reporter gene assay 
Expression of the reporter gene in the harvested cells was analysed using the 
Promega Dual Luciferase
®
 Reporter Gene assay kit on a TD 20/20 
luminometer (Turner Designs, USA). To perform the assay, 20μl of the cell 
lysate supernatant was added to a luminometer tube, and the tube was placed 
on the luminometer. Then 50μl of 1 × LARII was added to the luminometer 
tube and the firefly luciferase activity was measured for 10 seconds following 
a 2 second delay. Next 50μl of 1 × Stop and Glow® solution was added to the 
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reaction mix in the luminometer tube. Then the luminescent activity of Renilla 
luciferase was measured for 10 seconds following a 2 second delay. This was 
repeated for the sample from each well. 
 
2.7.3. Study of background luminescence 
It is possible that there is background luminescence emanating from HepG2 
cells and dual luciferase assay reagents. It is necessary to differentiate that 
from true luminescence. To investigate background luminescence a 12 well 
plate was plated with non-transfected HepG2 cells as was done in preparation 
for a transfection assay as described in paragraph one in section 2.7.2.1. Once 
it had reached 60-70% confluence, complete EMEM was removed, cells were 
washed twice with PBS, each well filled with 400μl of serum free EMEM, and 
incubated at 37
o
C with 5% CO2 for 1 hour. Then 800μl of complete EMEM 
was added to each well and the cells were incubated at 37
o
C in a humidified 
incubator with 5% CO2 for 24 hours. Following that cells were harvested as 
described in section 2.7.2.3 and a reporter gene assay was conducted as 
described in section 2.7.2.4. 
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2.8. Software tools and electronic database information 
The software and electronic databases used in these investigations are listed 
below: 
● SPSS for Windows, standard version release 11.0.0, 2001 (SPSS Inc., 
USA) was used to maintain phenotyping databases and for statistical 
analysis. 
● Sample Size Calculator (SPSS Inc, USA) and QUANTO version 0.5 
(Gauderman, 2002) were used for power calculations. 
● GenBank at the National Centre for Biotechnology Information (NCBI), 
USA was searched to obtain DNA sequences and gene mapping 
information. This is a free database that can be accessed online at URL: 
http://www.ncbi.nlm.nih.gov 
● Primer3 on the WWW for general users and for biologist programmers 
(Rozen and Skaletsky, 2000) was used to design oligonucleotide primers 
for PCR. This is a free program that can be accessed online at URL: 
http://www.broad.mit.edu/genome_software/other/primer3.html 
● Webcutter 2.0 was used to analyse restriction enzyme recognition sites on 
DNA sequences. This is a free program that can be accessed online at 
URL: http://www.firstmarket.com/cutter 
● Group centile calculator software (Gardosi and Francis, 2000) was used to 
calculate customised birth weight percentiles (Gardosi, Chang, Kalyan, 
Sahota and Symonds, 1992, Gardosi, Mongelli, Wilcox and Chang, 1995). 
This is a free programme distributed by the authors over the Internet at 
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URL: http://www.gestation.net/gest 
● The COCAPHASE program of the UNPHASED program suite 
(Dudbridge, 2002, 2003) was used to estimate haplotype frequencies from 
genotype data, measure linkage disequilibrium (see section 2.9.2) and to 
perform hypothesis testing using haplotypes in case-control candidate gene 
pre-eclampsia association studies. It is available to registered users from 
the Rosalind Franklin Centre for Genetic Research website at URL: 
http://www.rfcgr.mrc.ac.uk/~fdudbrid/software/unphased 
● The QTPHASE program of the UNPHASED program suite was used to 
estimate haplotype frequencies from genotype data and to perform 
hypothesis testing using haplotypes in candidate gene quantitative trait 
association studies. 
● MatInspector Release Professional 6.2.1 (Quandt, Frech, Karas, 
Wingender and Werner, 1995) was used to examine DNA sequences for 
transcription factor binding sites. This is a free program that can be 
accessed online at URL: http://www.genomatix.de 
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2.9. Statistical Methods 
2.9.1. Analysis of phenotyping data of women with pre-eclampsia and 
normotensive pregnant women 
Phenotyping data were entered directly into a SPSS database. Data was 
verified manually for errors. In the phenotype analysis, summary values are 
presented as mean (standard deviation (SD)) when data were normally 
distribution and as median (inter quartile range) when not. The χ
2
 or Fisher 
exact tests were used to determine departures from the hypothesised 
distribution of categorical data. Student-t test was used to test for differences 
between groups where the data were normally distributed and appropriate non-
parametric tests when the distribution was not normal.  
 
2.9.2. Analysis of population genetic data 
χ
2
 test was used to test the genotypes at each polymorphic locus for HWE and 
to compare allele frequency differences between racial groups. The 
COCAPHASE program of the UNPHASED suite of programs was used to 
estimate haplotype frequencies and to measure linkage disequilibrium (D' and 
r
2
) between genotypes at pairs of polymorphic sites. This programme uses the 
EM algorithm to obtain maximum likelihood haplotype frequency estimates.  
 
2.9.3. Analysis of case-control candidate gene pre-eclampsia association 
data 
Analysis of HWE and single locus allele frequency comparisons were 
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performed as described above in section 2.9.2. HWE was tested at each 
polymorphic locus for case and control groups separately. Haplotype 
frequency estimation and hypothesis testing was conducted using the 
COCAPHASE program. This program performs a likelihood ratio test that 
examines the differences between haplotype frequency profiles between the 
case and control groups and computes a likelihood ratio statistic for the 
estimated haplotype frequency likelihoods for the combined case and control 
groups (Zhao, Curtis and Sham, 2000). Rare haplotypes occurring in 
frequencies of ≤0.05 were dropped from the analysis in both case and control 
groups unless otherwise stated. 
 
2.9.4. Analysis of candidate gene quantitative trait association data 
The association of the AGT gene with systolic and diastolic blood pressures at 
booking in normotensive pregnant women, and the association of AGT, EGF 
and TGFA haplotypes with birth weight of their babies, were analysed using 
the QTPHASE programme of the UNPHASED software suite. This 
programme is similar to the COCAPHASE programme, but it uses a 
generalised linear model for a quantitative trait. The test assumes that the trait 
is normally distributed with its mean dependent only on the additive effects of 
haplotypes (Abecasis, Cardon and Cookson, 2000). This program performs a 
likelihood ratio test for the quantitative trait as described above. ANOVA was 
used to test the association of individual SNP genotypes with quantitative 
traits.  
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2.9.5. Analysis of reporter gene assay data 
Average ratios for firefly and Renilla luciferase activity were calculated for 
each triplicate after excluding any outliers (lying outside mean ± 4×SD). The 
activity of the constructs under basal and stimulated conditions was compared 
with the activity of the pGL3Promoter vector under basal conditions to 
calculate the increase/decrease in response. Furthermore, the activity of the 
constructs under stimulated conditions was compared with the activity of the 
constructs under basal condition to calculate the increase/decrease in response. 
Differences in response between the constructs under basal and stimulated 
conditions were analysed using ANOVA with Tukey HSD post hoc after  
log
 -10
 transformation. 
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2.10. Polymorphism nomenclature 
The nine polymorphisms that were studied in this thesis are referred to by the 
common names used to refer to them in scientific literature so that there is no 
confusion when comparisons are made. The only polymorphism that had not 
been named previously was the EGF 67149A polymorphism, which was 
named by the author based on the position of the polymorphism relative to the 
transcription start site of the gene on chromosome 4 (GenBank: 
gi|27477929:440000-550000 homo sapiens chromosome 4 genomic contig)  
 
There is however, a move to standardise nomenclature for description of 
sequence variations (Antonarakis, 1998, den Dunnen and Antonarakis, 2000). 
The polymorphisms studied in this thesis together with their corresponding 
standardised descriptions based on the above-mentioned recommendations are 
listed in table 2.13. 
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Polymorphism Standardised Nomenclature 
EGF 61G>A AJ131611:g.139G>A 
EGF 67149G>A NM_001963:c.2566G>A 
  
TGFA 3822G>A AF123243:g.599G>A 
TGFA 3827T>C AF123243:g.604T>C 
TGFA 3851T>C AF123243:g.628T>C 
  
AGT 174Thr>Met NM_000029:c.659C>T 
AGT 235Met>Thr NM_000029:c.842T>C 
AGT 11535C>A M24689:g.834C>A 
  
MTHFR 677C>T NM_005957:c.716C>T 
 
Table 2.13. A list of the polymorphisms studied in this thesis and a 
description of the polymorphism using standardised nomenclature (all 
accession numbers are from GenBank). 
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3. RESULTS 
3.1. The pre-eclampsia phenotype  
This section was aimed at analysing the phenotype of the 180 Sinhalese 
women with pre-eclampsia and comparing it with the 180 normotensive 
pregnant women from the same population. It was also hoped to compare this 
data with both previously published data and the phenotyping data of the 74 
white Caucasian women with pre-eclampsia and the 81 normotensive pregnant 
women. It was not possible to compare the Sinhalese data with other published 
studies as none of the studies reporting morbidity and mortality among women 
with pre-eclampsia were confined to nullipara. There are several carefully 
designed clinical trials conducted in nulliparous women that report on 
maternal and fetal morbidity and mortality (Hauth, Goldenberg, Parker, 
Philips, Copper et al., 1993, Sibai, Caritis, Thom, Klebanoff, McNellis et al., 
1993, Kyle, Buckley, Kissane, de Swiet and Redman, 1995, Levine, Hauth, 
Curet, Sibai, Catalano et al., 1997), but none of them report this information 
for women with pre-eclampsia separately, to enable comparison. The 
Sinhalese phenotype therefore, was compared with that of the white 
Caucasians. Where phenotyping data for the white Caucasians is incomplete 
(see section 2.4.2) the number of subjects analysed to derive the result is 
given. In this section of this thesis the presentation of results is combined with 
discussion. 
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3.1.1. Demographic characteristics 
The demographic characteristics of the Sinhalese and the white Caucasian 
women are in table 3.1. The Sinhalese women were matched for age and BMI. 
The white Caucasians were not matched, and the women with pre-eclampsia 
had a significantly higher BMI (P=0.001). When the BMI of women with pre-
eclampsia was considered, a majority (89.4%) of Sinhalese women had a BMI 
of <26 kg/m
2
. BMI of ≥30kg/m
2
 was an exclusion criterion for recruitment of 
Sinhalese women. However, only eight (2.2%) out of 356 women with pre-
eclampsia referred for recruitment were not recruited for this reason (see table 
2.4). These results were expected as the prevalence of obesity defined as BMI 
of >25 kg/m
2
 in Sri Lankan women between the ages of 30 to 44 years was 
reported to be 8.2% (Fernando, Siribaddana, De Silva and Perera, 1994). 
Among the white Caucasian women, only 44.1% (15/34) had a BMI of <26 
kg/m
2
. All Sinhalese women were nulliparous, but 20 women with pre-
eclampsia (20/180, 11%) were in their second pregnancy. Among the white 
Caucasians 85% (57 pre-eclamptic (PE) + 58 normotensive (NT); 115/136) 
were in their first pregnancy, 14% (8 PE + 11 NT; 19/136) in their second, and 
1% (1 PE + 1 NT; 2/136) in their third pregnancy. The average age of the 
Sinhalese and the white Caucasian women with pre-eclampsia as well as those 
of normotensive pregnant women were comparable. Among the white 
Caucasians 10.8% (8/66) were smokers and 1.4% (1/66) was an ex-smoker, 
but none of the Sinhalese women had ever smoked. This was not surprising as 
smoking is very rare among Sinhalese women in Sri Lanka. 
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   Sinhalese   White Caucasians 
  
Pre-eclamptic 
(n=180) 
Normotensive 
(n=180) 
P 
  
Pre-eclamptic 
(n=74) 
Normotensive 
(n=81) 
P 
           
Mean Age (Years) (SD) 27.1 (5.4) 27.2 (5.2) 0.96  27.9  (5.8) 27.7  (4) 0.75 
Mean Weight (kg) (SD) 49.6 (8.8) 48.8  (8) 0.33  68.7  (11.3) 64.5  (9.8) 0.05 
Mean Height (cm) (SD) 153.6 (5.5) 154.0  (6.4) 0.98  162.2  (5.8) 164.7  (7.1) 0.03 
Mean Body Mass Index (kg/m
2
) (SD) 21.0 (3.4) 20.7  (3.2) 0.34  26.2  (4.1) 23.7  (3.1) <0.01 
Nulliparous n(%) 180 (100) 180  (100)   74  (100) 81  (100)  
Ex and Current Smokers n(%) 0 (0) 0  (0)     9/66  (13.6) 8/70  (11.4) 0.62  
            
 
Table 3.1. Demographic characteristics of the Sinhalese and the white Caucasian women with pre-eclampsia and 
normotensive pregnant women. SD: Standard Deviation. Significance (P) is for comparison between women with pre-
eclampsia and normotensive pregnant women in each population. Note that the Sinhalese women were matched for BMI at 
recruitment; no such matching was done for the white Caucasian women. 
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3.1.2. Antenatal booking 
Characteristics of both groups of women in each population at the antenatal 
booking are in table 3.2. There was no difference in the gestation at booking of 
the Sinhalese and the white Caucasian women with pre-eclampsia and 
normotensive pregnant women. The blood pressure at booking, however, was 
significantly higher among the Sinhalese and the white Caucasian women who 
subsequently developed pre-eclampsia compared to their normotensive 
counterparts. In the white Caucasians, this difference in blood pressure was 
greater than in the Sinhalese. The systolic and diastolic blood pressures of the 
white Caucasian normotensive pregnant women were also higher than that of 
the Sinhalese normotensive pregnant women (SBP: P<0.001, DBP: P=0.018).  
 
The differences in blood pressure in the Sinhalese and the white Caucasians 
are interesting. The white Caucasian women had their antenatal booking later 
in pregnancy than the Sinhalese women, at a time when a greater 
physiological reduction in blood pressure was expected. However, their 
average SBP was nearly 15mmHg higher than that in the Sinhalese. A rise in 
SBP of ≥30mmHg and/or DBP of ≥15mmHg from blood pressure 
measurements taken at the pre-conception stage or in the first trimester had at 
one time been recommended and used by many to establish the diagnosis of 
pre-eclampsia (National High Blood Pressure Education Program Working 
Group, 1990, Australasian Society for the Study of Hypertension in 
Pregnancy, 1993). In the current study, on average, the Sinhalese women had 
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to have a 25% rise in their SBP from the antenatal booking average of 111.7 
mmHg to reach the diagnostic threshold of 140mmHg, compared with 12% for 
the white Caucasian women. The difference in the rise in DBP that was 
required was not as marked (19mmHg (27%) in the Sinhalese cf. 20mmHg 
(22%) in the white Caucasians). If the Sinhalese women were to begin 
pregnancy at a lower blood pressure than the white Caucasians and the 
absolute rise in SBP during pregnancy over pre-pregnancy blood pressure 
levels was more important than reaching a particular diagnostic blood pressure 
threshold, then that may perhaps explain why many Sinhalese women have 
severe disease by the time they are diagnosed with hypertension in pregnancy 
than women in the West (see section 1.1.1).  
 
There were differences in the pulse pressure as well. The average pulse 
pressure in normotensive women at booking was 40mmHg and 55.7mmHg in 
the Sinhalese and in the white Caucasians respectively. In Sri Lanka Korotkoff 
phase IV (K5) is used to record the DBP. When the white Caucasian women 
were recruited over a decade ago in Nottingham K4 was recommended to 
record the DBP in pregnancy in UK. If K5 were recorded in these women then 
the pulse pressure would have been even higher. There are no studies of the 
pattern of blood pressure of Sinhalese women in pregnancy. The average SBP 
and DBP of normotensive Sinhalese women at booking in this study is as 
expected lower than the average SBP (117.5mmHg) and DBP (78.2mmHg) 
reported in a group of non-pregnant women aged between 20 to 40 years
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   Sinhalese  White Caucasians 
   
Pre-eclamptic 
(n=180) 
Normotensive 
N(=180) 
P  Pre-eclamptic 
(n=74) 
Normotensive 
n=(70) 
P 
       
 
     
Gestation at booking (weeks) M(iqr) 13.6  (10.7-16.0) 13  (10.7-15.4) 0.449 
 
17  (14-18)
1
 17  (12-18)
3
 0.578 
       
 
     
Blood pressure at booking       
 
     
   Mean Systolic (mm Hg) (SD) 111.7  (9.9) 109  (9.3) 0.002 
 
125.2  (14.2)
2
 120.9  (12.9)
4
 0.066 
   Mean Diastolic (mm Hg) (SD) 71.1  (7.3) 69  (7.1) 0.002 
 
70.2  (8.9)
 2
 65.2  (8)
4
 0.001 
       
 
     
 
Table 3.2. A comparison of antenatal booking data and data at diagnosis of the Sinhalese and the white Caucasian women with 
pre-eclampsia and normotensive pregnant women. SD: Standard Deviation. M(iqr): median (inter quartile range).
 
The white 
Caucasian results were derived from data of 
1
35, 
2
65,
3
69, and 
4
70 subjects. Significance (P) is for comparison between women 
with pre-eclampsia and normotensive pregnant women in each population. 
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in Sri Lanka (Mendis, Athauda, Naser and Takahashi, 1999a). The average 
pulse pressure of those women (38.2mmHg), however, is similar to that in the 
current study.  
 
As expected the blood pressure recordings in both countries that were 
retrieved from case notes show end digit preference. As a result, in many 
women the recorded blood pressure would have underestimated their true 
blood pressure. 
 
3.1.3. Diagnosis and management 
Characteristics of both groups in each population at diagnosis and delivery are 
summarised in table 3.3. Most Sinhalese women were diagnosed (124, 69%) 
and delivered (120, 66%) before 37 weeks of gestation. 106 (58.9%) delivered 
within 48 hours of the diagnosis being made. Overall 140 (77.8%) women 
needed a Caesarean section for delivery. The majority of the white Caucasian 
women (36/66, 54.5%) delivered at term and required a Caesarean section 
(35/65, 53.8%). 
 
The Sinhalese women with pre-eclampsia on average had lengthy hospital 
stays. The number of in patient days in hospital from diagnosis to discharge 
ranged from two to 57 days (Median=9). Only 15 (7.2%) stayed in hospital for 
less than three days. They were women who had mild disease who left the 
hospital early against medical advice. 160 (76.8%) spent more than five days. 
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  Sinhalese  White Caucasians 
  Pre-eclamptic Normotensive P  Pre-eclamptic Normotensive P 
  n=180 n=180   n=74 n=81  
      
 
     
Gestation at presentation (weeks) M(iqr) 35  (31-38)   
 
35  (32-37)
1
    
   <34 Weeks n(%) 77  (43)   
 
13  (34)    
   34-36 Weeks n(%) 47  (26)   
 
14  (37)    
   37-42 Weeks n(%) 56  (31)   
 
11  (29)    
Gestation at delivery (weeks) M(iqr) 35  (32-38) 40 (39-40) <0.001 
 
37  (34-39)
2
 40  (39-41)
4
 <0.001 
   <34 Weeks n(%) 69  (38)    
 
13  (20)    
   34-36 Weeks n(%) 51  (28)    
 
17  (26)    
   37-42 Weeks n(%) 60  (33) 180  (100)  
 
36  (55) 69  (100)
4
  
Caesarean deliveries n(%) 140  (78)    
 
33  (54)
3
    
Diagnosis to delivery (days) M(iqr) 0  (0-3)    
 
     
Delivery to discharge (days) M(iqr) 7  (5-12)    
 
     
Diagnosis to discharge (days)  M(iqr) 9  (5-16)       
 
          
       
 
     
 
Table 3.3. A comparison of data on gestation at diagnosis and delivery, mode of delivery, and the hospital stay of the Sinhalese and the 
white Caucasian women with pre-eclampsia and the gestation at delivery of the Sinhalese and the white Caucasian normotensive pregnant 
women. M(iqr): median (inter quartile range). The white Caucasian results were derived from data of 
1
38, 
2
66, 
3
65 and 
4
69 subjects. 
 
 
 190 
Three women were managed expectantly for more than four weeks before 
delivery. Four women were in hospital for more than four weeks postpartum 
to accompany their babies who required prolonged neonatal care. 
 
3.1.4. Maternal morbidity and mortality 
Many Sinhalese and white Caucasian women experienced complications that 
are associated with adverse maternal and fetal outcomes (Mattar and Sibai, 
2000). These included severe blood pressure (SBP≥160mmHg and/or 
DBP≥110mmHg), severe proteinuria (HCT ≥3+ or Dipstick test ≥3+ or 
≥3g/day on 24 hour collection), elevated liver enzymes (AST ≥70IU and/or 
ALT ≥70IU), placental abruption, eclampsia, and even maternal death. The 
vast majority of Sinhalese women had severe blood pressure and proteinuria. 
Two women developed a combination of five of these severe complications. 
The first woman was diagnosed at 37 weeks of gestation, and her pregnancy 
was terminated immediately by Caesarean section; both the mother and the 
baby survived. The second woman was diagnosed at 24 weeks of gestation, 
her pregnancy too was terminated, but neither mother and nor baby survived.  
 
Since there is clear evidence that early onset pre-eclampsia is a more severe 
disease than late onset pre-eclampsia in Western populations (von Dadelszen, 
Magee and Roberts, 2003) data on complications in Sinhalese women is 
presented in table 3.4 dichotomising it into early (<34 weeks) and late onset 
groups by gestational age as has been suggested recently (von Dadelszen et 
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al., 2003). Women with early onset pre-eclampsia seem to experience more 
complications compared to women with late onset pre-eclampsia, although the 
differences did not reach statistical significance. Eclampsia, however, was 
slightly higher among women with late-onset pre-eclampsia. This discrepancy 
may be explained by the MgSO4 therapy given as eclampsia prophylaxis; 46% 
of women with early onset-pre-eclampsia received MgSO4 while only 29% of 
women with late-onset pre-eclampsia received it (P=0.02). Moreover, those 
who had early onset pre-eclampsia were more likely to receive closer 
monitoring in an intensive care unit (ICU) and more aggressive 
antihypertensive therapy as evidenced by the number of different 
antihypertensives used. In addition, in 50% of women with eclampsia (5/10) in 
the late onset group, the presenting symptom was eclampsia. In spite of the 
severe morbidity in both early onset and late onset groups, overall only 53% of 
women received care in an ICU because there were only six ICU beds in these 
two hospitals. 
 
A relatively high proportion (16, 8.9%) of the Sinhalese women with pre-
eclampsia also developed eclampsia. There was no difference between the age 
of the women who developed eclampsia and those who did not (26.1 (6.6) cf. 
27.2 (5.4); P=0.41), but they had lower BMI at the first antenatal visit (19.3 
(1.9) cf. 21.2 (3.4); P=0.03). The SBP (107.1 (12.7) cf. 112.0 (9.6); P=0.08) 
and the DBP (68.6 (6.6) cf. 71.3 (7.3); P=0.18) at booking, the SBP (160.6 
(21.4) cf. 155.7 (14.4); P=0.22) and the DBP (103.1 (13.6) cf. 102.1 (9.1); 
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P=0.22) at diagnosis and the highest recorded SBP (168.8 (18.2) cf. 166.2 
(16.1); P=0.55) and the highest recorded DBP (115.0 (11.3) cf. 114.1 (10.0); 
P=0.75) were not significantly different in women who had eclampsia and 
these who did not. Eclampsia occurred before delivery in 14 women and 
postpartum in two women. Six delivered before 34 weeks, six between 34 and 
36 weeks, and four at term. Only one baby was born alive and six (33%) of the 
babies were small for gestational age. One of these women died. 
 
The white Caucasian women too had severe hypertension and proteinuria.  
29.7% (22/74) had SBP≥160mmHg and/or DBP≥110mmHg. At recruitment 
all white Caucasian women with pre-eclampsia had significant proteinuria of 
≥500mg/day on a 24-hour urine protein estimations and/or ≥2+ dipstick 
testing. Of these women six had proteinuria of ≥3.0g/day and 10 had a dipstick 
recording of ≥3+. Overall, 21.6% had proteinuria of ≥3.0g/day or ≥3+ on 
dipstick testing.  
 
In addition to this, 10% (6/66) had thrombocytopaenia, but the liver enzyme 
levels were not available for them. None of them had eclampsia. In contrast to 
the Sinhalese women with pre-eclampsia, nearly all of whom (99%) required 
antihypertensive treatment, only 39% (25/64) of the white Caucasian women 
with pre-eclampsia received antihypertensive therapy and of them 14 were 
treated with MgSO4. In addition to them, three others had also received 
MgSO4 (27%, 17/63). The need to prolong pregnancy by medical intervention 
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Early Onset 
(<34 Weeks) 
n=77 
Late Onset 
(≥35 Weeks) 
n=103 Complication / Treatment 
No (%) No (%) 
P 
    
Complications    
SBP ≥160mmHg and/or DBP ≥110mmHg 73 (94.8) 88 (85.4) 0.04 
Proteinuria (≥3+ HCT) 65 (84.4) 91 (88.3) 0.44 
Renal impairment requiring dialysis 3 (3.9) 1 (0.9) 0.18 
Thrombocytopaenia (<100 000/μl)* 14/75 (18.7) 9/101 (8.9) 0.06 
Elevated liver enzymes (AST or ALT≥70 IU/L)** 12/65 (18.5) 7/63 (11.1) 0.24 
Placental abruption 4 (5.2) 3 (2.9) 0.43 
Eclampsia 6 (7.8) 10 (9.7) 0.66 
Maternal death 1 (1.3) 0 (0) 0.43 
      
Treatment    
ICU care 54 (70) 41 (40) <0.01 
MgSO4 therapy 35 (46) 30 (29) 0.02 
≥2 antihypertensives 72 (94) 69 (67) <0.01 
 
 
Table 3.4. Maternal complications in Sinhalese women with pre-eclampsia and the treatment 
received by them: SBP  Systolic Blood Pressure, DBP  Diastolic Blood Pressure, AST  
Aspartate Transaminase, ALT  Alanine Transaminase, HCT  The urine protein heat coagulation 
test. * Platelet counts were not available for four women. **AST/ALT levels were not available 
for 52 women. 
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when the diagnosis is made remote from term increases the likelihood of 
antihypertensives being used. This could be one explanation for the reason 
why more Sinhalese women received antihypertensive therapy than did white 
Caucasian women as only 33% of the Sinhalese women delivered at term 
compared to 55% of the white Caucasian women. Other factors that would 
influence the use of antihypertensives are local protocols that vary between 
hospitals and difference in facilities available for close monitoring of patients 
in different hospitals. 
 
3.1.5. Perinatal morbidity and mortality 
The outcome for the babies of Sinhalese women is summarised in table 3.5. Of 
them 106 (58.9%) were male. Others have also reported such distortions in the 
sex ratio of babies born to women with pre-eclampsia. Its significance, 
however, is not clear because in large studies such as the GOPEC study the 
sex ratio is almost 1:1 (Broughton Pipkin, F. Personal Communication). 
Fourteen (7%) pregnancies resulted in stillbirths. The neonatal morbidity and 
mortality among the Sinhalese babies was much more severe than among the 
white Caucasian babies. In total, 114 (68.7%) of the 166 babies who were a 
live at birth received care in a special care baby unit (SCBU). Thirty of them 
died during the immediate postpartum period, before the mother was 
discharged from hospital. Of the 136 babies who were taken home, one had 
died at the age of six days. The condition of 65 others at six weeks postpartum 
could not be verified, as the mothers could not be contacted for follow up (see 
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section 3.1.5). Of them, 33 were delivered pre-term and 39 had received 
SCBU care. Even if we assume that all of them remained alive, overall 45 
(25%) babies died during the perinatal period. The smallest surviving baby at 
six weeks postpartum weighed 750g at birth at 28 weeks of gestation. None of 
the other babies born following gestation periods shorter than that survived. Of 
the 77 babies born to mothers developing pre-eclampsia before 34 weeks of 
gestation, 12 (15.6%) were stillbirths and only 35 (46.7%) survived to go 
home with the mother. There were only three (2.9%) confirmed perinatal 
deaths among babies of women who developed late onset pre-eclampsia.  
 
Among the white Caucasians 58% (39/67) of babies were male. All except one 
(6.6%) of the babies of the 15 women with early onset pre-eclampsia survived, 
as did all the babies of the 51 women with late onset pre-eclampsia. The 
PNMR therefore was 1.5% (1/66). Eleven of 13 (84.6%) babies born to 
women with early onset pre-eclampsia required SCBU care, in comparison to 
only three of 24 (12.5%) babies born to women with late onset pre-eclampsia. 
 
Customised birth weight centile charts are not available for Sinhalese babies. 
Indian charts in the customised birth weight centile calculator software 
(Gardosi et al., 2000) were therefore used as a surrogate to calculate the birth 
weight centiles of Sinhalese babies. This software takes into consideration the 
mothers ethnicity, height, weight at antenatal booking, parity, and gestational 
age at delivery and the babys sex and birth weight to calculate an adjusted 
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birth weight that is compared with a standard ultrasound-derived curve for 
intra uterine weight gain to determine a customised birth weight centile for 
each baby (Gardosi et al., 1992). Birth weights that were below the 5th centile 
were considered small for gestational age (SGA). 47.8% (86/180) of babies 
born to Sinhalese women with pre-eclampsia and 5% (9/180) of babies born to 
normotensive Sinhalese women were SGA. The latter observation supports the 
use of Indian charts as a surrogate for this Sri Lankan population. Among the 
white Caucasians, the percentage of SGA babies in pre-eclamptic and 
normotensive groups were 20.7% (7/34) and 5.7% (4/70) respectively. In the 
GOPEC study, which examined 1001 women with pre-eclampsia, 33.8% of all 
babies born to them were SGA. However, the percentage rose to 62.3% for 
babies delivered prior to the 34
th
 week of gestation (Broughton Pipkin, F. 
Personal Communication).  
 
In the current study, overall, the perinatal mortality among babies of Sinhalese 
women with pre-eclampsia is very high in comparison to babies of the white 
Caucasian women with pre-eclampsia. However, this is not entirely 
unexpected because it is evident from the data presented above that the 
Sinhalese women had much more severe disease than the white Caucasian 
women. In addition, the scarcity of neonatal care facilities would have also 
contributed to it. In the SCBU at the CSHW there were only 15 cots with 
incubators and four cots with ventilators to cater to more than 15 000 babies 
born there annually. The situation in the other recruiting hospital, DSHW, 
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where more than 10 000 babies are born annually, was not much better. In 
Nottingham UK, babies of women with pre-eclampsia occupy about 16% of 
SCBU cots (Broughton Pipkin, Personal Communication). In the two 
recruiting hospitals, although such data is not available, a much higher 
percentage of beds are bound to be occupied by babies of women with pre-
eclampsia. National data for perinatal mortality is not available for Sri Lanka, 
as stillbirths are not registered in all areas. However, the overall PNMR in one 
of the recruiting hospitals, CSHW, was 1.79% and 1.76% in 2001 and 2002 
respectively (Castle Street Hospital for Women, 2003). In comparison it was 
25% in babies of Sinhalese women with pre-eclampsia. Among the white 
Caucasian women, the corresponding rate was 1.5%; this is nearly twice that 
of the PNMR of 0.83% in England and Wales in 2002 (Office for National 
Statistics, 2001). In the GOPEC study, the perinatal mortality rate was 2.4%, 
which is nearly three times that of the overall national rate (Broughton Pipkin, 
Personal Communication). This data while re-emphasising the severe 
morbidity in babies of Sinhalese women with pre-eclampsia, also highlight the 
urgent need to improve perinatal care services in Sri Lanka. 
 
3.1.6. Postnatal resolution of blood pressure and proteinuria 
Resolution of hypertension during the postpartum period (before the end of the 
13
th
 week) had been confirmed in all white Caucasian women. Postpartum 
follow up of Sinhalese women, however, was difficult as there was shared care 
between the recruiting hospital and the primary health care centre near the 
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womans place of residence. It was further complicated because Sinhalese 
women go back to live with their parents following delivery. As a result, the 
primary health care centre that looked after a woman during the antenatal 
period may not be the centre that looked after her post partum. Every attempt 
was made, however, to contact the 179 women at variable times after 13 
weeks postpartum to verify whether the condition had resolved. 65 women 
could not be contacted, but blood pressure and proteinuria had resolved in 26 
of them prior to discharge from hospital. A further 110 were confirmed to be 
normotensive and non-proteinuric postpartum. The condition therefore, was 
confirmed to have resolved postpartum in 137 women. Four women, however, 
were on antihypertensives and among them three had had early onset pre-
eclampsia. They were excluded from the case-control candidate gene pre-
eclampsia association study. A decision, however, had to be made regarding 
the inclusion of the 39 women, in whom postpartum blood pressure resolution 
could not be confirmed. It was decided to include them because excluding 
them would have undermined the power of the study to detect a genetic 
contribution. It is hoped, that it would be possible to trace at least some of 
these women once the author returns to Sri Lanka, for a future publication, but 
it is likely to be time consuming. 
 
3.1.7. Family history 
In what is possibly the only study of its kind, Cincotta and Brennecke (1998), 
who prospectively related the risk of development of pre-eclampsia in a group 
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Sinhalese   White Caucasian 
Early Onset Late Onset NT  Early Onset Late Onset NT 
Outcome   (n=77) (n=103) (n=180)   (n=15) (n=51) (n=81) 
               
Gestation at delivery (weeks) M(iqr) 30  (28.4-32.1) 37  (35.4-38.7) 40  (38.6-40.4)  31  (29-33) 38  (36-39) 40
2
  (39-41) 
SGA (<5
th
 percentile) n(%) 52  (67.5) 34  (33.0) 9  (5.0)  4/9  (44.4)  3/25  (12.0) 4/70  (5.7) 
      
  
       
Admission to SCBU n(%) 62  (100)
1
 52  (50.4) 16  (8.9)  11/13  (84.6)  3/24  (12.5) 0/68  (0.0) 
               
Perinatal losses               
  Fetal death n(%) 12  (15.6) 2  (1.9) 0  (0.0)  0/15  (0.0)  0/51  (0.0) 0/68  (0.0) 
  Postnatal death (up to six weeks) n(%) 30  (39.0) 1  (0.9) 0  (0.0)  1/15  (6.7) 0/51  (0.0) NA  
                              
Table 3.5. Perinatal outcome of babies of the Sinhalese and the white Caucasian women with pre-eclampsia and normotensive pregnant 
women. M(iqr): mode(inter quartile range).
 1
Twelve babies were stillborn, and two died soon after deliver before transfer to SCBU, 
information on one baby whose mother was transferred out of the recruiting hospital to a district hospital for delivery on her request is not 
available. The white Caucasian data, except gestation at delivery, is presented as number/number of babies for whom the data item was 
available;
2 
Derived from data of 69 women; NA - data not available. 
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of 368 primigravid women to their self reported family history of the 
condition, found a four fold increased risk of pre-eclampsia (relative risk 
(RR)=4.3, 95% CI, 1.6 to 11.5; P=0.017) among women who had a mother, 
sister or both who had had pre-eclampsia. In the current study as a part of 
phenotyping of Sinhalese women a four-generation pedigree was constructed 
and the history of the occurrence of hypertensive disorders of pregnancy in 
female relatives of either side of the family were recorded by questioning the 
woman. The response to the effect that a female family member developed 
high blood pressure or fits during pregnancy was taken as being indicative 
of a positive history of a hypertensive disorder during that womans 
pregnancy. No attempt however, was made to trace case notes to verify this 
information. Similar data had been collected for the white Caucasian women. 
An analysis of the reported family history of high blood pressure or fits in 
pregnancy in Sinhalese and white Caucasian women is given in table 3.6. The 
white Caucasian data, although very limited in size, are in agreement with the 
data of Cincotta et al. (1998), showing that primigravid women with a positive 
family history of hypertensive disorders of pregnancy in her side of the family 
carry a three-fold increase risk of pre-eclampsia. It is difficult to explain why 
this finding could not be replicated in Sinhalese women. It cannot be 
explained by any social factor such as literacy or non-contact with their 
extended family that may have influenced awareness of the occurrence of such 
a devastating condition in a female relative as literacy among Sinhalese 
women is over 90% and because for the most part Sinhalese have closely knit 
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extended families. Among the white Caucasians in Nottingham, the increased 
risk mainly came from a positive history among their mothers and maternal 
grandmothers (data not shown). Almost equal numbers of sisters of Sinhalese 
women with pre-eclampsia (176) and normotensive pregnant women (178) 
had completed at least one pregnancy, but interestingly none of the Sinhalese 
women gave a positive history in their maternal grandmothers. This may be a 
result of either a lack of awareness on the part of the women or the severe 
maternal mortality among women who developed pre-eclampsia/eclampsia in 
Sri Lanka two generations back (Seneviratne et al., 2000). 
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  Pre-eclamptic Normotensive Odds Ratio 95% CI 
       
FH+ in the woman’s family       
Sinhalese 19 (19/176,10.8%) 13 (13/178,  7.5%) 1.5 0.7 to 3.2 
White Caucasians 12     (12/26,46.2%) 12 (12/54,22.2%) 3.0 1.1 to 8.2 
       
FH+ in the partner’s family       
Sinhalese 9 (9/173, 5.2%) 4 (4/178,  2.2%) 2.4 0.7 to 7.9 
White Caucasians 4 (4/25,16.0%) 7 (7/46,15.2%) 1.1 0.3 to 4.0 
       
FH+ in both sides of the family       
Sinhalese  28 (28/176,15.9%) 17 (17/178,  9.6%) 1.8 1.0 to 3.5 
White Caucasians 12 (12/26,46.2%) 15 (15/53,28.3%) 2.2 0.8 to 5.8 
       
 
Table 3.6. Analysis of the reported family history of high blood pressure or fits in Sinhalese and white 
Caucasian women with pre-eclampsia and normotensive pregnant women. FH+: A positive family history. 
Percentages were calculated using the formula: number with positive history/number of women for whom 
family history data was available×100. 
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3.2. Results of the population genetic analysis 
The haplotype frequency estimates of the EGF, TGFA, and AGT genes and the 
frequency of the alleles of the MTHFR 677C>T polymorphism in each 
population is shown in table 3.7. The frequency of the variant allele of each 
polymorphism in the four candidate genes is shown in table 3.8. All 
polymorphisms in each population were in HWE. 
 
Overall there was very little difference in haplotype frequencies between the 
three Sri Lankan racial groups. The only exception was the difference in the 
haplotype frequencies of the TGFA gene between the Sinhalese and the 
Moors. Two polymorphisms (3822G>A and 3851T>C), which had 
significantly different allele frequencies (P<0.049 and P=0.005 respectively) 
contributed to this. The only other significant difference between allele 
frequencies in any polymorphism among the three Sri Lankan racial groups 
was the difference in the TGFA 3851T>C polymorphism between the Sri 
Lankan Tamils and the Moors (P=0.025). The haplotype frequencies in the 
EGF, TGFA and AGT genes in all three Sri Lankan racial groups were 
significantly different to that of the white Caucasians (P<0.01). Exceptions to 
this were the TGFA gene for the comparison between the Sinhalese and the 
white Caucasians, and the EGF gene for the comparisons between the Sri 
Lankan Tamils and the white Caucasians, and between the Moors and the 
white Caucasians.  
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The haplotype structure of the EGF, TGFA and AGT genes were interesting. In 
the EGF gene, out of a possible four haplotypes, only the 61G/67149A and the 
61A/67149G were common and the other two were rare. This was especially 
so in the three Sri Lankan racial groups. The 61G/67149G haplotype was also 
found in a frequency of 12% in the white Caucasians. In the TGFA gene, out 
of a possible eight haplotypes as expected, only four were found in all racial 
groups. In the AGT gene, out of a possible eight haplotypes, only six were 
present. Two of them were very rare. The 174Thr/235Met/11535A and 
174Thr/235Thr/11535C haplotypes were common in all four racial groups. 
The 174Thr/235Met/11535C haplotype was common among the white 
Caucasians, but was much less frequent in all three Sri Lankan racial groups. 
This is because of the low frequency of the 235Met allele in all these racial 
groups compared to that in the white Caucasians (P<0.001 in each 
comparison). Almost all the 235Thr and 11535C alleles seem to occur on the 
same chromosome in all racial groups with the possible exception of the white 
Caucasians. The absence of some of the possible haplotype combinations and 
the differences in the frequency of the different haplotypes of each gene in 
these four racial groups is a result of linkage disequilibrium. The results of 
pair-wise linkage disequilibrium analysis between polymorphisms in each 
gene in each racial group are summarised in table 3.9.  
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Haplotype Frequency   Significance (P) 
Genes Haplotypes 
S T M W   S v T S v M T v M S v W T v W M v W 
EGF 61 67149             
 G G  0.06 0.06 0.07 0.12  
 G A  0.53 0.47 0.44 0.37  
 A G  0.36 0.42 0.45 0.48  
  A A   0.05 0.04 0.05 0.03   
* * * 0.012 * * 
TGFA 3822 3827 3851            
 G T T 0.20 0.24 0.23 0.21  
 G C T 0.56 0.48 0.51 0.62  
 G C C 0.10 0.08 0.02 0.11  
  A C T 0.14 0.20 0.23 0.06   
* 0.007 * * 0.001 <0.001 
AGT 174 235 11535            
 T M C 0.06 0.11 0.13 0.34  
 T M A 0.31 0.25 0.24 0.29  
 T T C 0.53 0.51 0.50 0.22  
 M T C 0.08 0.11 0.11 0.09  
 T T A 0.02 0.01 0.01 0.04  
  M T A 0.00 0.01 0.00 0.01   
* * * <0.001 <0.001 <0.001 
MTHFR 677              
 C   0.87 0.91 0.91 0.69  
  T     0.13 0.09 0.09 0.31   
* * * <0.001 <0.001 <0.001 
Table 3.7. Haplotype frequency estimates of the EGF, TGFA, and AGT genes and the allele frequency of 
the MTHFR 677C>T polymorphism in the Sinhalese (S), the Sri Lankan Tamils (T), the Moors (M), and the 
white Caucasians (W). *P>0.05. P values for AGT haplotypes are based on the four common haplotypes. 
The P value for MTHFR is based on allele frequency. 
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Frequency of the variant allele 
Gene Polymorphism 
Variant 
Allele 
S T M W 
 
      
EGF 61G>A A 0.41 0.46 0.50 0.51 
 67149G>A A 0.58 0.51 0.49 0.40 
       
TGFA 3822G>A A 0.14 0.20 0.23 0.06 
 3827T>C C 0.80 0.76 0.77 0.79 
 3851T>C C 0.10 0.08 0.02 0.11 
       
AGT 174Thr>Met M 0.09 0.11 0.11 0.11 
 235Met>Thr T 0.64 0.63 0.63 0.37 
 11535C>A A 0.33 0.27 0.25 0.34 
       
MTHFR 677C>T T 0.13 0.09 0.09 0.31 
 
      
 
Table 3.8. Frequencies of the variant allele of the polymorphisms in the 
EGF, TGFA, AGT and MTHFR genes in the Sinhalese (S), the Sri Lankan 
Tamils (T), the Moors (M), and the white Caucasians (W). 
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Sinhalese  Tamil  Moor  White Caucasian 
Gene Loci Combination 
D' r2  D' r2  D' r2  D' r2 
              
EGF 61G>A 67149G>A 0.78 0.59  0.83 0.63  0.78 0.58  0.86 0.52 
              
TGFA 3822G>A 3827T>C 1 0.04  1 0.08  1 0.09  1 0.02 
 3822G>A 3851T>C 0.38 0.003  0.12 <0.001  0.06 <0.001  0.004 <0.001 
 3827T>C 3851T>C 1 0.03  1 0.03  1 0.008  1 0.03 
              
AGT 174Thr>Met 235Met>Thr 1 0.05  1 0.07  1 0.07  1 0.21 
 174Thr>Met 11535C>A 1 0.05  1 0.05  1 0.04  0.58 0.02 
 235Met>Thr 11535C>A 0.90 0.69  0.92 0.53  0.91 0.48  0.60 0.11 
                         
 
Table 3.9. Pair-wise linkage disequilibrium coefficient (D') and r2 between pairs of polymorphic loci in EGF, TGFA 
and AGT genes in the four racial groups. 
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3.3. Results of the case-control candidate gene pre-eclampsia association 
analysis 
All loci, with the exception of the EGF 61G>A polymorphic locus in women 
with pre-eclampsia in the Nottingham population, were in HWE. The results 
of haplotype analysis and single locus genotype analysis are shown in tables 
3.10 and 3.11 respectively. The only significant association was the 
association between the EGF gene and pre-eclampsia in the Sinhalese women 
(P=0.028). This effect was mainly due to the excess of the 67149G allele in 
Sinhalese women with pre-eclampsia (P=0.025). This association was not 
replicated in the white Caucasians (P=0.254). In the Sinhalese, using 
67149AA as the reference genotype, the OR (95% confidence interval) for 
pre-eclampsia associated with heterozygosity and homozygosity for the 
67149G allele was 1.61 (0.98 to 2.67) and 1.87 (1.05 to 3.31) respectively. 
The corresponding values for white Caucasians were 0.71 (0.28 to 1.81) and 
0.56 (0.23 to 1.38) respectively. 
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Sinhalese   White Caucasian 
Gene Haplotype 
PE NT   PE NT 
         
EGF 61 67149       
 G G  0.12 0.06  0.06 0.06 
 G A  0.43 0.50  0.36 0.28 
 A G  0.41 0.38  0.55 0.63 
 A A  0.04 0.05  0.02 0.03 
         
 Likelihood Ratio Statistic (P) 9.07 (0.025)*  2.74 (0.254) 
                  
         
TGFA 3822 3827 3851      
 G T T 0.18 0.21  0.26 0.31 
 G C T 0.59 0.57  0.39 0.46 
 G C C 0.08 0.06  0.20 0.15 
 A C T 0.16 0.16  0.16 0.09 
         
 Likelihood Ratio Statistic (P) 1.88 (0.598)  5.46 (0.141) 
                  
         
AGT 174 235 11535      
 T M C 0.09 0.09  0.29 0.24 
 T M A 0.30 0.29  0.30 0.26 
 T T C 0.50 0.47  0.25 0.32 
 M T C 0.10 0.13  0.12 0.17 
 T T A 0.01 0.01  0.00 0.00 
 M M C 0.01 0.01  0.00 0.00 
         
 Likelihood Ratio Statistic (P) 2.36 (0.883)  1.70 (0.638) 
                  
 
Table 3.10. Haplotype frequency estimates of EGF, TGFA, and AGT genes in 
the Sinhalese and the white Caucasian normotensive pregnant women (NT) 
and women with pre-eclampsia (PE). Haplotypes with frequencies ≤0.05 were 
dropped from hypothesis testing. *P when all haplotypes were included in the 
analysis was 0.028. 
 210 
Sinhalese White Caucasians 
Variant Allele Variant Allele Locus   
No Genotype frequency f 95%CI for 
difference in f 
  
No Genotype frequency f 95%CI 
difference in f 
                 
EGF 61G>A GG GA AA A      GG GA AA A    
 PE  175 57 (33) 79 (45) 39 (22) 0.45  74 20 (27) 23 (31) 31 (42) 0.57 
 NT  180 60 (33) 83 (46) 37 (21) 0.44 
-0.09 to 0.06 
 81 12 (15) 30 (37) 39 (48) 0.67 
-0.02 to 0.20 
EGF 67149G>A GG GA AA A      GG GA AA A    
 PE  176 51 (29) 85 (48) 40 (23) 0.47  74 32 (43) 27 (36) 15 (20) 0.39 
 NT  180 41 (23) 79 (44) 60 (33) 0.55 
0.01 to 0.16 
 81 42 (52) 28 (35) 11 (14) 0.31 
-0.18 to 0.03 
                          
TGFA 3822G>A GG GA AA A      GG GA AA A    
 PE  169 122 (72) 40 (24) 7 (04) 0.16  74 52 (70) 21 (28) 1 (01) 0.16 
 NT  178 129 (72) 41 (23) 8 (04) 0.16 
-0.05 to 0.05 
 79 67 (85) 10 (13) 2 (03) 0.09 
-0.14 to 0.01 
TGFA 3827T>C TT TC CC C      TT TC CC C    
 PE  176 8 (05) 46 (26) 122 (69) 0.82  74 3 (04) 33 (45) 38 (51) 0.74 
 NT  180 4 (02) 67 (37) 109 (61) 0.79 
-0.09 to 0.03 
 81 5 (06) 40 (49) 36 (44) 0.69 
-0.15 to 0.06 
TGFA 3851T>C TT TC CC C      TT TC CC C    
 PE  175 150 (86) 24 (14) 1 (01) 0.07  74 47 (64) 25 (34) 2 (03) 0.20 
 NT  180 160 (89) 19 (11) 1 (01) 0.06 
-0.05 to 0.02 
 81 57 (70) 24 (30) 0 (00) 0.15 
-0.13 to 0.04 
                          
Table 3.11. Continued in next page                   
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Sinhalese White Caucasians 
Variant Allele Variant Allele Locus   
No Genotype frequency f 95%CI for 
difference in f 
  
No Genotype frequency f 95%CI 
difference in f 
                          
AGT T174M   TT TM MM M      TT TM MM M    
 PE  176 143 (81) 30 (17) 3 (02) 0.10  29 20 (69) 9 (31) 0 (00) 0.16 
 NT  179 134 (75) 40 (22) 5 (03) 0.14 
-0.01 to 0.09 
 73 54 (74) 13 (18) 6 (08) 0.17 
-0.10 to 0.13 
AGT M235T   MM MT TT T      MM MT TT T    
 PE  175 32 (18) 75 (43) 68 (39) 0.60  73 24 (33) 40 (55) 9 (12) 0.40 
 NT  180 32 (18) 76 (42) 72 (40) 0.61 
-0.06 to 0.08 
 81 18 (22) 46 (57) 17 (21) 0.49 
-0.01 to 0.21 
AGT 11535C>A CC CA AA A      CC CA AA A    
 PE  175 84 (48) 73 (42) 18 (10) 0.31  72 36 (50) 27 (38) 9 (13) 0.31 
 NT  180 89 (49) 74 (41) 17 (09) 0.30 
-0.08 to 0.06 
 80 39 (49) 37 (46) 4 (05) 0.28 
-0.13 to 0.07 
                          
MTHFR 677C>T CC CT TT T      CC CT TT T    
 PE  176 137 (78) 36 (20) 3 (02) 0.12  74 34 (46) 36 (49) 4 (05) 0.30 
  NT   180 149 (83) 29 (16) 2 (01) 0.09 
-0.07 to 0.02 
  81 31 (38) 43 (53) 7 (09) 0.35 
-0.05 to 0.16 
                          
 
Table 3.11. Genotype and variant allele frequencies (%) and the 95% confidence interval (CI) for the difference between the variant 
allele frequencies in the Sinhalese and the white Caucasian normotensive pregnant women (NT) and women with pre-eclampsia (PE). 
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3.4. Results of the candidate gene quantitative trait association analysis 
Birth weight 
The results of the analysis of the association between the maternal EGF 
haplotypes and birth weight of babies born to women who were normotensive 
during their pregnancy are shown in table 3.12. The association was 
significant in the Sinhalese (P=0.02) and highly significant (P=0.0007) in the 
white Caucasians. Babies born to mothers with the 61G/67149A haplotype 
weighed significantly less than the pooled birth weight of babies of mothers 
who had the other haplotypes (Sinhalese χ
2
=5.8, P=0.016, white Caucasians 
χ
2
=11.8, P=0.0006). The babies of mothers who had the 61A/67149G 
haplotype weighed significantly more than the pooled birth weight of babies 
of mothers who had the other haplotypes (Sinhalese χ
2
=4.4, P=0.037, white 
Caucasians χ
2
=8.5, P=0.0035). The actual differences in the mean birth weight 
of babies born to mothers with these two haplotypes were 113g in the 
Sinhalese and 398g in the white Caucasians. The birth weight of the Sinhalese 
and the white Caucasian babies become heavier as the number of EGF 61A or 
EGF 67149G alleles that their mother had increased (Table 3.13).  
 
There was no association between the maternal TGFA gene or the AGT gene 
and the birth weight of babies born to women who were normotensive during 
their pregnancy. 
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AGT and Blood Pressure 
There was no association between AGT haplotypes and systolic or diastolic 
blood pressure at booking among women who were normotensive during their 
pregnancy (Table 3.14). 
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  Sinhalese   White Caucasian 
 Male  Female  All  Male  Female  All EGF haplotypes 
 (n=72)  (n=108)  (n=180)  (n=27)  (n=42)  (n=69) 
  61 67149   f MBW (g)   f 
MBW 
(g)   f 
MBW 
(g)   f 
MBW 
(g)   f 
MBW 
(g)   f 
MBW 
(g) 
                     
All babies (Mean(SD))  2904 (409)  3039 (413)  2985 (421)  3529 (513)  3439 (421)  3474 (464) 
                     
 G G  0.05 2715  0.07 3161  0.06 3023  0.04 3632  0.06 3518  0.05 3551 
 G A  0.48 2871  0.51 2968  0.50 2931  0.39 3367  0.26 3177  0.31 3270 
 A G  0.43 2979  0.35 3095  0.38 3044  0.55 3631  0.64 3533  0.61 3568 
 A A  0.04 2715  0.06 3161  0.05 3023  0.02 3632  0.04 3518  0.03 3551 
                     
      Likelihood ratio 
statistic (P)   
2.2 (0.14) 
  
4.15 (0.04) 
  
5.5 (0.02) 
  
3.2 (0.074) 
  
10.7 (0.001) 
  
11.5 (0.0007) 
 
Table 3.12. Quantitative trait loci analysis of EGF haplotypes and birth weight of babies of the Sinhalese and the 
white Caucasian normotensive pregnant women. Mean (Standard Deviation) given for birth weight of all babies 
in each group. Equal variance in the birth weight in each group is assumed by QTPHASE. Rare haplotypes with 
frequencies <0.10 were dropped from hypothesis testing. MBW: Mean Birth Weight. 
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Genotypes 
Population 
61 AA 61 GA 61 GG 
P 
Sinhalese No 41 79 60  
 BWT (kg) 3.1  (0.44) 3.0  (0.43) 2.9  (0.46) 0.06 
         
White Caucasian No 31 26 12  
 BWT (kg) 3.6  (0.51) 3.5  (0.47) 3.1  (0.33) 0.02 
  67149 GG 67149 GA 67149 AA  
Sinhalese No 41 79 60  
 BWT (kg) 3.1  (0.41) 3.0  (0.42) 2.9  (0.42) 0.02 
         
White Caucasian No 33 25 11  
 BWT (kg) 3.6  (0.50) 3.4  (0.47) 3.1  (0.38) 0.01 
 
Table 3.13. Mean (Standard Deviation) birth weight (BWT) of babies of the Sinhalese 
and the white Caucasian normotensive pregnant women as a function of 61G>A and 
EGF 67149G>A genotypes. 
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AGT haplotype   Sinhalese 
(n=180)   
White Caucasian 
(n=81) 
 174 235 11535  f 
Mean Blood 
Pressure 
(mmHg) 
 f 
Mean Blood 
Pressure 
(mmHg) 
          
Systolic blood pressure       
 
All normotensive pregnant women 108.5 (9.2)   121.7 (13.7) 
 T M C  0.09 107.9  0.24 121.7 
 T M A  0.29 108.4  0.26 125.4 
 T T C  0.47 108.1  0.32 127.4 
 M T C  0.13 110.5  0.17 128.2 
          
 Likelihood Ratio Statistic (P)  2.8 (0.43)  4.0 (0.26) 
                   
          
Diastolic blood pressure       
 
All normotensive pregnant women 68.6 (7.1)   65.2 (7.9) 
 T M C  0.09 68.5  0.23 66.02 
 T M A  0.29 68.6  0.27 65.88 
 T T C  0.47 68.4  0.32 65.77 
 M T C  0.13 69.4  0.17 62.17 
          
 Likelihood Ratio Statistic (P)  0.7 (0.86)  4.1 (0.25) 
                   
 
Table 3.14. Quantitative trait loci analysis of AGT haplotypes and blood 
pressure at booking in the Sinhalese and the white Caucasian 
normotensive pregnant women. Mean (standard deviation) of blood 
pressure for all women is given. Equal variance in blood pressure in each 
subgroup is assumed by QTPHASE. Rare haplotypes with frequencies 
≤0.05 were dropped from the analysis. 
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3.5. Results of the reporter gene assay analysis 
The dual luciferase reporter gene assay with non-transfected HepG2 cells to 
determine background luminescence revealed appreciable background signal 
for Renilla luciferase activity (0.144 ± 0.03). The background signal for firefly 
luciferase activity was much weaker (0.023 ± 0.016). Any reading of <0.204 
(mean + 2×SD) for Renilla luciferase and <0.056 for firefly luciferase 
therefore was deemed to be unreliable. Only one reading for Renilla luciferase 
from the transfected HepG2 cells recorded a reading below this cut-off point 
and was excluded from the analysis. 
 
The results of the reporter gene assay using HepG2 cells transfected with 
different constructs under basal and AngII stimulated conditions are 
summarised in tables 3.15 and 3.16 respectively. The pGL3Control vector was 
the positive vector used to evaluate transfection efficiency. The enhanced 
response obtained with it was expected, because it has a very potent Simian 
Virus 40 enhancer. The pGL3Promoter vector was the base vector against 
which the enhancer effects of the experimental constructs were compared. 
All three constructs showed significant repression in comparison to the 
pGL3Promoter vector under both basal and stimulated conditions (P<0.001). 
The response under basal conditions is illustrated in figure 3.1. There was no 
significant difference between the repression brought about by the three 
constructs under both basal and stimulated conditions (Figure 3.2). However, 
when the effect of stimulation of each construct was compared with the effect 
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under basal condition, construct E3 demonstrated differential response at 
various levels of AII. The post-hoc analysis indicated that this was due to a 
response to AII at 10
-11
M, which was greater than the response at the other 
concentrations of AII (for 10
-11
M vs. 10
-13
M: P=0.06, 95% CI  0.98 to 3.14-
fold; for 10
-11
M vs. 10
-9
M: P=0.03 , 95% CI  1.09 to 3.49-fold), but it did not 
differ significantly from the basal response (P=0.15).  
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Response over promoter  Significance 
Construct 
No of 
Repeats Response SEM  
Construct v 
Promoter 
Between 
Constructs 
pGL3C 8 13.48 5.86    
E1 7 0.17 0.08  <0.001 
E2 7 0.36 0.12  0.006 
E3 7 0.27 0.11  0.001 
0.220 
 
Table 3.15. Results of the Dual Luciferase Reporter Gene Assay under basal 
conditions. SEM: standard error of mean. pGL3C: pGL3Control. E1, E2, E3: the  
three experimental vectors (see table 2.12). 
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The response under AngII stimulated 
conditions compared with the 
response under basal conditions 
Construct 
Condition 
(AngII  
concentration) 
Mean fold 
response 
over basal 
response 
SEM Significance 
when compared 
with basal 
response 
Significance 
in response 
between 
different AngII 
concentrations 
E1 Basal 1 0.32   
 10
-9
M 0.75 0.20 0.84 
 10
-11
M 0.76 0.42 0.61 
 10
-13
M 0.76 0.16 0.89 
0.67 
E2 Basal 1 0.18   
 10
-9
M 1.24 0.22 0.33 
 10
-11
M 0.94 0.28 0.97 
 10
-13
M 0.85 0.25 0.90 
0.14 
E3 Basal 1 0.25   
 10
-9
M 0.80 0.11 0.57 
 10
-11
M 1.58 0.27 0.16 
 10
-13
M 0.89 0.12 0.88 
0.03 
 
Table 3.16. Results of the Dual Luciferase Reporter Gene Assay under stimulated 
conditions compared with results under basal conditions. SEM: standard error of 
mean. Each experiment was repeated three times. E1, E2 and E3: The three 
experimental vectors (see table 2.12). 
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Figure 3.1.  A bar chart comparing the enhancer effect of the pGL3Control vector with that 
of the enhancer effect of the constructs E1, E2, and E3. Y axis is a logarithmic scale. 
1=Promoter vector reference. Standard error bars are shown. 
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Figure 3.2. A bar chart comparing the response of each construct under AngII stimulated conditions with the response 
under basal conditions. Y-axis denotes the mean fold response over the response under basal conditions. Standard error 
bars are shown. Basal response for each construct is normalised to 1 and standard error bars have been adjusted 
proportionally. The scaled mean (SEM) for each construct under basal conditions is: E1 - 1 (0.32); E2 - 1 (0.18); E3 - 1 
(0.25). 
 9
M 11M 
13
M 
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4. DISCUSSION 
4.1. Population genetic results 
4.1.1. Epidermal Growth Factor 
This study is the first to report the EGF 61G>A and EGF 67149G>A 
polymorphisms frequencies in a non-white Caucasian population. It is also the 
first to report on haplotype structure in the EGF gene in any population 
although it is inferred from only two polymorphisms. There are significant 
differences in the allele frequencies at these polymorphic loci, linkage 
disequilibrium between the alleles at the two loci, and the haplotype structure 
between the Sinhalese and the white Caucasians. The Moors show a pattern 
closer to the white Caucasians than the Sinhalese, although they are not 
significantly different to the latter population. The EGF gene is a large gene of 
approximately 110-kb. It is therefore, not reasonable to assume that two 
polymorphisms would define the haplotype structure of the EGF gene 
adequately. Many other SNPs in the EGF gene have been deposited in the 
public SNP database at NCBI. Most SNPs in this database have been 
identified by in silico methods that ascertained SNPs from a small number of 
chromosomes in a limited number of populations. Some of them, however, 
have been validated in larger samples, and they may be used to select a set of 
SNPs that can be used to further refine the haplotype structure of the EGF 
gene experimentally. 
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4.1.2. Transforming Growth Factor Alpha 
This study is the first study to report on the TGFA 3822G>A, 3827T>C and 
3851T>C polymorphisms in the Sri Lankan population. In contrast to the EGF 
gene, in the TGFA gene, the allele and haplotype frequencies in the Sinhalese 
were similar to that of the white Caucasians, while the Sri Lankan Tamils and 
the Moors differed significantly from the white Caucasians. In previous 
studies, the haplotype structure of the TGFA gene defined by these 
polymorphisms in the white Caucasian and the Japanese populations has been 
similar (Table 1.2). The haplotype frequencies of the white Caucasians in 
Nottingham differed from that reported previously in the white Caucasians in 
Iowa, USA (Shiang et al., 1993). Among the white Caucasians in Nottingham, 
the 3822G/3827C/3851T haplotype was much more common (Nottingham: 
0.62 cf. Iowa: 0.50) and the 3822A/3827C/3851T haplotype rare (Nottingham: 
0.06 cf. Iowa: 0.20) than in the white Caucasians in Iowa. As for the EGF 
gene, there is a need to further characterise the haplotype structure of the 
TGFA gene using additional SNPs. 
 
4.1.3. Angiotensinogen 
The polymorphism at codon 174 deviated from HWE at P<0.05 in the white 
Caucasians. The sample used for the current study was a subset of 153 
samples reported previously (Morgan et al., 1996). In that report too the 
174Thr>Met genotype distribution of the entire sample collection deviated 
from HWE. Possible reasons for this have been discussed in that report. Since 
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that discussion applies to the present results as well it is reproduced here: 
There are no obvious explanations for this. This pattern is observed in the 
presence of two formerly isolated, genetically distinct, sub populations 
(Wahlund, 1928); however, there are no a priori reasons for believing that the 
Nottingham population would be other than a genetically homogeneous group. 
Methodical artefacts must be considered. Contamination of polymerase chain 
reactions with foreign DNA is a well-recognised problem; however, this 
causes an excess of heterozygotes, not a deficit, and cannot therefore account 
for the present findings. While ASO hybridisation is a useful technique for 
genotyping large numbers of samples, lack of specificity can be a problem 
with conventional methods; this problem has been largely overcome by the 
use of competitive hybridisation techniques, as employed in the present study. 
Selective polymerase chain reaction amplification of one allele would result in 
mistyping of a heterozygote as a homozygote; this would not of course be 
detected by sequencing of the amplified products, or by running positive 
control samples. It should be noted, however, that the amplimers used in this 
investigation for assessment of the 174 genotype were also used for 
genotyping at codon 235. Other probable reasons for such deviations are the 
close association of the polymorphism being studied with another selectable 
markers that increases the amount of homozygosity in the vicinity of the locus 
for which selection is made and the possibility of bias when the sample size of 
the study is small.   
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The frequency of alleles in the 235Met>Thr polymorphism in the three Sri 
Lankan racial groups is significantly different to that in the white Caucasians 
and it is closer to that reported in the Japanese (Nakajima et al., 2002). The 
174Met allele as reported before seems to occur exclusively in chromosomes 
carrying the 235Thr allele in all racial groups and it is reflected in the pair-
wise linkage disequilibrium data Table 3.9. The 11535C>A is known to split 
the haplotypes occurring on chromosomes carrying the 174Thr and 235Met 
alleles. The 11535C allele of this polymorphism occurs in far fewer 
chromosomes with the above mentioned allele combination in the 
174Thr>Met and 235Met>Thr polymorphisms. This together with the 
differences in the allele frequencies of the 235Met>Thr polymorphism 
accounts for the significant difference between the haplotype structure of the 
white Caucasians and all three Sri Lankan racial groups. 
 
4.1.4. 5,10-Methylenetetrahydrofolate Reductase 
This study is the first to report on the MTHFR 677C>T polymorphism 
frequency of the three Sri Lankan racial groups separately. Two previous 
studies that report on the frequency of the alleles of this polymorphism in Sri 
Lankans do not give the racial background of the population (Schneider et al., 
1998, Alagratnam et al., 2000). The low frequency of the 677T allele in the 
current study is in agreement with the pooled population data of Sri Lankans 
in the two previous studies. Although statistically not significant, the 677T 
allele seems to be commoner among the Sinhalese than the Sri Lankan Tamils 
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or the Moors. The previous studies reported failure to find 677TT 
homozygotes among Sri Lankans. In contrast two 677TT homozygous 
Sinhalese subjects were identified in the current study. One factor that could 
affect the frequency of the 677T allele is the age of the study group because 
the prevalence of the 677T allele is reportedly lower in older age groups 
possibly because 677TT homozygous individuals are more prone to 
cardiovascular disease (Matsushita, Muramatsu, Arai, Matsui and Higuchi, 
1997). The Sinhalese (33.0± 8.8) in this study, however, were older than the 
Sri Lankan Tamils (28.2±6.8; P<0.001) and the Moors (27.4±5.6; P<0.001). 
Age therefore is not a factor for the higher prevalence of the 677T allele in the 
Sinhalese compared to the Sri Lankan Tamils and the Moors in this study. 
Cardiovascular disease, anyway, is very unlikely to influence the frequencies 
of the 677T allele at these young ages in any population. 
 
Healthy Sri Lankans are reported to have high levels of homocysteine 
compared to western populations (Mendis, Athauda and Takashi, 1997). There 
is no evidence from this study to suggest that the 677C>T polymorphism may 
contribute to this in a major way. It is possible that low levels of folate in their 
diet (Mendis, Bulugahapitiya, Ranatunga, Gunawardene and Kandegedera, 
1999b) and other genetic and environmental factors may contribute to this. 
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4.1.5. Overview of population genetic results 
These results as expected show that the three Sri Lankan racial groups are 
more closely related to each other than to the white Caucasians. However, 
these results can only be used to draw broad conclusions as only a small 
number of polymorphic loci have been examined. These results are broadly in 
agreement with previous work on the population structure of the difference 
racial groups in the Sri Lankan population (Papiha et al., 1996a, Papiha, 
Mastana, Purandare, Jayasekara and Chakraborty, 1996b).  
 
Although the haplotype structure of the candidate genes in the three Sri 
Lankan racial groups appear similar, and for most part any differences 
statistically not significant, the differences that do exist may have an impact 
on case-control candidate gene pre-eclampsia association studies if any cryptic 
racial admixture were to be present among either women with pre-eclampsia 
or normotensive pregnant women (see section 4.2.1). As such, matching the 
two groups for their racial origin as was done in this study, is essential for 
case-control candidate gene association studies in Sri Lanka. 
 
The linkage disequilibrium data is also interesting. The r
2
 value is an index of 
the loss of statistical power if one analyses a marker SNP rather than the 
disease SNP. For a given power and significance threshold, the required 
increase in sample size to allow for reduced linkage disequilibrium is 
inversely proportional to r
2
. Therefore, for example, in the Sinhalese 
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population, if 235Met>Thr were a disease locus, but only 174Thr>Met was 
analysed, one would require a 20-fold (1/r
2
 = 1/0.05) increase in sample size 
compared with analysing 235Thr>Met in spite of the fact that these two loci 
are in strong linkage disequilibrium, with D' = 1. This justifies haplotype 
analysis in case-control candidate gene disease association studies in 
preference to analysing single SNPs (Kruglyak, 1999).  
 230 
4.2. Case-control candidate gene pre-eclampsia association results 
4.2.1. Epidermal Growth Factor 
This is the first study to report significant association between pre-eclampsia 
and the EGF gene in any population. The results, however, could not be 
replicated in the white Caucasians. There are several reasons for this. In the 
Sinhalese, the association was mainly related to the 67149G allele. It was the 
minor allele of that polymorphism in the Sinhalese, while in the white 
Caucasians it was the major allele. The allele frequencies were significantly 
different in the Sinhalese and the white Caucasians (P=0.002). Under these 
conditions the sample size of the study in the Sinhalese population had 80% 
power to detect a doubling of risk at a significance level of 0.05, while the 
sample size in the white Caucasians had only 26% power to detect a doubling 
of risk at a significance level of 0.05. In addition to this, to find an association, 
as already mentioned, it is necessary that the polymorphisms tested contribute 
to the disease phenotype or be in linkage disequilibrium (LD) with a 
polymorphism that contributes to the disease phenotype. There are differences 
in the frequency of the alleles of the 61G>A and 67149G>A polymorphisms, 
haplotypes in the EGF gene defined by them, and the LD between them in the 
Sinhalese and the white Caucasians. If the 67149G>A polymorphism is in LD 
with another polymorphism that was contributory to the pre-eclampsia 
phenotype, instead of being the contributory polymorphism by itself, and if the 
LD between the 67149G allele and the causative polymorphism was weaker in 
the white Caucasians than in the Sinhalese, that could also have contributed to 
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the failure to replicate the finding.  If this was so, then carrying out association 
analysis using a more refined haplotype structure using additional SNPs that 
capture the maximum haplotype diversity within the gene may help to clarify 
the association further.  The other possibility for failure to replicate is the 
presence of gene-gene interactions. The present study, however, is 
underpowered to extend the investigation to examine such interactions. 
 
A closer examination of the allele frequency of the EGF 67149G>A 
polymorphism in Sri Lankan population revealed that the 67149G allele, 
although not statistically significant, is commoner in the Moors than in the 
Sinhalese or the Sri Lankan Tamils. It is possible therefore, that an admixed 
Sinhalese population may be over represented among Sinhalese women with 
pre-eclampsia in this study. This scenario, however, is unlikely in the context 
of the pattern of inter racial marriages in Sri Lanka, which is more in favour of 
Sinhalese women marrying into the Moor community and assuming a Moor 
identity than vice versa, and the care that was taken to verify the racial origin 
of each recruit for this study 
 
The genotype distribution for the 61G>A polymorphism in white Caucasian 
women with pre-eclampsia differed significantly from HWE. This was as a 
result of a relative deficiency of heterozygotes. Such a deficiency of 
heterozygotes was also noted in Sinhalese women with pre-eclampsia, but it 
did not reach statistical significance. Given that the EGF gene is associated 
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with pre-eclampsia in the Sinhalese, this may reflect a true departure from 
HWE. Other probable reasons for such departure from HWE have already 
been discussed in section 4.1.3 above. 
 
4.2.2. Transforming Growth Factor Alpha 
This was the first study to examine the association of pre-eclampsia with the 
TGFA gene. However, there was no association in both the Sinhalese and the 
white Caucasians. TGFA was selected as a candidate gene because it is a 
structural and functional homologue of EGF and because the TGFA gene is 
located within the highly suggestive region for a pre-eclampsia susceptibility 
gene in genome wide studies. There did not appear to be any independent 
pathophysiological reports linking TGFA to pre-eclampsia. 
 
4.2.3. Angiotensinogen 
The angiotensinogen gene was not associated with pre-eclampsia in either 
population in this study. These results are consistent with most studies that 
have failed to find an association between pre-eclampsia and the 
angiotensinogen gene (summarised in table 1.3). It is difficult, however, to 
draw comparisons between all these studies because of inconsistencies in case 
and control groups such as the inclusion of multiparous women, inclusion of 
women with gestational hypertension, and the possible inclusion of women 
who carry a high risk of pre-eclampsia such as multiple pregnancies and 
diabetes mellitus in studies where they were not stated as exclusion criteria. In 
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addition, in some studies the sample size was too small to decide conclusively 
that the 235Thr allele was not in fact associated with pre-eclampsia. This 
study in the Sinhalese population had 80% power to detect a doubling of risk 
associated with the 235Thr allele at a significance level of 0.05.  In the 
Sinhalese, using 235Met/Met as the reference genotype, the OR (95% 
confidence interval) for pre-eclampsia associated with heterozygosity and 
homozygosity for the 235Thr allele was 1.01 (0.57 to 1.82) and 1.06 (0.59 to 
1.91) respectively. Therefore the contribution of the 235Thr allele to pre-
eclampsia, if any, is small.  
 
Recently association of the AGT haplotype 1035A/174Met/235Thr haplotype 
with pre-eclampsia was reported in a French Canadian population (Levesque 
et al., 2003). The 1035G>A polymorphism which is located at nucleotide 217 
upstream of the transcription start site was not examined in the current 
investigations. It may be useful to genotype these samples for the 1035G>A 
polymorphism to investigate whether this haplotype is associated with pre-
eclampsia in the Sinhalese and/or the white Caucasians. 
 
4.2.4. 5,10-Methylenetetrahydrofolate Reductase 
There was no association between the MTHFR 677C>T polymorphism and 
pre-eclampsia in either population. These results are again consistent with the 
large number of studies with a similar finding (summarised in table 1.4). As 
was the case with studies examining the association of the AGT 235Thr allele 
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with pre-eclampsia, it is difficult to draw comparisons between these studies 
for the reasons stated above. In the Sinhalese using 677CC as the reference 
genotype, the OR (95% confidence interval) for pre-eclampsia associated with 
combined data for heterozygosity and homozygosity for the 677T allele was 
0.73 (0.43 to 1.24). This study in the Sinhalese population had 80% power to 
detect a doubling of risk at a significance level of 0.05.  Therefore the 
contribution of the 677T allele to pre-eclampsia, if any, is small. 
 
Since non-association with the MTHFR 677T allele seems to be the emerging 
picture from most association studies, irrespective of whether they actually 
had sufficient power to detect an association or not, it is reasonable to re-
examine the original reasons for hypothesising MTHFR as a possible 
candidate. Several recent studies have reported interesting findings. Plasma 
homocysteine levels are low in normal pregnancies (Raijmakers, Zusterzeel, 
Steegers and Peters, 2001), and they seem to correlate with the MTHFR 
genotype, with 677TT homozygotes having significantly higher levels than 
677CC homozygotes when their folate status is low (Kim, Kim and Chang, 
2004). Interestingly, in pregnancies complicated by pre-eclampsia, although 
homocysteine levels are elevated compared to normal pregnancies, they are 
comparable to levels in non-pregnant women (Kim et al., 2004) and they do 
not correlate with the MTHFR genotype (Powers, Dunbar, Gallaher and 
Roberts, 2003). It is possible therefore, that hyperhomocysteinaemia in pre-
eclampsia may in fact be an artefact resulting from a relative reduction in 
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plasma volume. Women with pre-eclampsia, however, have higher levels of 
homocysteine early in their pregnancies before such changes occur in the 
circulatory system (Cotter et al., 2003). This is in favour of the possibility that 
women with the 677TT genotype (with low folate intake, and 
hyperhomocysteinaemia) begin pregnancy with an already damaged unhealthy 
endothelium that puts them at a higher risk of pre-eclampsia irrespective of 
their homocysteine status in pregnancy. Hyperhomocysteinaemia as stated 
before is reported to be a significant risk factor for cardiovascular disease 
among Sri Lankans, with normal Sri Lankans having higher levels of 
homocysteine in their plasma compared to western norms (Mendis et al., 
1997). Folate intake among healthy Sri Lankans is also reported to be low 
(Mendis et al., 1999b). It is not possible from this study to exclude the 
possibility that hyperhomocysteinaemia due to a mechanism other than the 
presence of the MTHFR 677TT genotype may be contributory to pre-
eclampsia in the Sinhalese. It may be premature, however, to discount the 
possible role of the MTHFR gene in the aetiology of pre-eclampsia (Pegoraro 
et al., 2004). 
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4.3. Candidate gene quantitative trait association results 
In this study the analysis of the association of genes with two quantitative 
traits was examined only in women with normal pregnancies. The complex 
disease process in pregnancies complicated by pre-eclampsia, which begins 
early in pregnancy, is likely to obscure the effects of a single gene on the 
expression of any quantitative trait, whether it be birth weight or blood 
pressure. In addition in such pregnancies the gestation at delivery is so 
variable and that of course would anyway affect the weight of babies at birth 
making any comparison meaningless. Therefore, although pregnancy data 
from both women who were normotensive during their pregnancy and women 
who had pregnancies complicated by pre-eclampsia were available, the 
quantitative trait association analysis was confined to the former group.  
 
4.3.1. Birth weight  
Only the maternal EGF gene was associated with the weight of babies at birth. 
The association was stronger in the white Caucasian population than in the 
Sinhalese. One possible reason for this is the difference in the haplotype 
frequency in the Sinhalese and the white Caucasians. The frequency of the 
61G/67149A haplotype in the Sinhalese was 0.53 while in the white 
Caucasians it was 0.37. Another reason is the possible influence of sample 
size. In both racial groups, the numbers of individuals studied were small  
(180 Sinhalese and 84 white Caucasian). It is possible that in such small 
samples the effects of statistically significant quantitative traits may be over 
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estimated (Barton and Keightley, 2002). Such an effect may account for the 
more significant result in the white Caucasians than in the Sinhalese. 
However, the difference in the mean weight between the lightest and the 
heaviest white Caucasian babies was nearly three and a half times that of the 
Sinhalese. 
 
Some authors believe that it is not possible to assume that there is no sex 
effect on any phenotype or trait unless proven otherwise (Yagil and Yagil, 
2003). Moreover, it is well known that male babies weigh heavier than female 
babies. In the current study subgroup analysis by sex of the babies showed that 
the EGF gene was associated with birth weight only in the female babies in 
both racial groups, but the numbers of male babies were less than the number 
of female babies in both racial groups. The trend in birth weight, however, 
remained the same as in the overall group in babies of both sexes in both racial 
groups. As expected the mean birth weight of the white Caucasian male babies 
was higher than that of the female babies; but the reverse was seen in the 
Sinhalese babies. 
  
These results support the association of EGF with the low birth weight of 
babies reported by Shigeta et al. (1992) and Lindqvist, Grennert and Marsal 
(1999). However, Shahbazi et al (2002) found that EGF production was 
significantly lower in peripheral blood mononuclear cell (PBMC) cultures of 
EGF 61AA individuals, but they were not genotyped at the 67149G>A 
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polymorphism. This indicates that the underlying pathophysiological 
mechanisms may be complex. It may also involve interaction with other 
genes. It is also possible that, since the maternal genotype partially determines 
the fetal genotype, what is important is not the maternal, but the fetal genotype 
or the interaction between them. To confirm that, TDT testing would have to 
be done using data in mother-father-baby trios. 
 
It is interesting to speculate on how EGF and other genes involved in 
placentation may affect birth weight and what implications it may have in the 
long term. The size attained in utero depends on the services which the 
mother is able to supply. These are mainly food and accommodation. 
(McCance, 1962). Provision of an adequate supply of nutrition to the baby not 
only requires good maternal nutrition, but also normal placentation. The 
possible role of EGF in placentation has already been discussed. Variations in 
the maternal EGF gene may result in the production of EGF that is 
functionally incapable of inducing the desired changes in cytotrophoblast cells 
to acquire the invasive phenotype, which is necessary for successful 
placentation. If the nutrition received by babies were to be determined by 
different grades of success or failure of placentation due to variations in one or 
more genes involved in placentation, then the effects of such genes may limit 
the efficacy of maternal nutritional interventions aimed at improving birth 
weight. It is possible therefore, on the basis of the Barker hypothesis, which 
states that adult diseases originate in fetal life, as evidenced by, for example, 
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the increased risk of cardiac disease among men who were small at birth 
(Barker, Winter, Osmond, Margetts and Simmonds, 1989); and the concept of 
the thrifty phenotype which is based on the observation that the effect of 
impaired fetal growth is modified by subsequent growth in infancy and 
childhood (Hales and Barker, 1992), that such genes may also determine 
whether or not one is susceptible to adult onset disease.  
 
4.3.2. Blood pressure 
There was no association between the AGT gene and blood pressure at 
booking in normotensive pregnant women in this study. Previous studies in 
non-pregnant subjects have reported both association and non-association 
between blood pressure variation and the AGT gene (Forrester, McFarlane-
Anderson, Bennet, Wilks, Puras et al., 1996, Kiema, Kauma, Rantala, Lilja, 
Reunanen et al., 1996, Bloem, Foroud, Ambrosius, Hanna, Tewksbury et al., 
1997, Sethi, Nordestgaard, Agerholm-Larsen, Frandsen, Jensen et al., 2001, 
Pereira, Mota, Cunha, Herbenhoff, Mill et al., 2003, Sethi, Nordestgaard, 
Gronholdt, Steffensen, Jensen et al., 2003, Sethi, Nordestgaard and Tybjaerg-
Hansen, 2003). In the current study, among the Sinhalese as well as the white 
Caucasians, women with the 174Thr/235Met/11535C haplotype had the 
lowest SBP and women with the 174Met/235Thr/11535C haplotype had the 
highest SBP. It is possible therefore, that the sample size of this study may not 
have been sufficient to detect subtle differences in the effect of different 
haplotypes on blood pressure. 
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4.4. Overview of case-control candidate gene pre-eclampsia association 
results and quantitative trait analysis results 
4.4.1. Correction for multiple testing 
The case-control candidate gene pre-eclampsia association studies described in 
this thesis fall into two broad categories. Association analysis with the AGT 
and MTHFR genes were aimed at replicating previously reported associations 
in the Sinhalese and the white Caucasians in Nottingham. In contrast, 
association analysis with EGF and TGFA genes were the first such studies. 
When such multiple testing is done, a question arises as to whether a more 
stringent definition of significance should be applied to confirm an 
association. Although a lower threshold for a significant P value would 
increase the confidence in the association, there is no consensus on whether 
significance levels should be adjusted for multiple testing or on how such 
adjustments should be made (Bland and Altman, 1995, Perneger, 1998). Some 
authors believe that replication of findings in a genetically different population 
is perhaps more important than correcting for multiple testing (Dekker and van 
Duijn, 2003). It is in this context that the association of the EGF gene with 
pre-eclampsia in the Sinhalese, that is reported above, has to be considered. It 
is the first such report, and therefore it is largely exploratory. It could not be 
replicated in the white Caucasians in this study because the white Caucasian 
sample collection was underpowered to detect a significant genetic effect. It 
needs therefore, to be replicated in other populations using a sufficiently 
powered collection of samples. The EGF polymorphism and haplotype 
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frequency data of the white Caucasian population presented above would be 
useful to plan out such a study. 
 
4.4.2. The EGF gene, pre-eclampsia and birth weight 
The most significant findings of these investigations were the association of 
the EGF gene with pre-eclampsia in the Sinhalese and the association of the 
EGF gene with the weight of babies at birth in the Sinhalese as well as in the 
white Caucasians. In the Sinhalese, the association of the EGF gene with pre-
eclampsia was mainly due to the high frequency of the 67149G allele in 
women with pre-eclampsia compared to normotensive pregnant women. 
However, among the white Caucasians the 67149G allele was found more in 
normotensive pregnant women than in women with pre-eclampsia. In that 
racial group it was the 61G allele that was commoner in women with pre-
eclampsia. In both the Sinhalese and the white Caucasians, the 61G and 
67149A alleles were in association with low birth weight.  
 
These discrepant results can only be explained if two independent 
polymorphic loci, one each contributing to the determination of birth weight or 
the development of pre-eclampsia, were present in the EGF gene, and the 
linkage disequilibrium between those loci and the marker polymorphisms 
studied in the current investigations differed between the Sinhalese and the 
white Caucasians. Such loci therefore need to be identified by further 
investigations. 
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4.5. Reporter gene assay results 
The aim of the angiotensinogen reporter gene expression studies was to 
examine how the AGT 3UTR/flanking region SNPs affect AGT gene 
expression and to examine whether they modify the enhancer activity reported 
by Nibu and colleagues (Nibu et al., 1994a, Nibu et al., 1994b) in this region. 
However, instead of enhancer activity, repression was discovered with the 
1660-bp AGT 3UTR/flanking region insert used in these investigations.  
 
Gene repression is a relatively new concept in the field of gene regulation. 
Position-independent elements that direct an active repression mechanism 
(generally by interfering with the General Transcription Factor (GTF) 
assembly) are called silencer elements. Position-dependent elements that 
direct a passive repression mechanism (generally by interfering with upstream 
elements) are referred to as negative regulatory elements (NRE). Transcription 
factors associated with NREs are known as repressors (Ogbourne and Antalis, 
1998). Such elements have only rarely been identified in the 3UTRs of genes 
(Le Cam and Legraverend, 1995, Paul, Simar-Blanchet, Ro and Le Cam, 
1998).  
 
The first 451-bp in the 5 end of the insert used in these investigations 
corresponded with the region showing enhancer activity in Nibus 
experiments. The balance 1209-bp of the insert, however, is found in another 
insert in that study that had been excluded from their investigations because 
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initial examination had revealed that it had no enhancer activity (Nibu et al., 
1994a). It is possible therefore, that repression was present in that region of 
the 3 flanking region and that it can even override the activity of the 3 
enhancer. The logical extension of this work now is to divide the 1660-bp 
inset into two inserts of 451-bp and 1209-bp each and to attempt to 
demonstrate, enhancer activity with the former, and repression with the latter. 
If this hypothesis is supported, then, the 1209-bp insert can be subjected to 
deletion analysis to define specific DNA elements carrying a repressive 
function. This could be followed by investigations to identify proteins 
interacting with those elements. These investigations would include 
electrophoretic mobility shift assays with nuclear extracts to confirm whether 
or not any regulatory proteins bind to this region, and should binding be 
observed, antibody-induced super-shifts to identify novel proteins.  
 
In addition to there being true transcription repression, there are other factors 
that could have also given similar results. Transfection efficiency with the 
insert is one concern. This is unlikely as the pGL3Control constructs gave 
results similar to the ones obtained previously by other researchers in our 
laboratory. It is also possible that the constructs were lethal, but there did not 
appear to be any difference in the appearance of the cells following 
transfection. It is difficult to comment on the viability of cells as a count of the 
number of cells in each well before transfection and at the time of harvesting 
was not kept. It is also possible that rather than binding a factor that repressed 
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transfection; the constructs may have affected the degradation rate of the 
luciferase gene. 
 
Only construct E3 demonstrated a differential response at various levels of 
AngII in the stimulation experiments. The insert in construct E3 differed from 
constructs E1 and E2 at positions 11535 and 11608. E3 had nucleotides A and 
T at 11535 and 11608 respectively, while both E1 and E2 had nucleotides C 
and C. In order to examine whether these changes may affect transcription 
factor binding at these two sites, the sequences of the inserts were examined 
with MatInspector software for transcription factor binding. At the 
polymorphic site at nucleotide 11608 there appears to be a consensus sequence 
for interferon (IFN) regulatory factor 2 (IRF-2) when the 11608C allele is 
present, but when it is substituted by the 11608T this consensus sequence is 
abolished. IRF-2 is a transcription factor involved in the regulation of the IFN 
system (Tanaka, Kawakami and Taniguchi, 1993). The available evidence so 
far suggest that at least interferon alpha does not stimulate the secretion of 
angiotensinogen from rat hepatoma cells (Itoh, Matsuda, Ohtani and Okamoto, 
1989). 
 
These experiments were conducted in the HepG2 cells because the 
experimental techniques in this cell line are well established in our laboratory. 
They could also be extended to other human cell lines expressing 
angiotensinogen such as the extravillous cytotrophoblast cell lines to examine 
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whether the regulatory elements behave similarly in those cell lines as well. 
The stimulation experiments were confined to AngII in these investigations. 
However, stimulation experiments could have also been performed with other 
factors, such as EGF, TGFA, corticosteroids, etc., for which HepG2 cells are 
known to have receptors. These could also be tested in future experiments. 
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5. CONCLUSIONS 
These investigations were undertaken to test the hypothesis that the EGF, 
TGFA, AGT and MTHFR genes are susceptibility genes for pre-eclampsia, and 
that the EGF, TGFA, and AGT genes contribute to determine the variation in 
birth weight and/or blood pressure. The hypotheses were tested using 
molecular genetic techniques in two populations  the Sinhalese in Sri Lanka 
and the white Caucasians in Nottingham, UK. The first step in these 
investigations was the recruitment of Sri Lankan research subjects. This 
afforded an opportunity to validate the urine protein heat coagulation test 
(HCT) and to collect phenotypic data, unique to Sri Lanka, in a group of 180 
Sinhalese women with strictly defined pre-eclampsia.  
 
The main focus of these investigations were the genetic studies, but the 
establishment of the research cut-offs for the detection of significant 
proteinuria using the cheap and effective HCT and the demonstration of its use 
in practice has wide implications for the developing world not just in research, 
but also in clinical practice. The establishment of a database of the pre-
eclampsia phenotype among the Sinhalese, which provides clear evidence of 
the severe morbidity among women who develop pre-eclampsia and the severe 
mortality in their babies too is important as it is a call for action on the part of 
obstetricians, paediatricians and health administrators in Sri Lanka. 
 
Successful subject recruitment was followed by the establishment of a DNA 
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resource containing both samples from population volunteers of the three main 
races in Sri Lanka and samples from Sinhalese women with pre-eclampsia and 
normotensive pregnant Sinhalese women. The only drawback in this part of 
the study was that resolution of blood pressure postpartum could not be 
confirmed in some women with pre-eclampsia. An already established DNA 
resource at the University of Nottingham was used to replicate the studies in a 
white Caucasian population. Population based DNA resources were 
successfully used to establish the frequency of polymorphism/haplotype of the 
candidate genes in the three main Sri Lankan populations. This information, in 
addition to providing useful information for the current investigation, will also 
be useful for future genetic research in Sri Lanka. The case-control DNA 
resources were used to examine the association of the candidate genes with 
pre-eclampsia; and to examine the association of the candidate genes with 
quantitative traits in normotensive pregnant women. 
  
The most important finding of these molecular genetic investigations was the 
discovery of a strong association between polymorphisms/haplotypes of the 
maternal EGF gene and the birth weight of babies in the Sinhalese, which was 
replicated more strongly in the white Caucasians. Moreover, the EGF gene 
was found to be associated with pre-eclampsia in the Sinhalese. It is not 
possible, however, with the study design to determine whether the genetic 
effect was acting in the mother, the fetus or both. These initial findings 
therefore have to be clarified further not only by more precise haplotyping of 
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the EGF gene in case and control groups, but also by TDT testing in a new 
sample collection containing mother-father-baby trios to determine whether 
the genetic effect is acting on the mother, the fetus or both. A central theme 
that emerged in the discussion was the need to validate these findings in a 
larger sample collection that has sufficient power to detect genetic effects. The 
creation of large white Caucasian pre-eclampsia DNA resources such as has 
been done in the GOPEC study, would facilitate that in the future. The 
subsidiary investigation outside the main theme of this thesis was the AGT 
reporter gene expression investigation. It resulted in the discovery of repressor 
activity in the 3UTR/flanking region of the AGT gene that has hitherto not 
been described and the preliminary observations made with regard to the 
possible effects of AGT 3UTR/flanking region polymorphisms on gene 
expression under AngII stimulated conditions. As elaborated in previous 
sections, these require further investigation. 
 
In conclusion therefore, it was possible to see almost all the investigations to a 
successful conclusion and achieve the objectives laid down at the outset. This 
thesis describes what is possibly the first investigation into genetics of any 
complex disorder in the Sri Lankan population and as such it has broad 
implications for genetic research in Sri Lanka in this post genomic era. It is 
hoped that the publication of these results will encourage researchers in Sri 
Lanka to take up investigations into the genetics of complex disorders, and 
there by turn a new leaf in the annals of biomedical research in Sri Lanka. 
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APPENDIX 1: LIST OF ABBREVIATIONS 
AGT  Angiotensinogen 
AMP  Actin Modifying Proteins 
AngI  Angiotensin I 
AngII  Angiotensin II 
AR  Amphiregulin 
ASO  Allele Specific Oligonucleotide 
AT1R  Angiotensin II type 1 receptor 
AT2R  Angiotensin II type 2 receptor 
bp  base pair 
BTC    Betacellulin (BTC) 
BMI  Body Mass Index 
BWT  Birth weight 
CBS  Cystathionine β Synthese 
CI  95% Confidence Interval 
CSHW  Castle Street Hospital for Women 
D'  Lewontins disequilibrium coefficient 
DBP  Diastolic Blood Pressure 
DIP  Deletion Insertion Polymorphism 
DMSO  Dimethylsulfoxide 
DSHW De Soysa Hospital for Women 
DZ  Dizygotic 
E  Eclampsia 
E1  construct containing pGL3P3GW and insert E1 
E2  construct containing pGL3P3GW and insert E2 
E3   construct containing pGL3P3GW and insert E3 
ECACC European Collection of Cell Cultures 
EDTA  Ethylenediamminetetraacetate 
EGF  Epidermal Growth Factor 
EGFR  Epidermal Growth Factor Receptor 
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EM  Expectation Maximisation 
EMEM Eagle Minimal Essential Medium 
EVT  Extra-villous cytotrophoblast 
ExoI  Exonuclease I 
GH  Gestational Hypertension 
GOPEC UK Genetics of Pre-eclampsia Collaborative Study 
GTF   General Transcription Factor 
HB-EGF Heparin Binding Epidermal Growth Factor 
HCT  Urine Protein Heat Coagulation Test 
HDL  High Density Lipoprotein 
HELLP  HELLP Syndrome  
HER  Human Epidermal Growth Factor Receptor 
HWE  Hardy-Weinberg equilibrium 
iqr  inter quartile range 
IFN  Interferon 
IHD  Ischaemic Heart Disease 
IRF-2 Interferon Regulatory Factor-2 
ISSHP International Society for the Study of Hypertension in 
pregnancy 
K4  Korotkoff phase IV 
K5  Korotkoff phase V 
kb  kilobase 
LARII  Luciferase Assay Reagent II 
LD  Linkage Disequilibrium 
LDL  Low Density Lipoprotein 
M  Moor 
MBW  Mean Birth Weight 
MEK  MAP kinase kinase 
MS  Methinoine Synthase 
MS-PCR Mutagenically Separated  Polymerase Chain Reaction 
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MTHFR 5,10-Methylenetetrahydrofolate reductase 
MZ  Monozygotic 
NADPH Nicotinamide Adenine Dinucleotidephosphate 
NCBI  National Centre for Biotechnology Information, USA. 
NPV  Negative Predictive Value 
NRE  Negative Regulatory Elements 
NT  Normotensive 
NTD  Neural Tube Defects 
OR  Odds Ratio 
ox-LDL Oxidized Low Density Lipoprotein 
PBMC  Peripheral Blood Mononuclear Cells 
PBS  Phosphate Buffered Saline 
PCR  Polymerase Chain Reaction 
PE  Pre-eclampsia/Pre-eclamptic 
pGL3C pGL3Control vector 
pGL3P  pGL3Promoter vector 
pGL3P3GW pGL3Promoter vector with 3 Gateway
®
 modifications  
PIP2  Phosphatidylinositol (4,5) Bisphosphate 
PKC  Protein Kinase C 
PLCγ  Phospholipase C-γ  
PlGF  Placental Growth Factor 
PNK  T4 polynucleotide kinase 
PNMR  Perinatal mortality rate 
PPV  Positive Predictive Value 
r
2  
Square of correlation coefficient between a pair of loci 
RAS  Renin Angiotensin System 
RFLP  Restriction Fragment Length Polymorphism 
rpm  revolutions per minute 
RR  Relative Risk 
S  Sinhalese 
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SAP  Shrimp Alkaline Phosphatase 
SAT  Sulphosalycilic Acid Test 
SBP  Systolic Blood Pressure 
SD  Standard Deviation 
SEM  Standard Error of the Mean 
sFlt1  Soluble fms-like tyrosine kinase 1 
SGA  Small for Gestational Age 
SNP  Single Nucleotide Polymorphism 
STS  Sequence Tagged Sites 
SV40  Simian Virus 40 
T  Sri Lankan Tamil 
tagSNPs The maximally informative set of common SNPs 
TDT  Transmission Disequilibrium Test 
TGFA  Transforming Growth Factor Alpha 
THF  Tetrahydrofolate 
UTR  Untranslated Region 
UV  Ultra violet 
VEGF  Vascular Endothelial Growth Factor 
W  White Caucasian 
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APPENDIX 2: BUFFERS AND CULTURE MEDIA 
 Amount in 1 
Litre 
 
20 × SSC 
Sodium chloride 
Sodium citrate 
Adjust the pH to 7.0 with 10N sodium hydroxide 
 
175.3g 
88.2g 
 
  
20 × SSPE 
Sodium chloride 
Sodium orthophosphate 
EDTA 
Adjust the pH to 7.4 with 10N sodium hydroxide 
 
175.3g 
27.6g 
7.4g 
 
  
50 × TAE 
Tris base 
Glacial acetic acid 
0.5 M EDTA
1
 (pH 8.0) 
242g 
57.1ml 
100ml 
 
Luria-Bertani (LB) Medium 
Bacto-tryptone 
Bacto-yeast extract 
Sodium chloride 
Adjust the pH to 7 .0 with 5N sodium hydroxide 
 
10g 
5g 
10g 
 
For media containing agar, add 15g bacto-agar to the components listed above 
  
SOC Medium 
Bacto-tryptone 
Bacto-yeast extract 
Sodium chloride 
250mM potassium chloride 
2M MgCl2 
1M Glucose 
Adjust the pH to 7 .0 with 5N sodium hydroxide 
 
20g 
5g 
0.5g 
10ml 
5ml 
20ml 
 
 
 
 294 
APPENDIX 3: LIST OF SUPPLIERS 
Amersham Biosciences 
UK Limited 
Amersham Place, Little Chalfont, 
Buckinghamshire HP7 9NA, UK. 
 
Applied Biosystems 7 Kingsland Grange, Woolston, 
Warrington, Cheshire, WA1 7SR, UK. 
 
Edge Biosystems 19208 Orbit Drive, Gaithersburg, MD 
20879-4149, USA. 
 
European Collection of 
Cell Cultures 
CAMR, Salisbury, Wiltshire, SP4 0JG, 
UK. 
 
 
Genetic Research 
Instrumentation, Ltd. 
Gene House, Queenborough Lane, Rayne, 
Braintree, Essex, CM77 6TZ, UK. 
 
Invitrogen Ltd. 3 Fountain Drive, Inchinnan Business Park, 
Paisley, PA4 9RF,UK. 
 
MBI Fermentas (Helena 
Biosciences Europe) 
Colima Avenue, Sunderland Enterprise 
Park, Tyne and Wear, SR5 3XB, UK. 
 
Promega UK Ltd. Delta House, Chilworth Research Centre, 
Southampton SO16 7NS, UK. 
 
Qiagen QIAGEN House, Fleming Way, Crawley, 
West Sussex, RH10 9NQ, UK. 
 
Randox Laboratories 
Ltd. 
Diamond Road, Crumlin, Co. Antrim, 
BT29 4QY, UK. 
 
Roche Diagnostics 
GmbH 
Roche Applied Sciences, Nonnenwald 2, 
82372 Penzberg, Germany. 
 
Roche Diagnostics Ltd. Bell Lane, BN7 1LG, Lewes, E. Sussex, 
UK. 
 
Sigma-Aldrich Co. Ltd. Fancy Road, Poole, BH12 4QH, UK. 
 
Techne Ltd. Duxford, Cambridge, CB2 4PZ, UK. 
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APPENDIX 4: URINE PROTEIN HEAT COAGULATION TEST 
Steps of the standardised HCT 
1. Apply 5 ml of the urine sample into a test tube. 
2. Add a few drops of dilute acetic acid to the tube to make the sample acidic. 
3. Heat the urine column in the tube over a burner without boiling over. 
4. Compare the tube against the diagrammatic result interpretation chart 
(Figure 1) and record the result. 
 
Interpretation of the HCT result 
 
Negative/Trace 
 
No or mild turbidity observed. When the urine 
column in the tube is placed in front of a typed 
sheet of paper, printed letters can be clearly read 
through the tube. 
 
+1 Definite turbidity observed. Printed letters can be 
clearly read through the tube. 
 
+2 Definite turbidity observed. Printed letters cannot 
be read clearly through the tube. 
 
+3 Definite turbidity observed. Nothing can be 
observed through the tube. 
 
+4 Protein clots are seen in the tube. 
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Figure 1. The urine protein heat coagulation test result interpretation chart. 
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APPENDIX 5: DOCUMENTS USED FOR SUBJECT RECRUITMENT 
IN SRI LANKA 
 
This appendix contains the English translations of the Sinhala and Tamil 
language documents listed below, which were used for subject recruitment in 
Sri Lanka. 
• Information leaflet for study participants used for the recruitment of 
women with pre-eclampsia and the normotensive pregnant women. 
• Consent form used for recruitment of women with pre-eclampsia and 
normotensive pregnant women 
• Consent form used for recruitment of volunteers for the population genetic 
studies 
• Consent from used for recruitment of subjects for the urine protein heat 
coagulation test validation study 
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Information Leaflet For Study Participants 
 
Invitation to take part in research into the inheritance of 
Pre-eclampsia (High Blood Pressure in Pregnancy) 
 
You are invited to take part in a research study. Before you decide whether or 
not you wish to take part it is important for you to understand why the study is 
being done and what it will involve if you take part. Please read the following 
information carefully. Discuss it with your friends and relatives if you wish. 
Ask us if there is anything you do not understand or if you would like more 
information. You can have as much time as you want to make a decision. 
 
We are asking you and 399 other women (200 women with pre-eclampsia and 
200 normal women) and their families to volunteer for this study because 
without your help we will not be able to carry it out. 
 
Who is organising the study? 
This study is organised by the Human Genetics Unit and the Obstetrics and 
Gynaecology Department of the Faculty of Medicine, University of Colombo. 
A group of researchers from the University of Nottingham, UK are also 
helping us to conduct this study. 
  
Why are we doing this study? 
We are doing this study because we want to find out why some women 
develop pre-eclampsia and others dont by studying your genes. Pre-eclampsia 
is a disease of pregnancy, associated with high blood pressure and loss of 
protein in the urine. It can endanger both mother and baby. In Sri Lanka, it 
affects about 1 in every 50 women during pregnancy and results in the death 
of about 20 women every year. If we know why women develop pre-
eclampsia then it may be possible to improve treatment, or prevent its 
occurrence. 
 
What help do you have to give us? 
We would like you to help us by donating 10ml of your blood and by allowing 
us to examine your medical records. We would also like to study your baby, 
but it is not necessary to obtain blood samples from the baby. We can use a 
piece of umbilical cord. We would also like to talk to your sisters and sisters in 
law if they have been pregnant before to find out whether they have had pre-
eclampsia, but they can decided whether they want to talk to us or not. It is not 
compulsory. They dont have to donate blood. 
 
What benefit do you get? 
We cannot guarantee to discover anything that will directly benefit you or 
your family. Neither you nor us (the researchers involved) will benefit 
financially from this research. Your participation in this study would be kept 
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strictly confidential and the results of all the tests done will not be divulged to 
anyone. 
 
Do you have to take part? 
Taking part in this study is voluntary. If you would prefer not to take part you 
do not have to give a reason. Even if you say yes now and decided to change 
your mind later, that is fine, you can tell us so. This will not affect your 
medical treatment.  
 
Whom should you contact with any concerns? 
If you have any problems, concerns, complaints or other questions about this 
study, you should contact Dr. Vajira H. W. Dissanayake by telephone on 
695300 ext 349 at the Human Genetics Unit of the Faculty of Medicine in 
Colombo. 
 
5/Aug/2001 
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Research Consent Form 
 
PROJECT:     Inherited Factors in Preeclampsia 
 
NAME OF INVESTIGATOR: Dr. Vajira H. W. Dissanayake 
 
I ... give 
consent for the researchers to examine my medical records to obtain data for 
this research project. 
 
I know that participation in this study does not bring any direct benefit me. I 
volunteer because the findings of this study may contribute to the well being 
of the community at large. I understand that my participation in this study will 
be kept strictly confidential. It is also my understanding that I can withdraw 
from this study whenever I wish without giving any reason and that such 
withdrawal will not result in discontinuation of medical care and treatment 
given to my daughter / my sister. 
 
 
 
.    .. 
Donors Signature       Date 
 
 
. 
Witnesss Signature 
 
 
. 
Principal Investigators Signature 
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Research Consent Form 
 
PROJECT: A study of genetic variations in Sri Lankans 
 
NAME OF INVESTIGATOR: Dr. Vajira H. W. Dissanayake 
 
 
I ... volunteer to 
donate 10 ml of venous blood to be used for research purposes. 
 
The blood will be used to study variations in genes. The potential risks of 
donating blood, none of which are likely to occur, include pain, bruising, 
fainting or an infection at the puncture site. There will be no direct benefit to 
me. I understand that my participation in this study will be strictly 
confidential. It is also my understanding that I can withdraw from this study 
whenever I wish without giving any reason. 
 
 
 
 
.    .. 
Donors Signature       Date 
 
 
 
. 
Witnesss Signature 
 
 
. 
Principal Investigators Signature 
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Research Consent Form 
 
PROJECT: Urine protein heat coagulation test validation study 
 
NAME OF INVESTIGATOR: Dr. Vajira H. W. Dissanayake 
 
 
I ... volunteer to 
take part in the above study.  
 
I understand that my participation in this study will be strictly confidential. It 
is also my understanding that I can withdraw from this study whenever I wish 
without giving any reason and that withdrawal will not result in 
discontinuation of medical care and treatment given to me.  
 
 
 
 
.    .. 
Volunteers Signature       Date 
 
 
 
. 
Witnesss Signature 
 
 
. 
Principal Investigators Signature 
 
